Document:

EX-10.50

 Exhibit 10.50 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
 LICENSE AGREEMENT 

THIS LICENSE AGREEMENT (this “Agreement”), dated as of September 3, 2010, is by and between SCHERING CORPORATION, a New
Jersey corporation having its principal place of business at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (hereinafter referred to as “Schering”) and Eiger Biopharmaceuticals, Inc., a corporation organized and existing
under the laws of the state of Delaware and having its principal place of business at 3350 W Bayshore Road, Suite 120, Palo Alto, CA 94303 (hereinafter referred to as “Licensee”). Schering and Licensee are sometimes referred to
herein individually as a “Party” and collectively as the “Parties”. 
 WHEREAS, Schering has developed the compound
known as Sarasar/Lonafarnib (SCH 66336) and Schering is seeking to out-license rights to develop and commercialize Sarasar/Lonafarnib (SCH 66336); 

WHEREAS, Licensee desires to develop and commercialize Sarasar/Lonafarnib (SCH 66336); and 

WHEREAS, Licensee and Schering desire to enter into a license arrangement whereby Licensee will develop and commercialize Sarasar/Lonafarnib
(SCH 66336). 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, Licensee and Schering
hereby agree as follows: 
 ARTICLE I - DEFINITIONS 

As used in this Agreement, the following capitalized terms, whether used in the singular or plural, shall have the respective meanings set
forth below: 
 1.1 “Additional Indication” means an indication in the Field for the treatment of a virus that is different
from the virus or disease condition caused by the virus that is the subject of the First Indication and any indication previously granted Regulatory Approval in the Field. 

1.2 “Affiliate” means any individual or entity directly or indirectly controlling, controlled by or under common control with
a Party to this Agreement. For purposes of this Agreement, the direct or indirect ownership of fifty percent (50%) or more of the outstanding voting securities of an entity, or the right to receive fifty percent (50%) or more of the
profits or earnings of an entity shall be deemed to constitute control. Such other relationship as in fact results in actual control over the management, business and affairs of an entity shall also be deemed to constitute control. 

  
 Page 1 of 52 

 1.3 “Business Day” means a day on which banking institutions in New York, New
York, United States are open for business. 
 1.4 “Bulk Licensed Product” means finished capsules of the Licensed Product to
be used in clinical trials packaged in bulk. 
 1.5 “Calendar Quarter” means the respective periods of three
(3) consecutive calendar months ending on March 31, June 30, September 30 and December 31, for so long as this Agreement is in effect. 

1.6 “Calendar Year” means each successive period of twelve (12) months commencing on January 1 and ending on
December 31, for so long as this Agreement is in effect. 
 1.7 “Combination Product” means a Licensed Product which
comprises two (2) or more active ingredients, at least one (1) of which is a Licensed Compound. 
 1.8
“Commercialization” means, with respect to Licensed Product, any and all activities directed to the marketing, promotion, distribution, offering for sale and selling such product, importing and exporting such product for sale, and
interacting with Regulatory Authorities regarding the foregoing. Commercialization shall also include Commercialization Studies. “Commercialize” has a correlative meaning. 

1.9 “Commercialization Studies” means a study or data collection effort for a Licensed Product that is initiated in the
Territory after receipt of Regulatory Approval for such Licensed Product and is principally intended to support the Commercialization of such Licensed Product in the Territory; provided, that such study or data collection effort is not principally
to support or maintain a Regulatory Approval or obtain a label change or maintain a label. 
 1.10 “Commercially Reasonable
Efforts” means the performance of obligations or tasks in a continuous, sustained manner consistent with the resources and efforts typically used in the pharmaceutical and biotechnology industries for an ethical drug of similar commercial
potential as the Licensed Product, at a similar stage in its lifecycle, taking into consideration its safety and efficacy, the cost to Develop and Commercialize the product, the risks inherent in the Development and Commercialization of the product,
its competitiveness compared to alternative products, the proprietary position of the product, the scope, timing and likelihood of Regulatory Approvals. 

1.11 “Compound Patent Rights” means all patents and patent applications which, as of the Effective Date, are Controlled by
Schering (and/or any of its Affiliates), other than the Program Patents, that are reasonably necessary for Licensee to make, have made, use, sell, offer for sale or import Licensed Product in the Territory and in the Field and that are listed on
Schedule 1.11, and all (a) substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, certificates of invention, confirmations, re-examinations, extensions, supplementary protection
certificates or the like, or the provisional applications of any such 
  
 [ * ] =
Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 2 of 52 

 
patents and patent applications of any of the foregoing; or (b) foreign equivalents of any of the foregoing. 

1.12 “Controlled” means, with respect to a Person, that such Person (or any of its Affiliates) has the legal authority to
grant a license or sublicense of intellectual property rights to another Person or to otherwise disclose proprietary information to another Person without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary
or trade secret information of a Third Party. 
 1.13 “Cross-Field Net Sales” means the total Net Sales of Licensed Product
that are attributable to Cross-Field Sales in any given calendar year. 
 1.14 “Cross-Field Cost of Goods” means the fully
burdened cost to manufacture all Licensed Product sold by a Party in the relevant calendar year (including both bulk and secondary packaging) divided by the total number of units of Licensed Product sold by such Party in the relevant calendar year
multiplied by the number of units of Licensed Product sold by such Party that constitute Cross-Field Sales. 
 1.15 “Cross-Field
Sales” means sales of Licensed Products Commercialized by (a) Schering or its collaborators for indications in the Field after the launch of Licensed Product in the Field, or (b) Licensee or its collaborators for indications
outside the Field after launch of Licensed Product by Schering outside the Field, in each case as may be applicable following the Commercialization by both Parties of Licensed Product. 

1.16 “Development” or “Develop” means all preclinical research and development activities and all clinical
drug development activities, including, among other things: drug discovery, toxicology, formulation, statistical analysis and report writing, conducting clinical trials for the purpose of obtaining and maintaining Regulatory Approval (including
without limitation, post-marketing studies), and regulatory affairs related to all of the foregoing. Development shall include all clinical studies (including Phase III-B) that are primarily intended to support or maintain a Regulatory Approval,
maintain a label or obtain any label change, but shall exclude Commercialization Studies. 
 1.17 “Effective Date” shall
have the meaning set forth in Section 12.1. 
 1.18 “Field” means the use of the Licensed Compound or
Licensed Product for all human antiviral applications, except for the treatment of Hepatitis C virus, Hepatitis B virus, or HIV infections; provided, however, that the Field specifically includes, without limitation, the treatment of Hepatitis D
virus infections, including the treatment of patients co-infected with Hepatitis D virus and either or both of (i) Hepatitis C virus and (ii) Hepatitis B virus.  

1.19 “First Commercial Sale” means, with respect to a country in the Territory, the date that commercial quantities of a
Licensed Product are first sold in such country to a Third Party on arm’s length terms by Licensee, its Affiliate or sublicensee for use in the Field after the receipt of Regulatory Approval in such country. Sales for test marketing, sampling
and 
  
 [ * ] = Certain confidential information contained in this document, marked by
brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 3 of 52 

 
promotional uses, clinical trial purposes or compassionate or similar use shall not be considered to constitute a First Commercial Sale. 

1.20 “First Indication” means treatment of the Hepatitis D virus infections in humans. 

1.21 “FTE” means a full time equivalent person year of professional, scientific and/or technical work. An FTE shall consist of
a total of [ * ] hours per year, with any portion of an FTE calculated based upon hours worked divided by such annual total. 
 1.22
“FTE Rate” means [ * ]. 
 1.23 “FTE Cost” means, for any period of time, the product of (i) the
actual total FTEs during such period and (ii) the FTE Rate. 
 1.24 “Good Clinical Practices” means the then current
Good Clinical Practices as such term is defined from time to time by the United States Food and Drug Administration (“FDA”) or other relevant Governmental Authority having jurisdiction over the Development, manufacture or sale of Licensed
Product in the Territory pursuant to its regulations, guidelines or otherwise. 
 1.25 “Good Laboratory Practices” means the
current good laboratory practice regulations of the FDA as described in the United States Code of Federal Regulations (“CFR”) or any comparable corresponding foreign regulations or their respective successor regulations. 

1.26 “Good Manufacturing Practices” means the then current Good Manufacturing Practices as such term is defined from time to
time by the FDA or other relevant governmental authority having jurisdiction over the Development, manufacture or sale of Licensed Product in the Territory pursuant to its regulations, guidelines or otherwise. 

1.27 “Governmental Authority” means any court, agency, authority, department, regulatory body or other instrumentality of any
government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or any supranational organization of which any such country is a member. 

1.28 “IND” means an investigational new drug application with respect to Licensed Product filed with the FDA for beginning
clinical trials in humans, or any comparable application filed with the regulatory authorities of a country other than the United States prior to beginning clinical trials in humans in that country, as well as all supplements or amendments filed
with respect to such filings. 
 1.29 “Know-How” means any and all proprietary data, information and materials (whether
patentable or not) necessary or useful to the Licensed Compound, formulations, the Licensed Product, any Licensed Product Improvements, or the Development, Commercialization, Manufacture or use of any of the foregoing, which are not in the public
domain, including, without limitation, (a) ideas, discoveries, inventions, improvements, 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 4 of 52 

 
technology or trade secrets, (b) pharmaceutical, chemical and biological materials, products, components or compositions, (c) methods, procedures, formulas, processes, tests, assays,
techniques, regulatory requirements and strategies, (d) biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, clinical, safety, Manufacturing and quality control data and information related thereto,
(e) technical and non-technical data and other information related to the foregoing, (f) drawings, plans, designs, diagrams, sketches, specifications or other documents containing or relating to such information or materials and
(g) all applications, registrations, licenses, authorizations, approvals and correspondence submitted to Regulatory Authorities. 
 1.30
“Licensed Compound” means that certain Schering compound currently known as Sarasar/Lonafarnib (SCH 66336) with the chemical structure described in Schedule 1.29, including any prodrug, metabolite, salt, ester,
solvate, hydrate and crystalline form thereof. 
 1.31 “Licensed Product” means any pharmaceutical product or product
candidate that contains the Licensed Compound, either alone or in combination with one or more other active pharmaceutical ingredients, including without limitation, all formulations, line extensions and modes of administration thereof. 

1.32 “Licensed Product Improvement” means any enhancement to Licensed Compound or any Licensed Product, including without
limitation, formulations thereof; the inclusion of any inactive ingredient; and any alternative preparation, presentation, means of delivery, dosage, packaging or manufacture. 

1.33 “Major European Country” means any of France, Germany, Italy, Spain or the United Kingdom. 

1.34 “Manufacture” means all activities related to the manufacturing of a pharmaceutical product, or any ingredient thereof,
including but not limited to test method development and stability testing, formulation, process development, manufacturing scale-up, manufacturing Licensed Compound or Licensed Product quality assurance/quality control development, quality control
testing (including in-process release and stability testing), packaging, shipment and release of product or any component or ingredient thereof, quality assurance activities related to manufacturing and release of product or any component or
ingredient thereof, and regulatory activities related to all of the foregoing. 
 1.35 “NDA” means a New Drug Application or
its equivalent filed with the FDA seeking approval to market and sell a Licensed Product in the United States or any comparable application filed with a Governmental Authority of a country other than the United States. 

1.36 “Net Sales” means, with respect to each country in the Territory, the aggregate gross amount invoiced by Licensee, its
Affiliates or sublicensees (other than Schering and its Affiliates) on all sales of Licensed Product to an unaffiliated Third Party (including distributors) in an arm’s length transaction, and exclusive of intercompany transfers or sales in the
Territory, less the reasonable and customary deductions from such gross amounts, including: (i) normal 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 5 of 52 

 
and customary trade, cash and quantity discounts, allowances and credits; (ii) credits or allowances actually granted for damaged goods, returns or rejections of Licensed Product and
retroactive price reductions; (iii) sales, use, tariff or similar taxes (including duties or other governmental charges levied on, absorbed or otherwise imposed on the sale of Licensed Product including, without limitation, value added taxes or
other governmental charges); (iv) transportation, freight, postage, shipping, customs duties and insurance charges; (v) charge back payments and rebates granted to managed health care organizations or their agencies, and purchasers and
reimbursers or to trade customers, including but not limited to, wholesalers and chain and pharmacy buying groups; (vi) commissions paid to Third Parties other than sales personnel and sale representatives or sales agents; (vii) bad debt [
* ]; and (viii) rebates (or equivalents thereof) granted to or charged by national, state or local Governmental Authorities in a country in the Territory. Each of the deductions set forth above shall be reasonable and customary, and shall be
determined on an accrual basis in accordance with United States Generally Accepted Accounting Principles (GAAP). Sales made in connection with test marketing, sampling and promotional uses, clinical trial purposes or charitable or compassionate use
shall not be included in Net Sales. 
 In the event that Licensed Product is sold in the form of a Combination Product, Net Sales for such
Combination Product will be calculated by multiplying actual Net Sales of such Combination Product by the fraction A/(A+B) where: A is the invoice price of the Licensed Product if sold separately by Licensee, or its Affiliate or sublicensee; and B
is the invoice price of any other pharmaceutical product containing an active component or components (not including the Licensed Compound) in the Combination Product if sold separately by Licensee, or its Affiliate or sublicensee. 

In the event that the Licensed Product is sold in the form of a Combination Product containing one or more active ingredients other than
Licensed Compound and one or more such active ingredients of the Combination Product are not sold separately, then the above formula shall be modified such that A shall be the reasonable fully allocated manufacturing cost to Licensee, and/or its
Affiliates or sublicenses of the Licensed Compound and B shall be the reasonable fully allocated manufacturing cost to Licensee, and/or its Affiliates or sublicenses of any other active component or components in the combination that is not the
Licensed Compound. 
 To the extent that any discounts or other similar deductions that are based on sales to the customer of Combination
Products are excluded from Net Sales of Licensed Products, such discounts or deductions shall be allocated to Licensed Products and the other relevant products on a pro rata basis based on the invoiced prices for such multiple products, which
allocation in any event shall not disproportionately be applied to the Licensed Product. 
 1.37 “Person” means any
individual, partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed herein. 

 
 [ * ] = Certain confidential information contained in this document, marked by brackets,
is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 6 of 52 

 1.38 “Phase II Study” means a controlled dose ranging clinical study in humans
of a Licensed Product that would fall within the description set forth in 21 C.F.R. Part 312.21(b) (as amended from time to time) or other comparable regulation imposed by an applicable regulatory authority in any country other than the United
States, to evaluate the efficacy and safety in the targeted patient population and to attempt to define an appropriate dosing regimen. For clarity, Phase II Study may include a Proof-of-Concept Trial. 

1.39 “Phase III Study” means a large scale, pivotal clinical study of a Licensed Product that would fall within the
description set forth in 21 C.F.R. Part 312.21(c) (as amended from time to time) or other comparable regulation imposed by an applicable regulatory authority in any country other than the United States performed after evidence suggesting
effectiveness and safety of such Licensed Product and establishing a dose has been obtained in Phase II Study(ies) and adequacy of Phase II Study data has been confirmed by the applicable Regulatory Authority in a successful end of Phase II meeting.
Phase III Studies are intended to evaluate the therapeutic efficacy and safety of a Licensed Product for the particular indication in question for purposes of submission to a Governmental Authority to obtain Regulatory Approval of the Licensed
Product. Phase III Studies have a sufficient number of patients needed to evaluate the overall benefit-risk relationship of the Licensed Product, to provide an adequate basis for extrapolating the results to the general population, and to transmit
that information in physician labeling. 
 1.40 “Price Approvals” means, with respect to a Licensed Product, pricing or
pricing reimbursement approval granted in each country in the Territory by the applicable Regulatory Authorities necessary for the commercial sale of such Licensed Product in such regulatory jurisdiction. 

1.41 “Program IP” means the Program Know-How and Program Patents, collectively. 

1.42 “Program Know-How” means any Know-How that is generated by or on behalf of one or more of the Parties and/or their
respective Affiliates as a result of the Development of the Licensed Compound and/or the Licensed Product during the Term. For clarity, Program Know-How shall not include Schering Know-How. 

1.43 “Program Patents” means (a) all patents and patent applications (other than the Compound Patent Rights) that claim
discoveries, inventions, developments and/or innovations related to the Licensed Compound, including without limitation, Licensed Product Improvements, made by or on behalf of one or more of the Parties and/or their respective Affiliates during the
term of this Agreement; (b) all substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, certificates of invention, confirmations, re-examinations, extensions, supplementary protection certificates or
the like, or the provisional applications of any such patents and patent applications; or (c) are foreign equivalents of any of the above. 

1.44 “Proof of Concept Trial” shall have the meaning set forth in Section 3.2(a). 

 
 [ * ] = Certain confidential information contained in this document, marked by brackets,
is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 7 of 52 

 1.45 “Proprietary Information” means, with respect to each of the Parties, any
and all proprietary data, information or materials disclosed or otherwise made available by a Party or its Affiliates to the other Party or any of its Affiliates, including, without limitation, any such data, information or materials related to
substances, formulations, devices (and/or any components thereof), techniques, technology, regulatory requirements and strategies, equipment, study results, reports, know-how, sources for manufacture and supply, patent position and business plans.

 1.46 “Regulatory Application” means (a) the single application or set of applications for approval and/or pre-market
approval to Manufacture and sell commercially a pharmaceutical therapeutic product submitted to the FDA including, without limitation, any related registrations with or notifications to the FDA, and (b) any foreign equivalents to such
applications filed with any other national or supranational Regulatory Authority in the Territory, and (c) all supplements and amendments that may be filed with respect to any of the foregoing. 

1.47 “Regulatory Approval” means any and all approvals (including Price Approvals), licenses, registrations, or authorizations
of any federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity necessary for the Manufacture, use, storage, import, export, transport, promotion, marketing or sale of a Licensed
Product in the applicable country in the Territory. 
 1.48 “Regulatory Authority” means any United States federal, state,
or local government, or any foreign government, or political subdivision thereof, or any multinational organization or authority or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative,
police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body with responsibility for granting licenses or approvals, including Regulatory
Approvals, necessary for the marketing and sale of the Licensed Product in the applicable country in the Territory. 
 1.49 “Schering
Know-How” means any and all Know-How owned or controlled by Schering and/or any of its Affiliates as of the Effective Date. 
 1.50
“[ * ]” means the earlier of [ * ] or [ * ]. 
 1.51 “[ * ]” means the earlier of [ * ] or the date [ * ]. 

1.52 “Territory” means the entire world. 

1.53 “Third Party” means any Person other than a Party or its Affiliates. 

1.54 “Valid Claim” means a claim of an issued and unexpired patent included within the Compound Patent Rights, which has not
been (a) revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, (b) finally cancelled, withdrawn, abandoned
or 
  
 [ * ] = Certain confidential information contained in this document, marked by
brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 8 of 52 

 
rejected by any administrative agency or other body of competent jurisdiction, (c) disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer or otherwise,
or (d) lost through an interference proceeding. 
 1.55 Additional Definitions. Each of the following definitions is set forth in
the Section of this Agreement indicated below. 
  

			
	 Definition
	  	 Section

		
	AAA	  	13.2(a)
	AEs	  	4.3(a)
	Agents	  	9.1(b)
	Agreement	  	Preamble
	Annual Commercialization Report	  	3.4
	CFR	  	1.21
	Change of Control	  	14.1(c)
	Data Services	  	3.7(c)(ii)
	Development Plan	  	3.2(a)
	Development Report	  	3.3
	Effective Date	  	Preamble
	FDA	  	1.20
	Force Majeure	  	15.8
	GAAP	  	1.36
	Liability	  	11.1
	LIBOR	  	7.5(e)
	Licensee Field Product	  	3.7(c)(i)
	Licensee Indemnified Party	  	11.2
	Non- Licensee Field Product	  	3.7(c)(i)
	Other Technology	  	2.5(d)
	Phase II Completion Date	  	2.5(d)
	Reacquisition License	  	2.5(b)
	ROFN Notice	  	2.5(b)
	ROFN Period	  	2.5(b)
	Sales Tracking Methodology	  	3.7(c)(ii)
	Schering Indemnified Party	  	11.1
	Schering Prosecution Patents	  	8.3
	Sublicense Agreement	  	2.5(e)
	Term	  	12.1
	Third Party Patent License	  	7.3(d)
	Third Party Sublicense Agreement	  	2.5(b)

 ARTICLE II - LICENSE 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 9 of 52 

 2.1 License Grant. Subject to the terms and conditions of this Agreement, Schering
hereby grants to Licensee an exclusive (even as to Schering), sublicensable (subject to the obligations and restrictions in Section 2.5), royalty bearing license, under the Compound Patent Rights, the Schering Know-How and Schering’s
interest in any solely or jointly owned Program IP to Develop, make, have made, use, import, export, Commercialize, sell, offer for sale, and market the Licensed Product in the Field in the Territory.  

2.2 No Non-Permitted Use. Licensee hereby covenants that it shall not, nor shall it cause any Affiliate or sublicensee to knowingly use
or practice, directly or indirectly, any Schering Know-How or Compound Patent Rights in conflict with the license granted under Section 2.1 above. 

2.3 Retained Rights; Covenants. Schering retains any and all other rights under the Compound Patent Rights and Schering Know-How that
are outside the scope of the license granted under Section 2.1. Licensee shall not grant any Third Party any license or right under any Compound Patent Rights and/or Schering Know-How, other than as expressly permitted in this Agreement. 

2.4 No Other Licenses. Neither Party grants to the other Party any rights or licenses in or to any intellectual property, whether by
implication, estoppel, or otherwise, other than the license rights that are expressly granted under this Agreement. 
 2.5 Sublicense
Agreements; Right of First Negotiation. 
 (a) Except as provided in Section 2.5(b) and (c) and subject to the obligations and
restrictions set forth in this Section 2.5, Licensee may grant sublicenses of the rights granted to it under Section 2.1 without Schering’s consent. 

(b) In the event Licensee intends to solicit bids from or determine the interest of a Third Party in connection with a sublicense to such Third
Party of all rights to the Licensed Product granted by Schering to Licensee in Section 2.1 in the US, the Major European Countries, five or more countries in Asia Pacific (except Japan) and/or Japan in the Field, Licensee shall notify Schering
of such intent in writing (“ROFN Notice”). In such an event, Licensee shall grant to Schering an exclusive right to enter into good faith negotiations with Licensee for an exclusive license to Schering for the rights to the Licensed
Product that Licensee intends to sublicense to a Third Party (“Reacquisition License”) for a period commencing on the date Schering receives the ROFN Notice and expiring [ * ] days thereafter (the “ROFN Period”). In
the event that the Parties are in active negotiations, they will discuss in good faith an extension to such ROFN Period. During the ROFN Period, the Parties will negotiate in good faith the Reacquisition License on commercially reasonable terms and
on financial terms that reasonably reflect Licensee’s actual reasonably documented expenditures and investment Developing and Commercializing the Licensed Product. During the ROFN Period, if [ * ] that [ * ], Schering shall promptly notify
Licensee [ * ] and the obligations of Licensee pursuant to this Section 2.5(b) and Section 2.5(c) shall terminate and Schering’s right of first negotiation shall be deemed terminated, whether or not notification from Schering is
provided hereunder. 
  
 [ * ] = Certain confidential information contained in this
document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 10 of 52 

 (c) In the event that (i) Schering waives its exclusive right to enter into good faith
negotiations with Licensee, (ii) Schering fails to notify Licensee that Schering elects to exercise its exclusive right to enter into good faith negotiations with Licensee within [ * ] of receipt of the ROFN Notice or (iii) the Parties are
unable to agree upon terms of an agreement for the Reacquisition License within the ROFN Period, then Licensee shall be free to enter into a sublicense agreement with a Third Party for the rights that were the subject of the ROFN Notice
(“Third Party Sublicense Agreement”); provided, however, that [ * ]. If [ * ], Licensee [ * ]. 
 (d) In the event that
Licensee receives Consideration (as defined herein) from its sublicensees in connection with any sublicense of the rights granted to Licensee in Section 2.1, Licensee shall pay to Schering, within [ * ] of the date Licensee receives such
Consideration, a portion of such Consideration equal to the following: (i) [ * ] of the Consideration if the agreement for such sublicense is executed prior to [ * ]; (ii) [ * ] of the Consideration if the agreement for such sublicense is
executed after [ * ] and prior to the date that [ * ]; and (iii) [ * ] if the agreement for such sublicense is executed after the date that [ * ]. For purposes of this section, “Consideration” means any and all amounts received
by Licensee from its sublicensee in consideration for granting such sublicensee a sublicense of any of the rights granted by Schering to Licensee in Section 2.1, including any and all payments, including without limitation, up-front payments
and milestone payments; provided, however, that the following payments shall be specifically excluded from the calculation of Consideration: (1) all past and future research and development funding, (2) any loan amounts, (3) the fair
market value of all equity issued by Licensee to a sublicensee (calculated according to the good faith determination of the board of directors of Licensee), (3) royalty payments, and (4) Development milestone payments for the corresponding
milestones set forth in Section 7.2 up to the amounts that are payable as Development milestone payments due under Section 7.2 of this Agreement. In the event that Licensee grants a sublicense to sublicensee under the rights granted to
Licensee in Section 2.1 above in conjunction with a license to other technology or products independently developed by Licensee that is not comprised of Compound Patent Rights or Schering Know-How (“Other Technology”), the
amounts that are allocable to the inclusion of such Other Technology, as reasonably established by Licensee and sublicensee and set out in the applicable Sublicense Agreement (as defined below), or if no such allocation is made in the Sublicense
Agreement, then the prorated portion of any fees or payments (not otherwise excluded or deducted pursuant to this Section 2.5(d)) made to Licensee under the applicable Sublicense Agreement in consideration for such Other Technology shall be
excluded from the definition of Consideration. In the event that Licensee receives non-cash consideration as part of any Consideration paid under an applicable Sublicense Agreement, the fair market value of such non-cash consideration on the date of
the transfer will be the cash amount used to calculate Schering’s percentage share of such Consideration under this Section 2.5(d). 

(e) Licensee shall, in each agreement under which it grants a sublicense under the license set forth in Section 2.1 (each, a
“Sublicense Agreement”), require the sublicensee to transfer to Schering, if this Agreement terminates for breach by sublicensee, and to Licensee, if only such sublicense terminates, (i) all regulatory filings and Regulatory
Approvals held, possessed or Controlled by such sublicensee and (ii) all patent rights and Know-How Controlled 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 11 of 52 

 
by such sublicensee relating to a Licensed Product or its use, Manufacture, sale, or importation (which patent rights and Know-How shall be transferred either by assignment or by a freely
sublicensable exclusive license). In the event that this Agreement terminates other than for breach by a sublicensee, Schering shall enter in an agreement with each sublicensee on the same terms as the existing Sublicense Agreement. All Sublicense
Agreements shall be consistent with the terms and conditions of this Agreement. Licensee shall use reasonable efforts to (I) procure the performance by any sublicensee of the terms of each applicable Sublicense Agreement, and (II) ensure that
any sublicensee will comply with the applicable terms and conditions of this Agreement. Licensee hereby guarantees the performance of its sublicensees that are party to a Sublicense Agreement as permitted herein, and the grant of any such sublicense
will not relieve Licensee of its obligations under this Agreement, except to the extent they are satisfactorily performed by such sublicensee. 

2.6 Third Party Agreements. Schering shall remain responsible for the payment of royalty, milestone and other payment obligations under
all agreements entered into by Schering prior to the Effective Date. In the event that Licensee reasonably determines that rights to intellectual property owned or Controlled by a Third Party are required in order to lawfully perform any activities
under this Agreement, Licensee shall have the right to negotiate and acquire such rights through a license or otherwise and to deduct from the payments due to Schering under this Agreement [ * ] of the royalties paid by Licensee to such Third Party;
provided, however, that such reduction shall not reduce the royalty rates otherwise applicable to the Net Sales of such Licensed Product by more than [ * ]. Licensee shall ensure that each Third Party clinical trial, contract
Manufacturing, or service agreement entered into by Licensee or its Affiliates with respect to the Development of Licensed Product contains provisions obligating such Third Party contractor to assign and/or convey the appropriate intellectual
property rights relating to Licensed Product to Licensee so that Licensee can assign and/or convey such rights to Schering as necessary under the terms and conditions of this Agreement. 

2.7 Schering Assistance. Subject to all applicable provisions of this Agreement, Schering shall, promptly following the Effective Date,
provide copies to Licensee of all information, including without limitation, Schering Know-How, except to the extent that such Schering Know-How has been previously disclosed to Licensee, that are in Schering’s actual possession as of the
Effective Date and are reasonably necessary for Licensee to use, make, have made, sell, offer to sale or import Licensed Product in the Field. Each Party shall bear its own costs in performing any activities pursuant to this Section 2.7. 

2.8 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this Agreement are,
and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(35A) of the Bankruptcy Code. Each Party shall retain and
may fully exercise all of its rights and elections under the Bankruptcy Code or equivalent legislation in any other jurisdiction. Upon the bankruptcy of either Party, the other Party shall further be entitled to a complete duplicate of (or complete
access to, as appropriate) any such intellectual property, and such, if not already in its possession, shall be promptly delivered to such other Party, unless 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 12 of 52 

 
the Party in bankruptcy elects to continue, and continues, to perform all of its obligations under this Agreement. 

ARTICLE III – DEVELOPMENT AND COMMERCIALIZATION 

3.1 Overview. As of the Effective Date, Licensee shall be solely responsible for the Development and Commercialization of the Licensed
Product in the Field in the Territory. Licensee shall perform all of its Development activities in accordance with each IND for each applicable Licensed Product and with all applicable laws, rules and regulations. 

3.2 Development and Commercialization Plans. 

(a) Proof of Concept. Not later than the Effective Date, the Parties shall have agreed on the initial proposed protocol for a proof of
concept trial for the Licensed Product in the Field, which shall be incorporated as part of this Agreement as Schedule 3.2(a) (the “Proof of Concept Trial”). The Parties acknowledge that the Proof of Concept Trial
protocol may change in light of regulatory and clinical developments affecting the Licensed Product. 
 (b) Initial Development Plan.
Not later than the Effective Date, the Parties shall have agreed on the initial Development plan and related timelines for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as Schedule
3.2(b) (as may be amended and updated annually in accordance with this Agreement, the “Development Plan”). Schering shall have the right to review and comment on the clinical protocols for studies conducted in accordance
with the Development Plan, including review of the design and endpoints of such studies so that such studies will lead to an outcome that is credible and reproducible, which comments Licensee shall consider and incorporate as Licensee deems
appropriate in good faith. At Schering’s written request, the President of Schering’s research division, or his designee, and the President of Licensee’s research division or equivalent position, or his designee, shall meet to discuss
such comments. Any revision of the clinical protocols shall be submitted to Schering promptly after their completion. 
 (c) Annual
Development Plan. Not later than thirty (30) days after December 31 of each Calendar Year, Licensee shall submit to Schering an updated Development Plan for the pending Calendar Year. Such update shall take into account completion,
commencement, changes in or cessation of Development activities not contemplated by the then-current Development Plan in sufficient detail to reflect the continued diligence of Licensee and shall reflect effort and resources consistent with other
priority projects of Licensee. Schering shall have the right to comment on such annual plan. In the event Schering reasonably disagrees with the plan, Licensee shall consider Schering’s comments for revising the plan. At Schering’s written
request, the President of Schering’s research division, or his designee, and the President of Licensee’s research division or equivalent position, or his designee, shall meet to discuss such comments. Any revision of the annual plan shall
be submitted to Schering promptly after its completion. 
  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 13 of 52 

 (d) Commercial Launch. Licensee shall give Schering prior written notice of at least sixty
(60) days of its intent to file an NDA for the Licensed Product and at that time shall further provide Schering with the anticipated date of First Commercial Sale for the Licensed Product in the country of filing. Licensee shall promptly
provide Schering with notice of any Regulatory Approval of Licensed Product. 
 (e) Performance. Licensee shall perform, and shall
ensure that its Affiliates, sublicensees, and Third Party contractors perform, the activities described in the Development Plan in a professional manner and in compliance with, to the extent applicable, Good Laboratory Practices, Good Clinical
Practices and/or Good Manufacturing Practices and in compliance with all other applicable laws, rules, and regulations. 
 (f) Program
Know-How. Each Party shall share Program Know-How owned or Controlled by it with the other Party in a reasonably detailed annual report (“Know-How Report”). Such Know-How Reports will be exchanged by the Parties prior to
January 31st of each Calendar Year of the Term. 
 3.3 Development Reports.
Licensee shall provide Schering with reasonably detailed reports describing its progress with respect to its Development efforts under this Agreement (hereinafter “Development Reports”). Such Development Reports shall be furnished
annually until the First Commercial Sale. Each Development Report shall include the following information for the Licensed Product: a description of the Development work to be conducted during the year in reasonable detail, including, to the extent
applicable, clinical studies, formulation work, Manufacturing work, other testing work and regulatory activity; timelines for such work; and key decision gates and milestones for such work. 

3.4 Commercialization Reports. Commencing with the First Commercial Sale and thereafter on an annual basis, Licensee shall provide
Schering with a written non-binding estimate of annual Net Sales for the Licensed Product in the Territory (“Annual Commercialization Report”). The Annual Commercialization Report shall also list all ongoing Commercialization
Studies and the status of such studies in the United States, the Major European Countries and Japan. 
 3.5 Contract Sales Force.
Notwithstanding anything to the contrary in this Agreement, Licensee shall not use the services of sales representatives employed by a Third Party as a contract sales force for Licensed Product without the prior written consent of Schering, such
consent not to be unreasonably withheld. 
 3.6 Development and Commercialization Costs. Licensee shall be solely responsible for all
costs related to the Development and/or Commercialization of the Licensed Product in the Field in the Territory following the Effective Date. 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 14 of 52 

 3.7 Commercialization of Licensed Product in the Field. 

(a) Sales in the Field. Licensee hereby covenants that it shall not, nor shall it authorize any Affiliate, permitted sublicensee or
Third Party contractor to Commercialize Licensed Product in the Territory for any use outside the Field. Schering hereby covenants that it shall not, nor shall it authorize any Affiliate, permitted sublicensee or Third Party contractor to
Commercialize Licensed Product in the Territory for any use in the Field. Each Party acknowledges and understands that the other Party cannot control the ultimate use of the Licensed Products it sells and that the purpose of the foregoing covenant
is to prevent such Party and its Affiliates and sublicensees from facilitating or encouraging uses in the other Party’s Field. To the extent either Party can prove the other Party materially breached this Section 3.7(a), such material
breach shall permit such non-breaching Party to terminate this Agreement for cause under Section 12.4. 
 (b) Licensed Product
Packaging. Each Party shall use reasonable efforts to ensure that Licensed Product it is Commercializing (in the Field with respect to Licensee and outside the Field with respect to Schering) is packaged and identified in a manner such that it
is distinguishable from Licensed Product that the other Party is Commercializing in its respective Field, including not using trademarks, trade dress, product appearance, product packaging, and other such distinguishing characteristics that the
other Party is using or is planning to use. The Parties shall cooperate in good faith to share information about each Party’s respective Licensed Product (which information shall constitute the Proprietary Information of the disclosing Party)
in order to allow each Party to comply with its obligations under this Section 3.7(b). 
 (c) Lost Sales. The Parties recognize
that Schering has the right to Commercialize Licensed Products for indications outside the Field. As a result, the Parties acknowledge and desire to address the potential for Cross-Field Sales such that the Parties agree as follows: 

(i) If at any time during the Term of this Agreement, Schering, its Affiliate, or licensees (other than Licensee) is Commercializing a product
containing a Licensed Compound approved by the relevant Regulatory Authority for an indication outside the Field (a “Non-Licensee Field Product”) and Licensee is at the same time Commercializing a Licensed Product approved by the
relevant Regulatory Authority for an indication in the Field (a “Licensee Field Product”), and a Party reasonably believes that (1) sales of a Non-Licensee Field Product are occurring or will occur for use in the approved
indication in the Field; or (2) sales of the Licensee Field Product are occurring or will occur for use in the approved indication outside the Field, then such Party may provide notice to the other Party of its desire to track sales of Licensed
Product for the relevant indications either in the Field or outside the Field, as applicable. 
 (ii) Upon receipt of notice under
Section 3.7(c)(i), Schering and Licensee shall meet and agree upon a method of tracking sales of each possible Cross-Field Sale (a “Sales Tracking Methodology”) including (1) the acquisition of one or more prescription
data products or services (including, by way of example, IMS Xponent, NDC, or DDD data, data from the UNOS database or other data from organizations tracking transplant surgeries or patients) or 

 
 [ * ] = Certain confidential information contained in this document, marked by brackets,
is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 15 of 52 

 
other relevant pharmaceutical sales tracking research services (including, for example, use of random sampling, use of data regarding distribution channels as a proxy for indication-specific
sales or development of mathematical models for approximating indication-specific sales) generally recognized in the pharmaceutical industry as having a reasonably high degree of accuracy and reliability in the tracking of sales of pharmaceutical
products that have a similar nature as and are prescribed by similar physicians as the applicable License Product (collectively, the “Data Services”), and (ii) the methodology for applying any such resulting data and
information provided by such Data Services to determine the extent of Cross-Field Sales. 
 (iii) In the event that Schering and Licensee are
unable to agree on a Sales Tracking Methodology pursuant to Section 3.7(c)(ii), then the following default methodologies shall apply: 

(1) With respect to each of the U.S., the Major EU Countries and Japan (collectively, the “Major Regulatory Jurisdictions”),
in which a Licensee Field Product and a Non-Licensee Field Product have received Regulatory Approval and in which Data Services are available at a reasonable cost (evaluated in light of the anticipated accuracy of such data and anticipated magnitude
of Cross-Field Sales in such country), sales in the approved indications in the Field in such country and sales in the approved indications outside the Field in such country shall be calculated for each Licensee Field Product and each Non-Licensee
Field Product based on the sales levels reported by the Data Services for such country. 
 (2) For all countries other than Major Regulatory
Jurisdictions, the percentage of sales of each Licensee Field Product attributable to use in the approved indications outside the Field and the percentage of sales of each Non-Licensee Field Product attributable to use in the approved indications in
the Field shall be calculated from total sales of such products based on the assumption that the ratio of Cross-Field Sales to total sales in such country is equal to the ratio of Cross-Field Sales to total sales calculated across all Major
Regulatory Jurisdictions in which Cross-Field Sales are evaluated pursuant to Section 3.7(c)(iii)(1). In the event that there are no Major Regulatory Jurisdictions in which Cross-Field Sales are evaluated pursuant to
Section 3.7(c)(iii)(1), then no Sales Tracking Methodology shall apply unless and until the Parties agree on a Sales Tracking Methodology pursuant to Section 3.7(c)(ii). 

(3) All costs associated with the acquisition and application of such Data Services and Sales Tracking Methodology shall be shared equally by
the Parties. In addition, the Parties shall also meet and confer with respect to: (A) how to account for prescriptions to patients with multiple afflictions that are both within and outside the Field (i.e., approved indications in the Field and
approved indications outside of the Field); (B) the right for each Party to audit, on a periodic basis, the application of the Data Services and Sales Tracking Methodology; and (C) a mechanism for addressing prescriptions that are tracked
back to sole source purchasing agreements. 
 (iv) If in the course of applying the foregoing Data Services and methodologies to track sales
of the Licensee Field Product and Non- Licensee Field Product pursuant to this Section 3.7, or in the course of performing an audit of such application by the other Party, a 

 
 [ * ] = Certain confidential information contained in this document, marked by brackets,
is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 16 of 52 

 
Party determines that Cross-Field Sales by the other Party are occurring at more than the greater of (A) [ * ] or (B) [ * ] of such Party’s total Net Sales of the Licensed Product,
then the Parties shall compensate each other as follows: 
 (1) In the event that there are Cross-Field Sales by Licensee, Licensee shall
make a payment to Schering equal to the amount of Licensee’s Cross-Field Net Sales less Licensee’s Cross-Field Sales Cost of Goods; and 

(2) In the event that there are Cross-Field Sales of Schering, Schering shall make a payment to License equal to the amount of Schering’s
Cross-Field Net Sales less Schering’s Cross-Field Cost of Goods. 
 (v) Both Parties acknowledge that in order to respect
confidentiality, it may not be possible to share non-publicly available data with each other. Therefore, any discussion or dispute in relation to the compensation for Cross-Field Sales under Section 3.7(iv) will be submitted to an independent
auditor acceptable to both Parties and that is subject to appropriate confidentiality obligations. 
 ARTICLE IV - REGULATORY 

4.1 Regulatory Filings Transfer. 

(a) Schering covenants that, as of the Effective Date, it does not have any INDs or other Regulatory Applications covering the Licensed Product
in the Field in the Territory. After the Effective Date, Licensee or its Affiliates or sublicensee, as applicable, shall hold all INDs and other Regulatory Applications and Regulatory Approvals for Licensed Product in the Field throughout the
Territory. Schering shall be the exclusive owner of all INDs and other Regulatory Applications related to the Licensed Compounds and/or Licensed Product outside the Field in the Territory. 

(b) As soon as practicable after the Effective Date (or such other date as mutually agreed by the Parties), Schering shall provide to Licensee
one (1) electronic copy in Microsoft Word or Adobe Acrobat (whichever format the document is currently available) of (i) all material documents and records that have been generated by or on behalf of Schering with respect to any existing
INDs and other Regulatory Applications covering the Licensed Product in the Territory sufficient for Eiger to file an IND in its own name; and (ii) any documents and records (not provided pursuant to (b)(i)) between Schering and Regulatory
Authorities related to Licensed Product in the Field, if any. 
 (c) Licensee shall oversee, monitor and coordinate all regulatory actions,
communications and filings with, and submissions to, the FDA and other Regulatory Authorities in the Territory with respect to Licensed Product in the Field. 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 17 of 52 

 (d) Licensee shall be solely responsible for interfacing, corresponding and meeting with the FDA
and other Regulatory Authorities throughout the Territory with respect to Licensed Product in the Field. Each Party shall provide the other Party with copies of any material correspondence with FDA or other Regulatory Authorities in the United
States, the Major European Countries and Japan relating to Regulatory Approval of Licensed Product, and respond to all reasonable inquiries by the other Party with respect thereto. Each Party shall also provide the other Party in a timely manner
with meeting minutes from any material meetings with Regulatory Authorities in the United States, the Major European Countries and Japan concerning the Regulatory Approval of Licensed Product in the Field. 

(e) Each Party shall provide to the other Party a table report on an annual basis that contains the status of Regulatory Approvals for the
Licensed Product in the Territory. 
 (f) In the event that any Regulatory Authority (a) threatens or initiates any action to remove a
Licensed Product from the market in any country in the Territory or (b) requires a Party, its Affiliates, or its sublicensees to distribute a “Dear Doctor” letter or its equivalent regarding use of Licensed Product in the Territory,
such Party shall notify the other Party of such event within one (1) Business Day after such Party becomes aware of the action, threat, or requirement (as applicable). The Parties shall consult prior to initiating a recall or withdrawal of
Licensed Product in the U.S., Japan, or a Major European Country; provided, however, that the final decision as to whether to recall or withdraw a Licensed Product in the Territory shall be made by (i) Licensee in the Field in its sole
discretion, or (ii) Schering outside the Field in its sole discretion. A Party initiating a recall shall be responsible, at its sole expense, for conducting such recalls or taking such other necessary remedial action. 

(g) Schering’s obligations to provide assistance and support under this Section 4.1 shall not extend beyond Licensee’s initial
IND filing date with respect to the Licensed Product in the Field. 
 (h) Schering shall also provide copies of all safety reports with
respect to Licensed Product outside of the Field in the Territory. 
 4.2 Right of Reference. Schering grants to Licensee, the right
to reference its Regulatory Application(s) or Regulatory Approval(s) covering the Licensed Product outside the Field in the Territory only to the extent required for Licensee to Develop, Manufacture and obtain and maintain Regulatory Approvals for
the Licensed Product in the Field in the Territory; provided, however, that (a) such right of reference shall be used solely for purposes of this Agreement and (b) all information which is subject to the right of reference shall be treated
by Licensee as Proprietary Information of Schering in accordance with Article 9. Except with the prior written consent of Licensee, which shall not be unreasonably withheld, conditioned or delayed, Schering shall not withdraw any Regulatory
Application or Regulatory Approval that is subject to reference by Licensee hereunder. 
 4.3 Pharmacovigilance.  

 
 [ * ] = Certain confidential information contained in this document, marked by brackets,
is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 18 of 52 

 (a) After the Effective Date, Licensee shall be solely responsible for the collection, review,
assessment, tracking and regulatory submission of safety-related information with respect to adverse events (“AEs”) associated with Licensed Product developed and commercialized by the Licensee in the Field, in accordance with 21
CFR 312.32, 314.80 and comparable applicable law governing AEs outside of the United States. 
 (b) Within a reasonable period of time
following the Effective Date, Schering will provide Licensee with all AEs for Licensed Product to the extent not previously provided to Licensee. In addition to the foregoing, Schering shall transfer to Licensee in an agreed upon format, all
relevant information (sufficient for Licensee to comply with its obligations to regulatory authorities and Investigators) regarding AEs that have been observed during any clinical trials conducted with the Licensed Product prior to the Effective
Date. 
 (c) Within a reasonable period of time following receipt of all such information described in this Section 4.3, Licensee shall
assume responsibility for maintaining a safety database for the Licensed Product developed and commercialized by the Licensee consistent with industry practices. 

(d) During the Term of this Agreement, Schering shall notify Licensee of all information coming into its possession concerning AEs associated
with commercial or clinical uses, studies, investigations or tests with Licensed Products in the Territory, involving the Licensed Product. In addition, Licensee shall forward to Schering, completed AE case reports associated with commercial or
clinical uses, studies, investigations or tests with Licensed Products in the Field, within 5 business days for any death/fatal-life threatening assessed AEs or, within 10 business days for all other serious AEs, to assure Schering remains in
compliance with Investigator notifications outside the Field. Such AE information should be faxed to Schering at (US) 973-921-7422. If deemed necessary by both Parties, within a reasonable period of time following the Effective Date, the Parties can
begin to negotiate a pharmacovigilance agreement between the Parties to revise this mutual exchange of AE reports and safety information associated with the Licensed Product. Such pharmacovigilance agreement shall be implemented at a time sufficient
to permit compliance, and shall supersede this Section 4.3(d). 
 ARTICLE V - DILIGENCE 

5.1 Generally. Licensee shall use Commercially Reasonable Efforts to Develop the Licensed Product in the Field in accordance with the
Development Plan and to Commercialize the Licensed Product in the Field in the Territory. The activities of any Affiliate or sublicensee of Licensee will be treated as activities of Licensee in any determination whether Licensee has satisfied its
obligation with respect to this Article V. 
 5.2 Failure. Any failure by Licensee to comply with the obligations set forth in this
Article V shall be deemed to be a material breach for which Schering may exercise its termination rights under Section 12.4(b). 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 19 of 52 

 ARTICLE VI – MANUFACTURING 

6.1 Manufacturing Responsibility. With the exception of the supplies of Bulk Licensed Product to be supplied by Schering to Licensee
pursuant to Section 6.2, Licensee will be responsible for the Manufacture of Licensed Product for Development and Commercialization of Licensed Product by Licensee, its Affiliates, and its sublicensees in the Field in the Territory. Schering
shall, if requested by Licensee, reasonably cooperate in the transfer of any Manufacturing Know-How related to the Manufacture of the License Product in the Field and existing Third Party manufacturing agreements to Licensee for use pursuant to the
license granted in Section 2.1. 
 6.2 Transfer of Bulk License Product. Promptly following the Effective Date of this Agreement,
Schering shall transfer to Licensee free of charge (except reasonable costs of transfer as set forth below), in a mutually agreed manner, quantities of Bulk Licensed Product and related documentation (eg, batch records, process and release testing
results, protocols, stability data and location of stability specimens) that are reasonably sufficient for Licensee to complete the Proof of Concept Trial and as are further described in Schedule 6.2. 

6.3 Quality. 
 (a) Licensee
shall be solely responsible for the release of Bulk Licensed Product transferred by Schering to Licensee pursuant to Section 6.2 to any clinical trial sites. 

(b) Licensee will, within three (3) Business Days of receipt, notify Schering in writing of any complaints related to the manufacture of
the Bulk Licensed Product transferred by Schering to Licensee pursuant to section 6.2. 
 (c) Licensee will, within one (1) Business
Day, notify Schering of any recalls or stock recovery of an Bulk Licensed Product due to the quality of the Bulk Licensed Product. 
 6.4
Transfer of Manufacturing Technology. 
 (a) Upon request by Licensee, Schering shall transfer or cause to be transferred to Licensee,
or a Third Party manufacturer designated by Licensee reasonably acceptable to Schering, all Schering Know-How that is reasonably necessary to enable Licensee or such Third Party manufacturer (as appropriate) to replicate the process employed by or
on behalf of Schering to Manufacture Licensed Compound and, if applicable, the Licensed Product, in the Field to the extent not previously transferred. 

(b) Licensee and/or its Third Party manufacturer shall use any information transferred pursuant to Section 6.3(a) in accordance with the
license granted in Section 2.1 and solely for the purpose of Manufacturing the Licensed Compound and Licensed Product under this Agreement and for no other purpose. 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 20 of 52 

 (c) At the request of Licensee, during the six (6) month period following Licensee’s
request under Section 6.3(a), Schering will make employees and consultants of it and its Affiliates available to Licensee or Licensee’s Third Party manufacturer for consultation, for a reasonable duration of time and at mutually agreed
locations, as reasonably required by the Licensee or its Third Party manufacturer to ensure an orderly transition of Schering’s manufacturing technology and operations. The scope of Schering’s efforts for such consultation shall be defined
in a written manufacturing transition plan to be agreed upon by the Parties promptly after Licensee’s request under Section 6.3(a). Licensee shall reimburse Schering for any FTE Costs and for all related reasonable out-of-pocket expenses,
including reasonable travel expenses. Schering shall invoice Licensee monthly for such support. 
 (d) Schering’s obligations to provide
assistance and support under this Section 6.2 shall not extend beyond six (6) months after Licensee’s request under Section 6.3(a). 

ARTICLE VII - PAYMENTS; ROYALTIES AND REPORTS 

7.1 Equity. Licensee shall contemporaneously issue equity in Licensee to Schering in the amount of Five Hundred Thousand Dollars
($500,000) pursuant to Share Purchase Agreement and related agreements dated as of even date herewith. 
 7.2 Development Milestones.

 (a) First Indication. Licensee shall make each of the following one-time, non-refundable, non-creditable milestone payments to
Schering upon first occurrence of the corresponding milestone event with respect to the Development of Licensed Product for the First Indication in the Field. 
  

			
	 Event
	  	 Payment

	[ * ]	  	[ * ]
	[ * ]	  	[ * ]
	[ * ]	  	[ * ]
	[ * ]	  	[ * ]
	[ * ]	  	[ * ]

 (b) Additional Indications. Licensee shall make each of the following one-time, non-refundable,
non-creditable milestone payments to Schering upon first occurrence of the corresponding milestone events with respect to the Development of a Licensed Product for up to [ * ] Additional Indications. 

 

			
	 Event
	  	 Payment

	[ * ]	  	[ * ]

  
 [ *
] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 21 of 52 

			
	[ * ]	  	[ * ]
	[ * ]	  	[ * ]
	[ * ]	  	[ * ]
	[ * ]	  	[ * ]

 (c) Payment of Milestones. Licensee shall notify Schering in writing within [ * ] after the achievement
of each such milestone event giving rise to a payment obligation under this Section and Licensee shall pay Schering the indicated amount no later than [ * ] after notification to Schering of achievement of the specified milestone. For clarity, each
of the milestones under this Section shall be payable to Schering regardless of whether Licensee, its Affiliates, or sublicensees achieves them. Under no circumstances will Licensee owe more than an aggregate total of Twenty-Seven Million Dollars
($27,000,000) pursuant to this Section 7.2. 
 7.3 Royalties. 

(a) Royalty Rates. Subject to the terms and conditions of this Agreement, Licensee shall pay to Schering during the Royalty Term
royalties on worldwide annual Net Sales of Licensed Product (for all indications and without regard to formulation) on a country-by-country basis in an amount equal to the following: 

 

			
	 Calendar Year Net Sales
	  	 Royalty Rate

	First [ * ]	  	[ * ]
		
	Portion above [ * ] and up to and including [ * ]	  	[ * ]
		
	Portion above [ * ] and up to and including [ * ]	  	[ * ]
		
	Portion above [ * ]	  	[ * ]

 (b) Term of Royalty Obligation. Royalties on the Licensed Product shall commence upon the First
Commercial Sale of a Licensed Product in a particular country in the Territory and will continue on a product-by-product, country-by-country basis until the later of (i) the expiration of the last to expire Valid Claim covering a Licensed
Product in such country or (ii) the [ * ] anniversary of the date of the First Commercial Sale of the Licensed Product in such country (“Royalty Term”). For clarity, during the Royal Term, the royalty payments pursuant to this
Section 7.3 shall be payable regardless of whether Licensee, its Affiliate, or its sublicensee is selling the Licensed Product. 
 7.4
Reports; Payment of Royalty; Payment Exchange Rate and Currency Conversions. 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 22 of 52 

 (a) Royalties Paid Quarterly. Within [ * ] following the end of each Calendar Quarter,
following the First Commercial Sale of a Licensed Product, Licensee shall furnish to Schering a written report for the Calendar Quarter showing the Net Sales of Licensed Product sold by Licensee, its Affiliates and its sublicensees in the Territory
during such Calendar Quarter and the royalties payable under this Agreement for such Calendar Quarter. Such written report shall include the gross sales of Licensed Product on a country-by-country basis, an itemized calculation of any deductions
taken from such gross sales to arrive at Net Sales for the applicable Calendar Quarter and the calculation of the amount of royalty payment due on such Net Sales. Simultaneously with the submission of the written report, Licensee shall pay to
Schering, for the account of Licensee or the applicable Affiliate or sublicensee, as the case may be, a sum equal to the aggregate royalty due for such Calendar Quarter calculated in accordance with this Agreement. 

(b) Method of Payment. All payments to be made by Licensee to Schering under this Agreement shall be paid by bank wire transfer in
immediately available funds to such bank account as is designated in writing by Schering from time to time. Royalty payments shall be made in United States dollars to the extent that free conversion to United States dollars is permitted. The rate of
exchange to be used in any such conversion from the currency in the country where such Net Sales are made shall be the rate of exchange used by Licensee for reporting such sales for United States financial statement purposes. If, due to restrictions
or prohibitions imposed by national or international authority, payments cannot be made as aforesaid, the Parties shall consult with a view to finding a prompt and acceptable solution, and Licensee will make such payments in any manner as Schering
may lawfully direct; provided that Licensee shall not be obligated to incur any additional out-of-pocket expenses in connection with such payments. Notwithstanding the foregoing, if royalties in any country cannot be remitted to Schering for any
reason within [ * ] after the end of the Calendar Quarter during which they are earned, then Licensee shall be obligated to deposit the royalties in a bank account in such country in the name of Schering. 

7.5 Maintenance of Records; Audits. 

(a) Record Keeping by Licensee. Licensee and its Affiliates shall keep complete and accurate records in sufficient detail to enable the
royalties payable hereunder to be determined. Upon [ * ] prior written notice from Schering, Licensee shall permit an independent certified public accounting firm of nationally recognized standing selected by Schering and reasonably acceptable to
Licensee, at Schering’s expense, to have access during normal business hours to examine the pertinent books and records of Licensee as may be reasonably necessary to verify the accuracy of the royalty reports hereunder. The examination shall be
limited to the pertinent books and records for any year ending not more than [ * ] prior to the date of such request. An examination under this Section 7.5(a) shall not occur more than [ * ] in any Calendar Year. Licensee may designate
competitively sensitive information which such auditor may not disclose to Schering, provided, however, that such designation shall not encompass the auditor’s conclusions. The accounting firm shall disclose to Schering only
whether the royalty reports are correct or incorrect and the specific details concerning any discrepancies. No other information shall be provided to Schering. All such accounting firms shall sign a confidentiality agreement 

 
 [ * ] = Certain confidential information contained in this document, marked by brackets,
is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 23 of 52 

 
(in form and substance reasonably acceptable to Licensee) as to any of Licensee’s or its Affiliate’s or sublicensee’s confidential information which such accounting firms are
provided, or to which they have access, while conducting any audit pursuant to this Section 7.5(a). 
 (b)
Underpayments/Overpayments. If such accounting firm correctly concludes that additional royalties were owed during such period, Licensee shall pay such additional royalties within [ * ] of the date Schering delivers to Licensee such
accounting firm’s written report so correctly concluding. If such underpayment exceeds [ * ] of the sums correctly due Schering then the fees charged by such accounting firm for the work associated with the underpayment audit shall be paid by
Licensee. Any overpayments by Licensee will be credited against future royalty obligations or refunded to Licensee within [ * ] following request by Licensee for the same, at Licensee’s option. 

(c) Record Keeping by Sublicensees. Licensee shall include in each Sublicense Agreement entered into pursuant to this Agreement a
provision requiring the sublicensee to make reports to Licensee and to keep and maintain records of sales made pursuant to such sublicense and provide copies of such records to Licensee upon reasonable request in order for Schering’s
independent accountant to review such records to the same extent required of Licensee under this Agreement. 
 (d) Confidentiality.
Schering shall treat all financial information subject to review under this Section 7.5, or under any Sublicense Agreement, in accordance with the confidentiality provisions of Article IX of this Agreement, and shall cause its accounting firm
to enter into an acceptable confidentiality agreement with Licensee obligating it to retain all such financial information in confidence pursuant to such confidentiality agreement. 

(e) Late Payments. Any amount owed by Licensee to Schering under this Agreement that is not paid within the applicable time period set
forth herein shall accrue interest at the lower of the rate of the one (1) month London Inter-Bank Offering Rate (“LIBOR”) plus [ * ] as set by the British Bankers Association as of the due date, or the maximum extent allowable
by applicable law. 
 ARTICLE VIII – INTELLECTUAL PROPERTY 

8.1 Ownership of Intellectual Property. The Parties acknowledge and agree that Schering is and shall remain the owner of Compound
Patent Rights and Schering Know-How. 
 8.2 Ownership of Program IP. All rights title and interest in or to any and all Program IP
shall be determined in accordance with the following terms and conditions: 
 (a) Schering shall own all Program IP that is conceived solely
by one or more employees, agents or consultants of Schering, its Affiliates, or Schering’s subcontractors. 
 (b) Licensee shall own all
Program IP that is conceived solely by one or more employees, agents or consultants of Licensee, its Affiliates, its subcontractors or its sublicensees. 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 24 of 52 

 (c) Licensee and Schering shall jointly own all Program IP that is conceived by one or more
employees, agents or consultants of Schering or its Affiliates, together with one or more employees, agents or consultants of Licensee, its Affiliates, its subcontractors or its sublicensees. 

(d) Licensee hereby grants to Schering an exclusive, sublicensable, royalty free license, under all Program IP to which Schering does not have
an interest (either solely or jointly) solely to the extent necessary to Develop, make, have made, use, import, export, Commercialize, sell, offer for sale, and market the Licensed Product outside the Field in the Territory. 

(e) Schering hereby grants to Licensee a non-exclusive, sublicensable (subject to the obligations and restrictions in Section 2.5),
royalty free license, under all Program IP to which Licensee does not have an interest (either solely or jointly) solely to the extent necessary to Develop, make, have made, use, import, export, Commercialize, sell, offer for sale, and market the
Licensed Product in the Field in the Territory. 
 (f) In the event of a dispute regarding inventorship, the Parties shall establish a
procedure to resolve such dispute, which may include engaging independent Third Party patent attorneys jointly selected by the Parties to resolve such dispute. The Parties acknowledge that the ownership rights set out in this Section 8.2 are
subject to the terms and conditions of this Agreement (including the licenses granted by Schering to Licensee), and subject thereto, each Party shall be free to use and exploit (which shall include the right to grant licenses under) any jointly
owned Program IP, without any duty of accounting to the other Party. 
 8.3 Prosecution and Maintenance of Patents. Schering shall be
solely responsible for the prosecution and maintenance in the Territory, on its own or through outside counsel, of the Compound Patent Rights and Program Patents solely owned or Controlled by Schering (“Schering Prosecution
Patents”). Licensee shall be solely responsible for the prosecution and maintenance in the Territory, on its own or through outside counsel, of the Program Patent Rights solely owned or Controlled by Licensee or jointly owned by Schering
and Licensee (“Licensee Prosecution Patents”). In connection with the Schering Prosecution Patents and the Licensee Prosecution Patents, each Party shall keep the other Party reasonably advised of the prosecuting Party’s patent
prosecution and maintenance and upon the written reasonable request of the other Party, will provide advance copies of any substantive papers related to the prosecution and maintenance of such patent filings. 

8.4 Option of Licensee to Prosecute and Maintain Patents. Schering shall give notice to Licensee of any desire to cease prosecution
and/or maintenance of the Schering Prosecution Patents and, in such case, shall permit Licensee, at Licensee’s sole discretion, to continue the prosecution or maintenance at its own expense. If Licensee elects to continue the prosecution or
maintenance, Schering shall execute such documents and perform such acts, at Licensee’s expense, as may be reasonably necessary to effect an assignment of such Schering Prosecution Patents to Licensee. Any such assignment shall be completed in
a timely manner to allow Licensee to continue such prosecution or maintenance. Any patents or patent applications so 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 25 of 52 

 
assigned shall no longer be considered Compound Patent Rights or Program Patents, as applicable. 

8.5 Enforcement. In the event that either Licensee or Schering becomes aware of any alleged or threatened infringement in a country in
the Field in the Territory of any issued patent within the Schering Prosecution Patents, it will notify the other Party in writing to that effect. [ * ] shall have three (3) months from the date of said notice to obtain a discontinuance of such
infringement or bring suit against the Third Party infringer if such infringement relates to the use of the Licensed Product in the Field. If [ * ] fails to proceed within the specified 3-month period of time, then [ * ] shall have the right to
obtain a discontinuance of such infringement or bring suit against the Third Party infringer only in the event that: (i) [ * ] a discontinuance of such infringement or [ * ] suit against the Third Party infringer [ * ] or (ii) [ * ] a
discontinuance of such infringement or [ * ] suit against the Third Party infringer [ * ] and, in such discontinuance or suit, if [ * ], [ * ] discontinuance or suit. In the event that [ * ] is able to exercise its “step-in” rights to
enforce Schering Prosecution Patents under this Section 8.5, [ * ] shall reimburse [ * ] costs and expenses for cooperation following the exercise of [ * ] step-in rights and all costs of enforcement going forward (provided, however, that if [
* ] later joins the enforcement action, then [ * ] shall be obligated for [ * ] costs and expenses after joining). The Party not initiating an action hereunder shall be notified prior to commencement of the trial, suit or action brought by the other
Party and may join any such suit or action. In the event a Party joins an action hereunder, it shall pay one-half of the costs of such suit or action. In the event that a Party has joined in the action and shared in the costs thereof as set forth
above, no settlement, consent judgment or other voluntary final disposition of the suit may be entered into without the consent of joining Party, which consent shall not be unreasonably withheld. In the event that a Party has not joined the suit or
action, such Party will in any event reasonably cooperate with the acting Party in any such suit or action and shall have the right to consult with such acting Party and be represented by its own counsel at its own expense. Any recovery or damages
derived from a suit which a Party has joined and shared costs shall be used first to reimburse each of the Parties for its documented out-of-pocket legal expenses relating to the suit, with any remaining amounts to be shared [ * ], and [ * ]. Any
recovery or damages derived from a suit which a Party has not joined shall be [ * ]. Schering shall incur no liability to Licensee as a consequence of litigation or any unfavorable decision resulting therefrom, including any decision holding any of
the Schering Prosecution Patents invalid or unenforceable. Licensee shall incur no liability to Schering as a consequence of litigation or any unfavorable decision resulting therefrom brought pursuant to this Section 8.5. 

8.6 Infringement and Third Party Licenses. 

(a) Course of Action. In the event that Licensee’s, its Affiliates’ or its sublicensees’ making, having made, importing,
exporting, using, manufacturing, having manufactured Licensed Compound or Licensed Product or distributing, marketing, promoting, offering for sale or selling Licensed Product infringes, will infringe or is alleged by a Third Party to infringe, a
claim of a patent that specifically covers the Licensed Compound, Licensed Product or its Manufacture, the Party becoming aware of same shall promptly notify the other. The Parties shall thereafter attempt to agree upon a course of action which may
include: (i) modification of 
  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 26 of 52 

 
the Licensed Product or Licensed Compound or its use and Manufacture so as to be non-infringing; or (ii) obtaining a license or assignment from said Third Party. 

(b) Licensee Right to Negotiate. In the event the Parties cannot agree on modifying the Licensed Product or Licensed Compound pursuant
to Section 8.6(a), Licensee shall have the first right, but not the obligation, to negotiate with said Third Party for a suitable license or assignment. In the event that such negotiation results in a definitive agreement and the claimed
infringement is for the making, using or selling of the Licensed Compound, then any lump sum or royalty payment made thereunder shall be paid by Licensee and Licensee shall have the right to offset such amount in accordance with Section 2.6. If
Licensee fails to enter into a license or assignment pursuant to this Section 8.6(b), then following written notice from Licensee of such failure, Schering shall have the right to negotiate with said Third Party for a suitable license or
assignment. 
 8.7 Third Party Infringement Suit. In the event that a Third Party sues Licensee alleging that Licensee’s, its
Affiliates’ or its sublicensees’ making, having made, importing, exporting, using, manufacturing, having manufactured Licensed Compound or Licensed Product or distributing, marketing, promoting, offering for sale or selling Licensed
Product infringes or will infringe a claim of a patent that specifically covers the Licensed Compound, Licensed Product or its manufacture, then Licensee may elect to defend such suit and, during the period in which such suit is pending,
notwithstanding Licensee’s obligation to indemnify Schering under Section 11.1 herein, Licensee shall have the right to apply up to [ * ] of the royalties due Schering on sales of the allegedly infringing Licensed Product against its
reasonable out-of-pocket litigation expenses. 
 8.8 Abandonment. Schering shall promptly give notice to Licensee of the grant lapse,
revocation, surrender, invalidation or abandonment of any Schering Prosecution Patents licensed to Licensee. 
 8.9 Patent Term
Extension. The Party obtaining first Regulatory Approval for the Licensed Product in the United States shall be entitled to seek patent term extension in connection with the Compound Patent Rights. In the event that Licensee obtains such first
Regulatory Approval, Schering agrees to cooperate with Licensee in the event that Licensee seeks patent term extension for the Compound Patent Rights; provided that Licensee reimburses all Schering’s costs and expenses in connection therewith,
including Schering’s internal costs. 
 ARTICLE IX - CONFIDENTIALITY AND PUBLICATION 

9.1 Confidentiality. 
 (a)
Nondisclosure Obligation. Each of Schering and Licensee shall use any Proprietary Information received by it from the other Party only in accordance with this Agreement and shall not disclose, except as expressly provided herein, to any Third
Party any such Proprietary Information without the prior written consent of the other Party. The foregoing 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 27 of 52 

 
obligations shall survive the expiration or termination of this Agreement for a period of [ * ]. These obligations shall not apply to Proprietary Information that: 

(i) is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the disclosing Party, as documented by
the receiving Party’s competent written records; 
 (ii) is at the time of disclosure, or thereafter becomes, published or otherwise
part of the public domain without breach of this Agreement by the receiving Party; 
 (iii) is subsequently lawfully disclosed to the
receiving Party by a Third Party who has the right to make such disclosure, as documented by the receiving Party’s competent written records; 

(iv) is independently developed by the receiving Party or its Affiliates and without the aid, use or application of any of the disclosing
Party’s Proprietary Information, and such independent development can be documented by the receiving Party’s competent written records; 

(v) is disclosed to any institutional review board of any entity conducting clinical trials with Licensed Product or to any governmental or
other regulatory agencies in order to obtain patents or to gain approval to conduct clinical trials or to market Licensed Product, provided that such disclosure may be made only to the extent reasonably necessary to obtain such patents or
authorizations. 
 (b) Permitted Disclosures. 

(i) Notwithstanding anything to the contrary herein, the receiving Party may disclose the Proprietary Information of the disclosing Party
solely to the extent such disclosure is required by applicable law, regulation, rule, act or order of any Governmental Authority or agency to be disclosed, provided that notice is promptly delivered to the disclosing Party in order to provide an
opportunity to seek a protective order or other similar order with respect to such Proprietary Information and thereafter the receiving Party discloses to the requesting entity only the minimum information required to be disclosed in order to comply
with the request, whether or not a protective order or other similar order is obtained by the disclosing Party. 
 (ii) Each of the Parties
agrees not to disclose the terms and conditions of this Agreement to any Third Party and shall not make any public announcement or issue any press release in relation thereto, or otherwise publicize the existence or contents of this Agreement
without the prior written approval by the other Party of the form, content and timing of such announcement, press release or other public disclosure. The foregoing provisions of this Section 9.1(b)(ii) notwithstanding, each Party shall have the
right to disclose information related to the existence and/or terms and conditions of this Agreement as follows: (i) to the extent necessary (as reasonably determined by its legal counsel) to be disclosed in order to comply with the rules and
regulations of the United States Securities and Exchange Commission (or another similar 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 28 of 52 

 
securities exchange authority in Territory); (ii) to existing or potential acquirers or merger candidates, potential sublicensees or collaborators (to the extent contemplated hereunder), or
to Affiliates, each of whom prior to disclosure must be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 9; (iii) to investment bankers, existing or potential investors, venture
capital firms or other financial institutions or investors for purposes of obtaining financing, if such recipients are bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 9; or
(iv) in response to a valid order of a court or other governmental body. In each such event, the Party so required to disclose shall notify the other Party in advance of any such disclosure, shall provide the other Party with a reasonable
opportunity to review and comment on the form and content of any such disclosure, shall disclose only the minimum information required in order to comply with such disclosure requirements, and shall use commercially reasonable efforts to obtain
confidential treatment (to the fullest extent available). 
 9.2 Return of Confidential Information. The receiving Party will return
all documents, and copies thereof, including those in the possession of the receiving Party’s Agents pursuant to Section 9.1(b), containing the disclosing Party’s Proprietary Information at any time upon the written request of the
disclosing Party. However, the receiving Party may retain one (1) copy of such documents in a secure location solely for the purposes of (a) determining its obligations hereunder, (b) complying with any applicable regulatory
requirements, or (c) defending against any product liability claim. 
 9.3 Breach of Confidentiality. The Parties agree that the
disclosure of the disclosing Party’s Proprietary Information in violation of this Agreement may cause the disclosing Party irreparable harm and that any breach or threatened breach of this Agreement by the receiving Party entitles disclosing
Party to seek injunctive relief, in addition to any other legal or equitable remedies available to it, in any court of competent jurisdiction. 

9.4 No Publicity. A Party may not use the name of the other Party in any publicity or advertising and may not issue a press release or
otherwise publicize or disclose any information related to the existence of this Agreement or the terms or conditions herein, except (a) on the advice of its counsel as required by law (e.g., any Securities and Exchange Commission filings and
disclosures) and provided the Party who will be disclosing such information has consulted with the other Party to the extent feasible prior to such disclosure with respect to the substance of the disclosure; or (b) as consented to in advance by
the other Party in writing. The Parties shall agree on a form of initial press release that may be used by either Party on an ongoing basis to describe this Agreement. Each Party shall use good faith efforts to provide the other Party with
reasonable advance written notice of any press release or other public disclosure of the results of any of its work on Licensed Products during the Term, provided that a Party’s failure to do so shall not constitute a material breach of this
Agreement. 
 9.5 Publication. To the extent that any proposed publication or public presentation (including without limitation any
abstracts or manuscripts for publication, slides and texts of oral or other public presentations, and texts of any transmission through any electronic media (e.g., any computer access system such as the Internet, World Wide Web etc.) collectively or

  
 [ * ] = Certain confidential information contained in this document, marked by
brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 29 of 52 

 
individually a “Public Presentation”) to be made by a Party or its Affiliates may contain Proprietary Information of the other Party, the Party intending to make such publication
or presentation shall provide to such other Party an advance copy of any such proposed publication or presentation prior to its submission or dissemination to any Third Party. The Party receiving such proposed publication or presentation shall have
a period of at least [ * ] to review and recommend any changes it reasonably believes are necessary to protect its Proprietary Information. The Party intending to make such publication or presentation shall remove any Proprietary Information of the
other Party therefrom; other changes recommended by such other Party shall not be unreasonably refused. In addition, if such publication could in the reviewing Party’s reasonable judgment be expected to have a material adverse effect on the
commercial value of the reviewing Party’s Proprietary Information (or in the case of a proposed publication by Schering, on the Licensed Product in the Field), then the reviewing Party shall have the right to delay or prevent such publication
as proposed by providing written notice to that effect during such [ * ] period. In the case where such publication may disclose any Program IP, any such delay shall be sufficiently long to permit the timely preparation and filing of a patent
application(s) (or application(s) for other appropriate forms of protection) on the Proprietary Information involved. 
 ARTICLE X -
REPRESENTATIONS AND WARRANTIES 
 10.1 Representations and Warranties of Each Party. Each of Schering and Licensee hereby
represents, warrants and covenants to the other Party hereto as follows: 
 (a) it is a corporation duly organized and validly existing under
the laws of the state or other jurisdiction of its incorporation; 
 (b) the execution, delivery and performance of this Agreement by such
Party has been duly authorized by all requisite corporate action; 
 (c) it has the power and authority to execute and deliver this Agreement
and to perform its obligations hereunder; 
 (d) the execution, delivery and performance by such Party of this Agreement and its compliance
with the terms and provisions herein does not and will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) a loan agreement, guaranty, financing agreement, agreement affecting a
product or other agreement or instrument binding or affecting it or its property; (ii) the provisions of its corporate charter or other operative documents or bylaws; or (iii) any order, writ, injunction or decree of any court or
governmental authority entered against it or by which any of its property is bound; 
 (e) except for the governmental and Regulatory
Approvals required to market the Licensed Product in the Territory, the execution, delivery and performance of this Agreement by such Party does not require the consent, approval or authorization of, or notice, declaration, filing or registration
with, any governmental or Regulatory Authority and the execution, delivery or 
  
 [ * ]
= Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 30 of 52 

 
performance of this Agreement will not violate any law, rule or regulation applicable to such Party; 

(f) this Agreement has been duly authorized, executed and delivered and constitutes such Party’s legal, valid and binding obligation
enforceable against it in accordance with its terms subject, as to enforcement, to bankruptcy, insolvency, reorganization and other laws of general applicability relating to or affecting creditors’ rights and to the availability of particular
remedies under general equity principles; and 
 (g) it shall comply with all applicable material laws and regulations relating to its
activities under this Agreement. 
 10.2 Schering’s Representations. Schering hereby represents, warrants and covenants to
Licensee as follows: 
 (a) to the best of Schering’s knowledge, as of the Effective Date the Compound Patent Rights and Schering
Know-How in the Field are subsisting and are not invalid or unenforceable, in whole or in part; 
 (b) as of the Effective Date, it has the
full right, power and authority to grant all of the right, title and interest in the license granted under Article II herein; 
 (c) as of
the Effective Date, it has not assigned, transferred, conveyed or otherwise encumbered, and during the Term of this Agreement will not assign, transfer, convey or otherwise encumber, its right, title and interest in the Compound Patent Rights or
Schering Know-How in the Field except in accordance with this Agreement; 
 (d) to the best of Schering’s knowledge, as of the Effective
Date, it is the sole and exclusive owner of the Compound Patent Rights and Schering Know-How in the Field, all of which is free and clear of any liens, charges and encumbrances, and no other person, corporate or other private entity, or governmental
entity or subdivision thereof, has or shall have any claim of ownership with respect to the Compound Patent Rights and Schering Know-How in the Field, whatsoever; 

(e) to the best of Schering’s knowledge, as of the Effective Date, the Manufacture, use or Commercialization of Licensed Compound and
Licensed Product in the Field do not infringe any valid and enforceable patent rights owned or possessed by any Third Party; 
 (f) as of the
Effective Date there are no claims, judgments or settlements against or owed by Schering or pending or threatened claims or litigation against Schering relating to Compound Patent Rights and Schering Know-How in the Field; 

(g) to the best of Schering’s knowledge as of the Effective Date, there are no commitments under or activities ongoing under any
agreements with any third parties for the 
  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 31 of 52 

 
Manufacture of Licensed Product for Development and Commercialization of Licensed Product; and 

(h) as of the Effective Date, it is in compliance in all material respects with any agreements with Third Parties concerning the Compound
Patent Rights and Schering Know-How in the Field and during the Term of this Agreement (i) it will use Commercially Reasonable Efforts not to diminish the rights under the Compound Patent Rights, Schering Know-How and Program Know-How owned or
Controlled by Schering in the Field granted to Licensee hereunder, including without limitation, by not committing or permitting any actions or omissions which would cause the breach of any such agreements between itself and Third Parties which
provide for intellectual property rights applicable to the Manufacture or use of Licensed Compound or the Development, distribution, marketing, promotion or sale of Licensed Product in the Field, and (ii) it will provide Licensee promptly with
notice of any such alleged breach. 
 10.3 Licensee’s Representations. Licensee hereby represents, warrants and covenants to
Schering as follows: 
 (a) during the Term of this Agreement it will not use in any capacity, in connection with performing its obligations
under this Agreement, any individual who has been debarred pursuant to the United States Food, Drug and Cosmetic Act; 
 (b) it has or will
have the capacity and resources to Develop and Commercialize Licensed Product and to Manufacture Licensed Compound as such obligations come due under this Agreement. 

10.4 No Inconsistent Agreements. Neither Party has in effect, and after the Effective Date neither Party shall enter into, any oral or
written agreement or arrangement that would be inconsistent with its obligations under this Agreement. 
 10.5 Representation by Legal
Counsel. Each Party hereto represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting of this Agreement. In interpreting and applying the terms and
provisions of this Agreement, the Parties agree that no presumption shall exist or be implied against the Party which drafted such terms and provisions. 

10.6 Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 10, THE LICENSED COMPOUND, LICENSED PRODUCT, COMPOUND PATENT RIGHTS AND
SCHERING KNOW-HOW ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE
USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY. 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 32 of 52 

 10.7 No Warranty. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY
HERETO MAKES ANY REPRESENTATION AND EXTENDS NO WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED. IN PARTICULAR, BUT WITHOUT LIMITATION, SCHERING MAKES NO REPRESENTATION AND EXTENDS NO WARRANTY CONCERNING WHETHER THE DESIGNATED COMPOUND OR A
DESIGNATED PRODUCT IS FIT FOR ANY PARTICULAR PURPOSE OR SAFE FOR HUMAN CONSUMPTION. 
 ARTICLE XI - INDEMNIFICATION AND LIMITATION ON
LIABILITY 
 11.1 Indemnification by Licensee. Licensee shall indemnify, defend and hold harmless Schering and its Affiliates,
and each of its and their respective employees, officers, directors and agents (each, a “Schering Indemnified Party”) from and against any and all Third Party liability, loss, damage, cost, and expense (including reasonable
attorneys’ fees), subject to the limitations in Section 11.5 (collectively, a “Liability”) which a Schering Indemnified Party may incur, suffer or be required to pay resulting from or arising out of (a) the
Development, Manufacture, promotion, distribution, use, marketing, sale or other disposition of the Licensed Product in the Field by Licensee, its Affiliates or sublicensees, and (b) any material breach by Licensee of any of its
representations, warranties and covenants contained in herein. Notwithstanding the foregoing, Licensee shall have no obligation under this Agreement to indemnify, defend or hold harmless any Schering Indemnified Party with respect to claims,
demands, costs or judgments which result from the negligence or willful misconduct of Schering, its Affiliates, or any of their respective employees, officers, directors or agents, or Schering’s breach of its obligations under this Agreement.

 11.2 Indemnification by Schering. Schering shall indemnify, defend and hold harmless Licensee and its Affiliates, and each of its
and their respective employees, officers, directors and agents (each, a “Licensee Indemnified Party”) from and against any Third Party Liability which a Licensee Indemnified Party may incur, suffer or be required to pay resulting
from or arising out of (i) the Development, Manufacture, promotion, distribution, use, marketing, sale or other disposition of the Licensed Product outside the Field by Schering, it Affiliates or sublicensees, and (ii) any material breach
by Schering of any of its representations, warranties and covenants contained herein. Notwithstanding the foregoing, Schering shall have no obligation under this Agreement to indemnify, defend or hold harmless any Licensee Indemnified Party with
respect to claims, demands, costs or judgments which result from the negligence or willful misconduct of Licensee, its Affiliates, or any of their respective employees, officers, directors or agents, or Licensee’s breach of its obligations
under this Agreement. 
 11.3 Conditions to Indemnification. The obligations of the indemnifying Party under Sections 11.1 and 11.2
are conditioned upon the delivery of written notice to the indemnifying Party of any potential Liability promptly after the indemnified Party becomes aware of such potential Liability. The indemnifying Party shall have the right to assume the
defense of any suit or claim related to the Liability if it has assumed responsibility for the suit or claim in writing; however, if in the reasonable judgment of the indemnified Party, such suit or claim involves an issue or matter which could have
a materially adverse effect on the business operations or assets 
  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 33 of 52 

 
of the indemnified Party, the indemnified Party may retain control of the defense or settlement thereof by providing written notice of such effect to the indemnifying Party, but in no event shall
such action or notice be construed as a waiver of any indemnification rights that the indemnified Party may have at law or in equity. If the indemnifying Party defends the suit or claim, the indemnified Party may participate in (but not control) the
defense thereof at its sole cost and expense. The foregoing notwithstanding, the Parties acknowledge and agree that failure of the indemnified Party to promptly notify the indemnifying Party of a potential Liability shall not constitute a waiver of,
or result in the loss of, such Party’s right to indemnification under Section 11.1 or 11.2, as appropriate, except to the extent that the indemnifying Party’s rights, and/or its ability to defend against such Liability, are materially
prejudiced by such failure to notify. 
 11.4 Settlements. Neither Party may settle a claim or action related to a Liability without
the consent of the other Party, which consent shall not be unreasonably withheld, if such settlement would impose any monetary obligation on the other Party or require the other Party to submit to an injunction or otherwise limit the other
Party’s rights under this Agreement. Any payment made by a Party to settle any such claim or action shall be at its own cost and expense. 

11.5 Limitation of Liability. With respect to any claim by one Party against the other arising out of the performance or failure of
performance of the other Party under this Agreement, the Parties expressly agree that the liability of such Party to the other Party for such breach shall be limited under this Agreement or otherwise at law or equity to direct damages only and in no
event shall a Party be liable for punitive, exemplary or consequential damages, except to the extent the liability of such Party relates to its indemnification obligations of the other Party pursuant to this Article XI or a breach of the obligations
of confidentiality and non-use set forth in Article IX. 
 11.6 Insurance. Each Party acknowledges and agrees that during the Term of
this Agreement it shall maintain adequate insurance and/or a self-insurance program for liability insurance, including products liability and contractual liability insurance, to cover such Party’s obligations under this Agreement. In the case
of Licensee, it will maintain a minimum of [ * ] of coverage for such insurance. Each Party shall provide the other Party with evidence of such insurance and/or self-insurance program, upon request. 

ARTICLE XII - TERM AND TERMINATION 

12.1 HSR Act. To the extent required by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR
Act”), each Party will (i) file or cause to be filed, as promptly as practicable after the date hereof, with the United States Federal Trade Commission (“FTC”) and the United States Department of Justice
(“DOJ”), all reports and other documents required to be filed by such Party under the HSR Act concerning the transactions contemplated hereby and (ii) promptly comply with or cause to be complied with any requests by the FTC or
DOJ for additional information concerning such transactions, in each case so that the waiting period applicable to this Agreement and the transactions contemplated hereby under the HSR Act will expire as soon as practicable after the date hereof.
Each Party agrees to request, and to cooperate with the other Party in requesting, early termination of any applicable waiting 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 34 of 52 

 
period under the HSR Act. Each Party shall be responsible for its own costs, expenses, and filing fees in connection with the filings. This Agreement is effective on the earlier of: (i) the
date after which the waiting period pursuant to the HSR Act has expired, (ii) the date on which the transaction contemplated in this Agreement has been approved by the FTC and DOJ, and (iii) if the Parties agree that no filing is required
under the HSR Act, the date first written above (“Effective Date”). 
 12.2 Term and Expiration. This Agreement shall be
effective as of the Effective Date and unless terminated earlier by mutual written agreement of the Parties or pursuant to Sections 12.3 or 12.4 below, the Term of this Agreement shall continue in effect on a country-by-country and
product-by-product basis until the expiration of Licensee’s obligation to pay royalties under Article VII herein (the “Term”). Upon expiration of this Agreement in its entirety, Licensee’s license pursuant to
Section 2.1 shall become a fully paid-up, non-exclusive, perpetual license. 
 12.3 Termination by Licensee. 

(a) Licensee’s Right to Terminate. Notwithstanding anything contained herein to the contrary, Licensee shall have the unilateral
right to terminate this Agreement in its entirety with or without cause, at any time by giving [ * ] advance written notice to Schering. In the event of such termination, the rights and obligations hereunder shall terminate; provided, however, that
any payment obligations due and owing as of the termination date shall continue. For clarity, milestones achieved prior to the date of notice shall continue to be payable, but no additional milestone payments shall apply for activities conducted
during the [ * ] notice period. 
 (b) Effect of Termination. Notwithstanding anything contained herein to the contrary, following any
termination of this Agreement in its entirety under Section 12.3(a), all rights and licenses granted to Licensee hereunder shall revert back to Schering pursuant to Section 12.6. 

12.4 Termination for Cause. 

(a) Termination for Cause. This Agreement may be terminated, in its entirety by written notice by either Party at any time during the
Term of this Agreement: 
 (i) if the other Party is in breach of its material obligations hereunder (except with respect to a breach by
Licensee of its obligations under Section 5.2, for which termination pursuant to Section 12.4(b) shall be Schering’s sole and exclusive remedy) and has not cured such breach within [ * ] after receipt of written notice requesting cure
of the breach, or in the event that the breach cannot be reasonably cured within such [ * ] period, has not initiated actions reasonably expected to cure such breach within [ * ] after receipt of such notice; or 

(ii) upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings by or against the other Party, or
upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party, or in the event a receiver or custodian is appointed for such Party’s business, or if a substantial portion of such Party’s 

 
 [ * ] = Certain confidential information contained in this document, marked by brackets,
is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 35 of 52 

 
business is subject to attachment or similar process; provided, however, that in the case of any involuntary bankruptcy proceeding, such right to terminate shall only become effective if the
proceeding is not dismissed within [ * ] after the filing thereof. 
 (b) Termination for Breach of Section 5.2. Subject to the
terms and conditions of this Section 12.4(b), Schering shall have the right, and such right shall be its sole and exclusive remedy and Licensee’s sole and exclusive liability, to terminate this Agreement in the event Licensee and its
Affiliates and sublicensees have ceased employing Commercially Reasonable Efforts to Develop and Commercialize Licensed Products in the Field for a period of [ * ] or more. In order to exercise such termination right, Schering shall first provide
written notice to Licensee stating Schering’s reasons for concluding that Licensee and its Affiliates and sublicensees have ceased employing Commercially Reasonable Efforts to Develop and Commercialize Licensed Product in the Field for the
aforementioned period. If Licensee disagrees with the conclusion that Licensee and its Affiliates and sublicensees have ceased employing Commercially Reasonable Efforts to Develop and Commercialize Licensed Product in the Field for the
aforementioned period, Licensee shall have a period of [ * ] after such written notice to provide Schering with evidence that Licensee or any of its Affiliates or sublicensees has not ceased employing Commercially Reasonable Efforts to Develop and
Commercialize Licensed Product in the Field for the aforementioned period. If Licensee has not provided Schering with such evidence within such [ * ] period, this Agreement shall terminate at the end of such [ * ] period upon written notice from
Schering. Notwithstanding the foregoing, if Schering gives Licensee a notice pursuant to the second sentence of this Section 12.4(b), and Licensee provides notice during the [ * ] period set forth above that Licensee disputes the conclusion
that Licensee and its Affiliates and sublicensees have ceased employing Commercially Reasonable Efforts to Develop and Commercialize Licensed Product in the Field for the aforementioned period, then this Agreement shall not terminate unless and
until an arbitrator issues a final award pursuant to Article 13 upholding the basis for termination under this Section 12.4(b). 
 (c)
Effect of Termination for Cause on License. 
 (i) Termination by Licensee for Cause. In the event this Agreement is properly
terminated by Licensee under Section 12.4(a), Licensee’s license pursuant to Section 2.1 shall become a fully paid-up, perpetual license and the payments to be made to Schering by Licensee hereunder shall be reduced by [ * ].
Notwithstanding the preceding sentence, Licensee shall be responsible for the full amount of all payments due and owed to Schering prior to any written notice of termination. 

(ii) Termination by Schering for Cause. In the event this Agreement is terminated by Schering under Section 12.4(a), the rights and
license granted to Licensee under Section 2.1 of this Agreement shall terminate and all rights to the Licensed Compound and Licensed Product shall revert to Schering pursuant to Section 12.6. 

12.5 Effect of Termination Generally. Expiration or termination of this Agreement shall not relieve the Parties of any obligation
accruing prior to such expiration or termination, and the provisions of Sections 10.6, 10.7, 12.3(b), 12.4(c), 12.5 and 12.6 and Articles IX, XIII 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 36 of 52 

 
and XIV shall survive the expiration or termination of this Agreement. Any expiration or early termination of this Agreement shall be without prejudice to the rights of either Party against the
other that has accrued and is owed under this Agreement prior to termination, including the obligation to pay royalties for Licensed Product sold prior to such termination. 

12.6 Licensed Product Reversion. Upon termination of this Agreement in its entirety by Schering for any reason or by Licensee pursuant
to Section 12.3, the following provisions shall apply: 
 (a) Effective upon such termination, without further action by either Party, [
* ] license from Licensee under any Program IP that is owned or Controlled by Licensee that is necessary or useful for the use, Development, Manufacture, or Commercialization of the Licensed Product in the Field. 

(b) Licensee shall reasonably cooperate with Schering in order to enable Schering to assume responsibility for the Development, Manufacture
and/or Commercialization of all Licensed Products then being Developed, Manufactured or Commercialized by Licensee. Such cooperation and assistance shall be provided in a timely manner and shall include without limitation: 

(i) Licensee shall transfer to Schering (or its nominee) all INDs, Regulatory Approvals, drug approval applications for
Regulatory Approvals, and all supporting documentation for such filings and applications (to the extent assignable and not cancelled), made or obtained by Licensee or its Affiliates or any of its sublicensees to the extent relating to Licensed
Product then being Commercialized or in Development. 
 (ii) Licensee shall assign to Schering all of its rights in any
trademarks and shall transfer to Schering all of its rights in any domain names containing trademarks, in each case to the extent owned or Controlled by Licensee and to the extent that such trademarks have actually been or are planned to be utilized
by Licensee in connection with the Commercialization of Licensed Product in the Field. Any assignment or transfer to Schering pursuant to this Section 12.6(b)(ii) shall be at no cost to Schering. 

(iii) Licensee shall transfer to Schering (or its nominee), to the extent not previously provided, a copy of all Know-How owned
or Controlled by Licensee relating to any Licensed Product then being Commercialized in the Field or in clinical Development by Licensee in the Field and reasonably necessary or useful for its continued Development, Manufacture and/or
Commercialization in the Field, including without limitation all information contained in Licensee’s regulatory and/or safety databases, all in the format then currently maintained by Licensee. 

(iv) Upon the request of Schering, Licensee shall use reasonable and Commercially Reasonable Efforts to assign to Schering any
Sublicense Agreements previously granted by Licensee related to the Development of Licensed Product in the Field. 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 37 of 52 

 (v) Upon the request of Schering, Licensee, its Affiliates and its sublicensees
shall complete any clinical studies related to Licensed Product in the Field that (x) are being conducted under Licensee’s IND for Licensed Product and are ongoing as of the date this Agreement is terminated, and (y) for which it is
not practicable to transfer responsibility for conducting such studies to Schering; provided, however, that Schering agrees to reimburse Licensee for all Development costs incurred by Licensee after termination in completing such studies. 

(vi) Upon the request of Schering, Licensee shall transfer to Schering, at a price to be agreed in good faith, which shall not
be more than [ * ] of Licensee’s fully allocated manufacturing cost for the Licensed Product, all quantities of Licensed Product in the possession of Licensee or its Affiliates (including, without limitation, clinical trial supplies and
Licensed Product intended for commercial sale). 
 (vii) At Schering’s request, Licensee shall promptly provide to
Schering copies of all clinical trial, contract manufacturing, or service agreements entered into by Licensee or its Affiliates with respect to the Development or Manufacture of Licensed Product in the Field. At Schering’s request, Licensee
shall promptly assign (or cause to be assigned), such agreements to Schering, to the extent such assignment is permitted under such agreement or, in the case that such agreements involve products other than the Licensed Product, to the extent that
the portion of the agreement involving solely the Development or Manufacture of Licensed Product in the Field can be assigned. In the event that such an assignment is not permitted under a particular clinical trial, contract manufacturing, or
service agreement, then Licensee shall reasonably cooperate (at Schering’s request) to assist Schering in obtaining the benefits of such agreement. 

The Parties shall use commercially reasonable efforts to complete the transition of the Development, Manufacture and Commercialization of the
Licensed Product from Licensee to Schering pursuant to this Section 12.6 as soon as is reasonably possible. 
 ARTICLE XIII –
DISPUTE RESOLUTION 
 13.1 Informal Discussions. Except as otherwise provided herein, in the event of any controversy or claim
arising out of or relating to this Agreement, or the rights or obligations of the Parties hereunder, or the relationship between the Parties with respect to the Licensed Compound or Licensed Product, the Parties shall first try to settle their
differences amicably between themselves. Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other Party, and within [ * ] after such notice appropriate representatives of the Parties shall meet
for attempted resolution by good faith negotiations. If such representatives are unable to resolve promptly such disputed matter within the said [ * ], either Party may refer the matter by written notice to the other to the Chief Executive Officer
of Schering, or his designee, and the Chief Executive Officer of Licensee, or his designee, for discussion and resolution. If such individuals or their designees are unable to resolve such dispute within [ * ] of such written notice, either Party
may initiate arbitration proceedings in accordance with the provisions of this Article XIII. 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 38 of 52 

 13.2 Arbitration. All disputes arising out of or relating to this Agreement, or the rights
or obligations of the Parties hereunder, or relating in any way to the relationship between the Parties with respect to the Licensed Compound or Licensed Product, other than disputes relating to patent rights which shall be submitted to a court of
competent jurisdiction (unless mutually agreed by the Parties), shall be finally and exclusively settled by arbitration by a panel of three (3) arbitrators. 

(a) The arbitration proceeding shall be conducted under the Commercial Arbitration Rules of the American Arbitration Association
(“AAA”) with such proceedings to be held in Newark, New Jersey, United States should a dispute be brought to arbitration by Licensee or in San Francisco, California should a dispute be brought to arbitration by Schering. In all
cases, the arbitration proceedings shall be conducted in the English language, and all documents that are submitted in the proceeding shall be in the English language. Judgment upon the award rendered by arbitration may be issued and enforced by any
court having competent jurisdiction. 
 (b) If a Party intends to begin an arbitration to resolve a dispute, such Party shall provide written
notice to the other Party, informing the other Party of such intention and any statement of claim required under the applicable arbitration rules (as determined in accordance with Section 13.2(a)). Within [ * ] after its receipt of such notice,
the other Party shall, by written notice to the Party initiating arbitration, add any additional issues to be resolved which would be considered mandatory counterclaims under New York law. For clarity, the resolution of any disputes regarding such
counterclaims shall be conducted in the same proceedings as the initial claims. 
 (c) Within [ * ] following the receipt of the notice of
arbitration, the Party referring the matter to arbitration shall appoint an arbitrator and promptly notify the other Party of such appointment. The other Party shall, upon receiving such notice, appoint a second arbitrator within [ * ], and the two
(2) arbitrators shall, within [ * ] of the appointment of the second arbitrator, agree on the appointment of a third arbitrator who will act with them and be the chairperson of the arbitration panel. In the event that either Party shall fail to
appoint an arbitrator within [ * ] after the commencement of the arbitration proceeding, the arbitrator shall be appointed by the AAA. In the event of the failure of the two (2) arbitrators to agree within [ * ] after the commencement of the
arbitration proceeding to appoint the chairperson, the chairperson shall also be appointed by the AAA. 
 (i) All of the arbitrators shall
have significant legal or business experience in pharmaceutical licensing matters. The arbitrators shall not be employees, directors or shareholders of either Party or any of their Affiliates. 

(ii) Each Party shall have the right to be represented by counsel throughout the arbitration proceedings. 

(iii) To the extent possible, the arbitration hearings and award will be maintained in confidence. 

 
 [ * ] = Certain confidential information contained in this document, marked by brackets,
is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 39 of 52 

 (iv) In any arbitration pursuant to this Agreement, the award or decision shall be rendered by a
majority of the members of the panel provided for herein, with each member having one (1) vote. The arbitrators shall render a written decision with their resolution of the dispute, which decision shall set forth in reasonable detail the facts
of the dispute, and the reasons for their decision. The decision of the arbitrators shall be final and non-appealable and binding on the Parties. 

13.3 Injunctive Relief. By agreeing to arbitration, the Parties do not intend to deprive any competent court of such court’s
jurisdiction to issue a pre-arbitral injunction, pre-arbitral attachment or other order in aid of the arbitration proceedings and the enforcement of any award or judgment. Without prejudice to such provisional remedies in aid of arbitration as may
be available under the jurisdiction of a national court, the court of arbitration shall have full authority to grant provisional remedies and to award damages for failure of any Party to respect the court of arbitration’s order to that effect.

 13.4 Expenses of Arbitration and Expert Determination. Each Party shall bear its own attorneys’ fees, costs, and disbursements
arising out of the arbitration, and shall pay an equal share of the fees and costs of the arbitrators; provided, however, that the arbitrators shall be authorized to determine whether a Party is the prevailing Party, and if so, to award to
that prevailing Party reimbursement for its reasonable attorneys’ fees, costs and disbursements (including, for example, expert witness fees and expenses, photocopy charges and travel expenses). Absent the filing of an application to correct or
vacate the arbitration award as permitted by applicable law, each Party shall fully perform and satisfy the arbitration award within [ * ] of the service of the award. 

ARTICLE XIV - MISCELLANEOUS 

14.1 Assignment/Change of Control. 

(a) Assignment. Neither this Agreement nor any or all of the rights and obligations of a Party hereunder may be assigned, delegated,
sold, transferred, sublicensed (except as otherwise provided herein) or otherwise disposed of, by operation of law or otherwise, to any Third Party without the prior written consent of the other Party, and any attempted assignment, delegation, sale,
transfer, prohibited sublicense or other disposition, by operation of law or otherwise, of this Agreement or of any rights or obligations hereunder contrary to this Section 14.1 shall be a material breach of this Agreement by the attempting
Party, and shall be void and without force or effect; provided, however, that either Party may, without such consent of such Party, assign the Agreement and its rights and obligations hereunder to an Affiliate or in connection with the
transfer or sale of all or substantially all of its assets related to the division or the subject business, or in the event of its merger or consolidation or change in control or similar transaction. This Agreement shall be binding upon, and inure
to the benefit of, each Party, its Affiliates, and its permitted successors and assigns. Each Party shall be responsible for the compliance by its Affiliates with the terms and conditions of this Agreement. 

 
 [ * ] = Certain confidential information contained in this document, marked by brackets,
is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 40 of 52 

 (b) Change of Control of Licensee. In the event that any Change of Control (as defined
below) causes Licensee’s rights and obligations hereunder to pass to any Third Party, such Third Party shall, within [ * ] after the effective date of such Change of Control, notify Schering of its intentions with regard to the Development and
Commercialization of the Licensed Product under this Agreement. If the Third Party succeeding to Licensee’s rights and obligations under this Agreement decides it will not continue the Development and/or Commercialization of the Licensed
Product, then Schering shall have the right to terminate this Agreement upon [ * ] written notice to Licensee without any opportunity to cure and the effects of such termination shall be as set forth in Section 12.6. If the Third Party
succeeding to Licensee’s rights and obligations under this Agreement decides to continue the Development and Commercialization of the Licensed Product, then all of the rights and obligations of Licensee under this Agreement shall inure to such
Third Party; provided, that for the immediate [ * ] period following such Change of Control, such Third Party shall follow the same Development Plan and budget as was in effect prior to such Change of Control; and provided,
further that within such [ * ] period the Third Party successor shall submit to Schering a new Development Plan for the next succeeding [ * ] period, which shall not, without the prior written approval of Schering, which approval shall not be
unreasonably withheld, materially differ from the Development Plan in effect prior to such Change of Control. 
 (c) Definition of Change
of Control. As used in this Section 14.1 the term “Change of Control” means (i) any merger, reorganization, consolidation or combination in which Licensee is not the surviving corporation, or (ii) any “person”
(within the meaning of Sections 13(d) and 14 (d)(2) of the Securities Exchange Act of 1934), excluding Licensee and its Affiliates, is or becomes the beneficial owner, directly or indirectly, of securities of Licensee representing 50% or more of
either (A) the then-outstanding shares of common stock of Licensee or its parent corporation, or (B) the combined voting power of Licensee’s then-outstanding voting securities; or (C) if individuals who as of the Effective Date
constitute the Board of Directors of Licensee or its parent corporation (the “Incumbent Board”) cease for any reason to constitute at least a majority of such Board of Directors; provided, however, that any individual becoming a
director subsequent to the Effective Date whose election, or nomination for election by Licensee’s stockholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though
such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of
directors or other actual or threatened solicitation of proxies or consents by or on behalf of a person other than the Incumbent Board; or (D) approval by the stockholders of Licensee of a complete liquidation or the complete dissolution of
Licensee. 
 14.2 Governing Law. This Agreement shall be governed, interpreted and construed in accordance with the laws of the State
of New York, without giving effect to its conflict of law principles. Subject to the terms of this Agreement, all disputes under this Agreement shall be governed by binding arbitration pursuant to the mechanism set forth in Article XIII herein. 

14.3 Waiver. Any delay or failure in enforcing a Party’s rights under this Agreement or any waiver as to a particular default or
other matter shall not constitute a waiver of such 
  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 41 of 52 

 
Party’s rights to the future enforcement of its rights under this Agreement, nor operate to bar the exercise or enforcement thereof at any time or times thereafter, excepting only as to an
express written and signed waiver as to a particular matter for a particular period of time. 
 14.4 Independent Relationship. Nothing
herein contained shall be deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for
the act or failure to act of the other Party. Neither Party shall have any power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect
whatsoever. 
 14.5 Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical
information from the United States of America which may be imposed upon or related to Schering or Licensee from time to time by the government of the United States of America. Furthermore, Licensee agrees that it will not export, directly or
indirectly, any technical information acquired from Schering under this Agreement or any products using such technical information to any country for which the United States government or any agency thereof at the time of export requires an export
license or other governmental approval, without first obtaining the written consent to do so from the Department of Commerce or other agency of the United States government when required by an applicable statute or regulation. 

14.6 Entire Agreement; Amendment. This Agreement, including the Exhibits and Schedules hereto and thereto, sets forth the complete,
final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto and supersedes and terminates all prior agreements and understandings between the
Parties with regard to the subject matter of this Agreement in the Territory. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set
forth herein and therein. No subsequent alteration, amendment, change, waiver or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. As of the Effective Date, this
Agreement supersedes and terminates that certain Secrecy Agreement between the Parties effective as of November 20, 2008. 
 14.7
Notices. Any notice required or permitted to be given or sent under this Agreement shall be hand delivered or sent by express delivery service or certified or registered mail, postage prepaid, or by facsimile transmission (with written
confirmation copy by registered first-class mail) to the Parties at the addresses and facsimile numbers indicated below. 
 If to Schering,
to: 
 Schering Corporation 

c/o Merck & Co., Inc. 

One Merck Drive 
 Attention: Chief
Licensing Officer 
  
 [ * ] = Certain confidential information contained in this
document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 42 of 52 

 P.O. Box 100, WS2A-30 

Whitehouse Station, NJ 08889-0100 

Facsimile: (908)735-1214 
 with a
copy to: 
 Schering Corporation 

c/o Merck & Co., inc. 

One Merck Drive 
 P.O. Box 100

 Whitehouse Station, NJ 08889-0100 

Attn: Vice President and Associate General Counsel, 

  Business Development & Licensing 

Fax No.: 908-735-1345 
 If to
Licensee, to: 
 Eiger BioPharmaceuticals, Inc. 

3350 W Bayshore Road, Suite 120 

Palo Alto, CA 94303 
 Attn: Chief
Executive Officer 
 Fax No.: 650-320-9901 

with a copy to: 
 Cooley, LLP

 3000 El Camino Real 
 Five
Palo Alto Square 
 Palo Alto, CA 94306 

Attn: Glen Y. Sato, Esq. 
 Fax
No.: 650-849-7400 
 Any such notice shall be deemed to have been received on the earlier of the date actually received or the date five (5) days after
the same was posted or sent. Either Party may change its address or its facsimile number by giving the other Party written notice, delivered in accordance with this Section 14.7. 

14.8 Force Majeure. Failure of any Party to perform its obligations under this Agreement (except the obligation to make payments when
properly due) shall not subject such Party to any liability or place them in breach of any term or condition of this Agreement to the other Party if such failure is due to any cause beyond the reasonable control of such non-performing Party
(“Force Majeure”), unless conclusive evidence to the contrary is provided. Causes of non-performance constituting Force Majeure shall include, without limitation, acts of God, fire, explosion, flood, drought, earthquake, war, riot,
sabotage, embargo, strikes or other labor trouble, failure in whole or in part of suppliers to deliver on schedule materials, equipment 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 43 of 52 

 
or machinery, interruption of or delay in transportation, a national health emergency or compliance with any order or regulation of any government entity acting with color of right. The Party
affected shall promptly notify the other Party of the condition constituting Force Majeure as defined herein and shall exert reasonable efforts to eliminate, cure and overcome any such causes and to resume performance of its obligations with all
possible speed; provided that nothing herein shall obligate a Party to settle on terms unsatisfactory to such Party any strike, lockout or other labor difficulty, any investigation or other proceeding by any public authority or any litigation by any
Third Party. If a condition constituting Force Majeure as defined herein exists for more than ninety (90) consecutive days, the Parties shall meet to negotiate a mutually satisfactory resolution to the problem, if practicable. If the Parties
cannot in good faith reach a satisfactory resolution to the problem within sixty (60) days of meeting, the matter shall be handled pursuant to the dispute resolution provisions of Article XIII herein. 

14.9 Severability. If any provision of this Agreement is declared illegal, invalid or unenforceable by a court having competent
jurisdiction, it is mutually agreed that this Agreement shall continue in accordance with its terms except for the part declared invalid or unenforceable by order of such court, provided, however, that in the event that the terms and conditions of
this Agreement are materially altered, the Parties will, in good faith, renegotiate the terms and conditions of this Agreement to reasonably substitute such invalid or unenforceable provisions in light of the intent of this Agreement. 

14.10 Counterpart. This Agreement shall become binding when any one or more counterparts of it, individually or taken together, shall
bear the signatures of each of the Parties hereto. This Agreement may be executed in any number of counterparts, each of which shall be an original as against either Party whose signature appears thereon, but all of which taken together shall
constitute but one and the same instrument. 
 14.11 Captions. The captions of this Agreement are solely for the convenience of
reference and shall not affect its interpretation. 
 14.12 Further Actions. Each Party agrees to execute, acknowledge and deliver
such further instruments, and to do all other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

IN WITNESS WHEREOF, this Agreement has been executed by the duly authorized representatives of the Parties. 

 

									
	SCHERING CORPORATION	 		 	EIGER BIOPHARMACEUTICALS, INC.
					
	By:	 	 /s/ David Nicholson
	 		 	By:	 	 /s/ David Cory

	Title: SVP Licensing & Knowledge Management	 		 	Title: CEO

  
 [ * ] = Certain confidential information contained in
this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 44 of 52 

 SCHEDULE 1.11 

COMPOUND PATENT RIGHTS 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 45 of 52 

													
	 Case Number
	  	Status	  	Appln No.	  	Appln Date	  	Patent Number	  	Grant Date	  	Exp Date
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]

  
 [ * ] = Certain confidential information contained in
this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 46 of 52 

 SCHEDULE 1.29 

LICENSED COMPOUND 
  

 
 Sarasar/Lonafarnib (SCH 66366) 

(4(2[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]-cyclohepta 

[1,2b]pyridin-11yl)-piperidino]-2-oxoethyl]-1-piperidinecarboxamide). 

 
 [ * ] = Certain confidential information contained in this document, marked by brackets,
is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 47 of 52 

 SCHEDULE 3.2(a) 

PROOF OF CONCEPT PROTOCOL 
 [ * ] 

Patients will undergo pre-study screening, which may include the following assessments: 

 

	 	•	 	[ * ] 

 [ * ]. 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 48 of 52 

 SCHEDULE 3.2(b) 

INITIAL DEVELOPMENT PLAN 
 The initial plan for
development of the Licensed Compound in the Field includes the following studies. 
 [ * ] 

 

			
	Goal:	  	[ * ]
		
	Dosages assessed:	  	[ * ]
		
	Primary outcome:	  	[ * ]
		
	Primary endpoint:	  	[ * ]
		
	Secondary outcomes:	  	
		
	[ * ]	  	
		
	Projected number of patients:	  	[ * ]
		
	Study location:	  	[ * ]
		
	Number of sites:	  	[ * ]
		
	Projected study initiation:	  	[ * ]
		
	Projected study termination:	  	[ * ]
		
	[ * ] Study	  	
		
	[ * ]	  	
		
	Goal:	  	[ * ]
		
	Dosages assessed:	  	[ * ]

  
 [ * ] = Certain confidential information contained in
this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 49 of 52 

			
	Primary outcome:	  	[ * ]
		
	Primary endpoint:	  	[ * ]
		
	Secondary outcomes:	  	
		
	[ * ]	  	
		
	Projected number of patients:	  	[ * ]
		
	Study location:	  	[ * ]
		
	Number of sites:	  	[ * ]
		
	Projected study initiation:	  	[ * ]
		
	Projected study termination:	  	[ * ]

  
 [ * ] = Certain confidential information contained in
this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 50 of 52 

 [ * ] Study 
 [ * ]

  

			
		
	Goal:	  	[ * ].
		
	Dosage assessed:	  	[ * ]
		
	Primary outcome:	  	[ * ]
		
	Primary endpoint:	  	[ * ]
		
	Secondary outcomes:	  	
		
	[ * ]	  	
		
	Projected number of patients:	  	[ * ]
		
	Study location:	  	[ * ]
		
	Number of sites:	  	[ * ]
		
	Projected study initiation:	  	[ * ]
		
	Projected study termination:	  	[ * ]

  
 [ * ] = Certain confidential information contained in
this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 51 of 52 

 SCHEDULE 6.2 

BULK LICENSE PRODUCT TO BE TRANSFERRED 
 The Bulk
Licensed Product to be transferred from Schering to Licensee is [ * ] of Licensed Product in the form of [ * ]. 
  

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 Page 52 of 52EX-10.51

 Exhibit 10.51 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
 LICENSE AGREEMENT 

This LICENSE AGREEMENT (the “Agreement”) is made and effective as
of either the date of execution by the last Party to sign below (the “Effective Date”), by and between EB Pharma, LLC.,a company organized and existing under the laws of the State of Delaware having a business address at 1115
Lafayette Street, Santa Clara, CA 95050 (“EBP”), and Janssen Pharmaceutica NV, a company organized and existing under the laws of Belgium having a business address at Turnhoutseweg 30, 2340 Beerse, Belgium
(“Janssen”). EBP and Janssen are each referred to individually as a “Party” and together as the “Parties.” 

RECITALS 
 WHEREAS,
EBP has experience in researching and developing antiviral agents, including agents active against novel targets in the treatment of hepatitis; 

WHEREAS, Janssen owns, directly and through its Affiliates, certain rights relating to its proprietary compounds known as tipifarnib
(also known as R115777) and a related proprietary back-up compound (also known as R208176); and 
 WHEREAS, EBP wishes to obtain from
Janssen certain rights to develop and commercialize tipifarnib for human use in the field of virology, and Janssen is willing to grant such rights in accordance with the terms and conditions of this Agreement. 

NOW THEREFORE, in consideration of the mutual covenants and agreements contained herein, the Parties agree as follows: 

1. DEFINITIONS AND INTERPRETATION 
 1.1
Definitions. Unless the context otherwise requires, the terms in this Agreement with initial letters capitalized, shall have the meanings described below, or the meaning as designated in the indicated places throughout this Agreement.

 “AAA” means the American Arbitration Association. 

“Accounting Standards” means Generally Accepted Accounting Principles in the United States or the International
Financial Reporting Standards, as appropriate, as generally and consistently applied in compliance with Applicable Laws throughout the relevant Party’s organization at the relevant time. 

“Affiliate” means, in reference to a particular Party, any corporation or other entity that directly or indirectly
controls, is controlled by, or is under common control with such Party. For purposes of this definition, “control” or “controlled” means ownership, directly or indirectly, of more than fifty percent (50%) of
the shares of stock entitled to vote for the election of directors in the case of a corporation, or more than fifty percent (50%) of the equity interest in the case of any other type of legal entity (or if the jurisdiction where such
corporation or other entity is 

  
 Page 1 of 60 

 
domiciled prohibits foreign ownership of such entity, the maximum foreign ownership interest permitted under such laws, provided that such ownership interest provides actual control over such
entity), status as a general partner in any partnership, or any other arrangement whereby an entity controls or has the right to control the board of directors or equivalent governing body of the entity. 

“Alliance Manager” shall have the meaning set forth in Section 3.2. 

“Applicable Laws” means the applicable provisions of any and all national, supranational, regional, state and local
laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, permits (including Marketing Authorizations) of or from any court, arbitrator, Regulatory Authority or
governmental agency or authority having jurisdiction over or related to the subject item, including to the FCPA, Export Control Laws, and other laws and regulations pertaining to domestic or international corruption, commercial bribery, fraud,
embezzlement, or money-laundering. 
 “EBP Indemnified Party” shall have the meaning set out in Section 12.2.

 “EBP Patent Rights” means all Development Program Patent Rights Controlled by EBP or any of its Affiliates during
the Term that include any claim Covering any Reverted Product or Compound therein for which Janssen exercises its option rights under Section 15.2(b), use of such a Reverted Product or a Compound therein in the Field, formulation, preparation
or manufacture of such a Reverted Product or Compound therein, or material for formulating, preparing or manufacturing such a Reverted Product or Compound therein. For the sake of clarity, Eiger Patent Rights include all related Patent Rights
arising in the course of Prosecution of the foregoing Patent Rights. 
 “EBP Sublicensee” means any of
EBP’s Affiliates or any Third Party licensee or sublicensee of rights granted by Janssen to EBP under this Agreement, but not including any Third Party to the extent that it functions as a distributor.  

“Bankruptcy” means, with respect to a Party, that: (a) the Party has been declared insolvent or bankrupt by a
court of competent jurisdiction; or (b) a voluntary or involuntary petition in bankruptcy is filed in any court of competent jurisdiction against the Party and such petition has not dismissed within ninety (90) days after filing; or
(c) the Party has made or executed an assignment of substantially all of its assets for the benefit of creditors. 

“Bioequivalent” means, with respect one drug substance (or active pharmaceutical ingredient) contained in one
pharmaceutical product in reference to the drug substance (or active pharmaceutical ingredient) of another pharmaceutical product, that: (i) the two substances are pharmaceutically equivalent to each other and their bioavailabilities (rate and
extent of availability) after administration in the same molar dose are similar to such a degree that their 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 2 of 60 

 
effects, with respect to both efficacy and safety, can be expected to be essentially the same; or (ii) the two substances are or would be recognized by a Regulatory Authority as
being biologically equivalent in vivo.  
 “Breaching Party” shall
have the meaning set out in Section 14.2. 
 “Business Day” means any day, other than Saturday or Sunday, on
which the banks in New York, New York and San Francisco, California are generally open for business. 
 “Claims”
shall have the meaning set out in Section 13.1. 
 “Combination Product” means (a) any Product containing
or comprising a Compound and at least one (1) active ingredient that is not a Compound; or (b) any combination of a Product and another pharmaceutical product containing or comprising at least one (1) active ingredient that is not a
Compound where the Product and such other product are not formulated together but are sold together and invoiced as one product. 

“Commercialize” means, in reference to a Product, performing any activities directed to marketing, promoting, offering
for sale, or selling a Product for use in the Field, including detailing and medical affairs activities, and distribution and importation activities in support thereof. 

“Commercially Reasonable Efforts” means the carrying out of obligations or tasks in a commercially diligent manner
consistent with the efforts that a similarly situated biotechnology company in the pharmaceutical industry would reasonably devote to a research, development or marketing program owned by such company or to which such company has exclusive rights,
of similar market potential and at a similar stage of development, based on conditions then prevailing, and taking into account efficacy, safety, regulatory authority approved labeling, the competitiveness of alternative products in the marketplace,
the patent and other proprietary position of the products, ability to finance the program, medical and clinical considerations, the likelihood of regulatory approval given the regulatory structure involved, the profitability of the products,
including the royalties payable to licensors of patent or other rights, and the costs of development, manufacture and marketing. 

“Compound” means: (a) the compound known as R115777 or tipifarnib, which has the structure shown in
Exhibit 1, or the compound known as R208176, which has the structure shown in Exhibit 1; or (b) or a Bioequivalent of either such compound (such as a pharmaceutical salt, acid, base, hydrate, solvate, ester, polymorph, or
stereoisomer thereof); or (c) an active metabolite, prodrug, or radiolabeled form of any of the foregoing defined in clause (a) or (b). 

“Confidential Information” means any: (a) Know-How or other proprietary or unpublished business, scientific,
technical, formulation, process, manufacturing, clinical, non-clinical, regulatory, marketing, financial or commercial information or data, which is generated by or on behalf of a Party or which one Party or any of its Affiliates has supplied or
otherwise 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 3 of 60 

 
made available to the other Party either during the Term for purposes contemplated by this Agreement or pursuant to the Confidentiality Agreement, whether made available orally, in writing, or in
electronic form, including information comprising or relating to concepts, discoveries, inventions, data, designs or formulae in relation to this Agreement; or (b) sample of any compound, reagent, biological specimen, or other material which
one Party or any of its Affiliates has supplied or otherwise made available to the other Party during the Term of this Agreement for purposes contemplated hereunder. 

“Confidentiality Agreement” means the Confidential Disclosure Agreement between Janssen Research &
Development, LLC (an Affiliate of Janssen) and Eiger BioPharmaceuticals, Inc. dated June 12, 2014. 
 “Control”
(and, with correlative meaning, “Controlled”) means, with respect to any Know-How, Patent Rights or other intellectual property rights, the legal authority or right (whether by
ownership, license or otherwise, but without taking into account any rights granted by one Party to the other Party under the terms of this Agreement) of a Party to grant access, a license or a sublicense of or under
Know-How, Patent Rights, or intellectual property rights to the other Party, or to otherwise disclose proprietary or trade secret information to the other Party, without breaching the terms of any agreement
with a Third Party. 
 “Cover” means, with respect to a claim of any Patent Rights in reference to a specified
invention or technology, reading on, or literally encompassing such invention or technology under principles of applicable patent law, whether generically or specifically. 

“Date of Delivery” shall have the meaning set out in Section 2.2(b). 

“Develop”means, in reference to a Product, performing any Pre-Phase I research, clinical trials (including Phase I
Studies, Phase II Studies, Phase III Studies, and post-marketing studies), and other activities to study a drug candidate or product and develop it toward approval, and to maintain approval, for marketing or Commercialization of the Product in the
Field, including toxicology and ADME tests, analytical method development, stability testing, process development and improvement, process validation, process scale-up, formulation development, delivery system development, quality assurance and
quality control development, statistical analysis, pre- and post-approval clinical studies or trials, regulatory affairs, and regulatory activities. 

“Development Plan” means the written plan of activities to be performed by or on behalf of EBP hereunder to Develop
any Licensed Product for use in the Field, as such plan may be supplemented or otherwise amended from time to time. 

“Development Program” means the activities of either or both of the Parties conducted hereunder after the Effective
Date in Developing any Products for use in the Field. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 4 of 60 

 “Development Program Invention” means an invention (whether or not
patentable) arising in the Development Program directly from any Development activities performed by or on behalf of EBP hereunder, which invention is necessary or useful for the Manufacturing or Development of any Compound or Product, or for the
Commercialization of any Product, including any invention made in the Development Program pertaining to the Manufacture, preparation, formulation, administration, delivery, dosing, or use in the Field of any Compound or Product. 

“Development Program IP” means the Development Program Know-How and Development Program Patent Rights, collectively.

 “Development Program Know-How” means any and all Know-How generated or developed in the Development Program from
any Development activities performed by or on behalf of EBP hereunder, which Know-How relates to any Compound or Product, including for purposes of illustration: any Development Program Inventions; clinical trial data or other information relating
to any form of any Compound or Product, any method of using any Compound or Product, any process or material for Manufacturing, formulating, or delivering any Compound or Product, the use of any Compound in any Combination Product, any companion
diagnostic for use in Developing or Commercializing a Product in the Field, any material or process for making any Compound or Product, any method of using, testing, or characterizing any Compound or Product; and any data and other information
contained in any regulatory filings relating to any Product. 
 “Development Program Patent Right” means any Patent
Right filed after the Effective Date, and Controlled by EBP, that includes (as filed or at any other time during its pendency in a Patent Office) any claim Covering (generally or specifically) any Development Program Invention. For purposes of
illustration, exemplary Development Program Patent Rights may include one or more claims Covering any Compound or Product form, any method of using any Compound or Product, any process or material for manufacturing, formulating, or delivering any
Compound or Product, any Combination Product to the extent it directly relates to a Compound hereunder (excluding, for the avoidance of doubt, Patent Rights directed to other active ingredients alone), or any companion diagnostic for use in
Commercializing any Product in the Field. 
 “Dispute” means any dispute, claim, or controversy arising from or
regarding this Agreement, including the interpretation, application, breach, termination or validity of any provision hereof. 

“Effective Date” or “Execution Date”means the last date of execution by the Parties hereto.

 “EMA” means the European Medicines Agency and any successor thereto. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 5 of 60 

 “Excluded Claim” means a dispute, controversy or claim that concerns
(i) the validity, enforceability or infringement of a patent, trademark or copyright; or (ii) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory. 

“Exercise Notice” shall have the meaning set out in Section 2.2(c). 

“Existing Third Party Agreements” means the agreements between Janssen or an Affiliate and a Third Party that are
listed in Exhibit 5, as such agreements and Exhibit may be amended from time to time. For clarity, the Existing Third Party Agreements exclude the UT License. 

“Export Control Laws” means all applicable U.S. laws and regulations relating to (a) sanctions and embargoes
imposed by the Office of Foreign Assets Control of the U.S. Department of Treasury or (b) the export or re-export of commodities, technologies, or services, including, but not limited to, the Export Administration Act of 1979, 24 U.S.C.
§§ 2401-2420, the International Emergency Economic Powers Act, 50 U.S.C. §§ 1701-1706, the Trading with the Enemy Act, 50 U.S.C. §§ 1 et. seq., the Arms Export Control Act, 22 U.S.C. §§ 2778 and 2779, and the
International Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986 (as amended). 

“FCPA” means the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et. seq.) as amended. 

“FDA” means the United States Food and Drug Administration and any successor thereto. 

“Field” means all therapeutic and diagnostic uses in humans, for including the prevention, treatment, control or
diagnosis of any human virology diseases, disorders or medical conditions, excluding any oncology diseases. 
 “First Commercial
Sale” means the first arm’s length sale of a Product in a country in the Territory to a Third Party following receipt of Marketing Authorization in such country, if such Marketing Authorization is required. 

“Generic Product” means, with respect to a Product, any pharmaceutical product (a) that is sold by a Person other
than a Party or its Affiliates, or any licensee of such Party or its Affiliates, and who did not purchase such product in a chain of distribution that included such Party or its Affiliate or licensee of either of the foregoing, (b) contains the
same Compound as such Product, and (c) whose Marketing Authorization Application is approved by a Regulatory Authority in reliance, in whole or in part, on the prior approval (or on safety or efficacy data submitted in support of the prior
approval or on the finding by a Regulatory Authority of the safety or efficacy) of such Product, including any product authorized for sale (i) in the U.S. pursuant to Section 505(b)(2) or Section 505(j) of the Act (21 U.S.C. 355(b)(2)
or 355(j), respectively), (ii) in the EU pursuant to a provision of Articles 10, 10a or 10b of Parliament and 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 6 of 60 

 
Council Directive 2001/83/EC as amended (including an application under Article 6.1 of Parliament and Council Regulation (EC) No 726/2004 that relies for its content on any such provision) or
(iii) in any other country or jurisdiction pursuant to all equivalents of such provisions. 
 “Good Clinical
Practice” or “GCP” means the then-current good clinical practice standards applicable to the clinical Development of a Product under Applicable Law, including ICH guidelines, or in the event such standards are
less stringent than the current U.S. Good Clinical Practice, then such term shall mean the then-current U.S. Good Clinical Practice. 

“Good Laboratory Practice” or “GLP” means the then-current good laboratory practice standards
applicable to the Development of a Product under Applicable Law, including 21 C.F.R. Part 58, or in the event such standards are less stringent than the current U.S. Good Laboratory Practice, then such term shall mean current U.S. Good Laboratory
Practice. 
 “Good Manufacturing Practice” or “GMP” means the then-current good
manufacturing practice standards applicable to the Manufacturing of a Product under Applicable Law, including 21 C.F.R. parts 210 and 211 and all applicable FDA rules, regulations, orders and guidances, or in the event such standards are less
stringent than the current U.S. Good Manufacturing Practice, then such term shall mean the then-current U.S. Good Manufacturing Practice. 

“IND”means an investigational new drug application filed with the FDA or the corresponding application filed with the
Regulatory Authority in any other country, for authorization to proceed with the clinical investigation of a Product in any country or group of countries, as defined in the Applicable Laws. 

“Indication” means an application or use set forth in labeling (including any package insert) for a Product as
approved by a Regulatory Authority, identifying a specific therapeutic or prophylactic indication for which the Product may be used, where the approval is based on data from a pivotal clinical trial in the Development Program. For clarity, an
Indication may be the initial one or a later-approved one such as for an expanded or additional patient population, or for using the Product in combination with another treatment or drug product. 

“Indemnified Losses” shall have the meaning set out in Section 12.1. 

“Indemnified Party” shall have the meaning set out in Section 12.3(a). 

“Indemnifying Party” shall have the meaning set out in Section 12.3(a). 

“Janssen Indemnified Party” shall have the meaning set out in Section 12.1. 

“Janssen IP” means the Janssen Patent Rights and Janssen Know-How. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 7 of 60 

 “Janssen Know-How” means the Know-How Controlled by Janssen as of the
Effective Date that is specific to any Compound and contained in the records identified in Exhibit 3, as such Exhibit may be amended from time to time including such Know-How pertaining to: processes; techniques; toxicological,
pharmacological, clinical, and chemical data; specifications; medical uses; adverse reactions; and manufacture and quality control methods.  

“Janssen Patent Rights” means the Patent Rights Controlled by Janssen identified in Exhibit 2(A) and Exhibit
2(B) as updated pursuant to Section 8.2(b), and any Patent Rights related thereto Controlled by Janssen that are filed or issued after the Effective Date.  

“Joint Development Committee” or “JDC” means a joint committee established by the Parties
pursuant to Section 3.3 to monitor and discuss Development of Product hereunder. 
 “Know-How”
means all technical information, know-how and data, including: inventions, discoveries, trade secrets, specifications, instructions, processes, formulae, materials, expertise and other technology applicable to formulations, compositions or products
or to their manufacture, development, registration, use or marketing or to methods of assaying or testing them or processes for their manufacture, formulations containing them or compositions incorporating or comprising them, and including all
biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical and analytical, safety, quality control, manufacturing, preclinical and clinical data, instructions, processes, formulae, expertise and information, relevant
to the development, manufacture, use or sale of and/or which may be useful in studying, testing, developing, producing or formulating products, or intermediates for the synthesis thereof. 

“MAA” means an application for the authorization for marketing of a Product in any country or group of countries
outside the United States, and all supplements, including all documents, data and other information concerning the Product, as defined in the Applicable Laws and filed with the Regulatory Authority of a given country or group of countries. 

“Major Market Country” means each of the following countries: France, Germany, Italy, Spain, the United Kingdom, and
the United States (including their respective territories and possessions). 
 “Manufacturing” means, in reference
to a Product, performing any activities to manufacture the Product into final form for end use in the Field, including producing intermediates or building blocks used to manufacture the Compound of the Product, manufacturing such intermediates or
building blocks into Compound (e.g., in bulk form), formulating the Compound into Product in finished dosage form, filling, finishing, packaging, labeling, performing quality assurance testing and release, and shipping and storing the packaged
Product. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 8 of 60 

 “Marketing Authorization” means the grant of any and all approvals
(including supplements, amendments, pre- and post-approvals, pricing and reimbursement approvals), licenses, registrations or authorizations of any national, supra-national (e.g., the European Commission or the Council of the European Union),
regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, that are necessary for the manufacture, distribution, use and sale of a Product in a regulatory jurisdiction, including where required,
pricing and reimbursement approvals. 
 “NDA” means a new drug application and all supplements filed with the FDA,
including all documents, data and other information concerning a Product which are necessary for, or included in, a Marketing Authorization to use, sell, supply and market the Product in the United States. 

“Net Sales” means the gross amounts invoiced on sales, or gross operating revenues earned for other commercial
dispositions, of a Product by EB or any EB Sublicensee to a Third Party purchaser that is not an EB Sublicensee in an arms-length transaction, less the following customary deductions, determined in accordance with Accounting Standards, to the extent
specifically and solely allocated to such Product and actually taken, paid, accrued, allowed, included or allocated based on good faith estimates in the gross sales prices with respect to such sales (and consistently applied as set forth below):

 (a) normal and customary trade, cash and/or quantity discounts, allowances (including wholesaler allowances), and credits allowed or paid
(including for returned, damaged or expired Product), in the form of deductions or credits actually allowed or fees actually paid with respect to sales of such Product (to the extent not already reflected in the amount invoiced) excluding
commissions for commercialization; 
 (b) excise taxes, use taxes, tariffs, sales taxes and customs duties, and/or other government charges
imposed on the sale of Product to the extent included in the price and separately itemized on the invoice price (but specifically excluding, for clarity, any income taxes assessed against the income arising from such sale) (including VAT, but only
to the extent that such VAT taxes are not reimbursable or refundable); 
 (c) outbound freight, shipment and insurance costs to the extent
included in the price and separately itemized on the invoice price; 
 (d) compulsory payments and cash rebates related to the sales of such
Product paid to a governmental authority (or agent thereof) pursuant to Applicable Laws by reason of any national or local health insurance program or similar program, to the extent allowed and taken; including government levied fees as a result of
healthcare reform policies; 
 (e) retroactive price reductions, credits or allowances actually granted upon rejections or returns of
Product, including for recalls or damaged good and billing errors; and 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 9 of 60 

 (f) rebates, chargebacks, and discounts (or equivalent thereof) actually granted to managed
health care organizations, pharmacy benefit managers (or equivalent thereof), federal, state/provincial, local or other governments, or their agencies or purchasers, reimbursers, or trade customers. 

All aforementioned deductions shall only be allowable to the extent they are commercially reasonable and shall be determined, on a country-by-country basis,
as incurred in the ordinary course of business in type and amount consistent with EB or the EB Sublicensee’s (as the case may be) business practices consistently applied across its product lines and in accordance with Accounting Standards and
verifiable based on its sales reporting system. All such discounts, allowances, credits, rebates, and other deductions shall be fairly and equitably allocated to Product and other products of Janssen or the Janssen Sublicensee such that Product does
not bear a disproportionate portion of such deductions. 
 In the event Product is sold as a Combination Product and the Third Party customer receives a
specific discount for such “bundling” of products (for clarity, this situation describes bundling of two or more separate products, each in finished dosage form, and not a fixed combination of two active pharmaceutical ingredients), the
Net Sales of such Combination Product, for the purposes of determining royalty payments due hereunder, shall be determined by multiplying the relevant Net Sales by the fraction A/(A+B), where A is the weighted (by sales volume) average sale price in
a particular country of the Product in the previous Calendar Year when sold separately and B is the weighted average sale price in that country in the previous Calendar Year of the other product sold separately. In the event that such average
sale price cannot be determined for either the Product or the other product it has been sold with, in combination, (1) for purposes of determining any royalties due hereunder, the bundling discount granted shall be considered as having been
granted in its entirety with respect to the other product only and shall not be applied to the sales of any Product or (2) Net Sales for purposes of determining royalties due shall be multiplied by an adjustment factor which will be the
fraction equal to one divided by the number of active ingredients in such Combination Product. 
 “Non-Breaching
Party” shall have the meaning set out in Section 14.2. 
 “Option” shall have the meaning set
forth in Section 2.2(a). 
 “Option Term” shall have the meaning set forth in Section 2.2(a). 

“Paragraph IV Certification” shall have the meaning set forth in Section 8.3(a). 

“Patent Expenses” means the actual out-of-pocket fees, expenses and disbursements (including payments made to Third
Party agents) paid by a Party to any Third Party such as its outside patent counsel or agent, or any Patent Offices, in connection with the Prosecution of particular Janssen Patent Rights, including the costs of patent interference and opposition
proceedings, reissues, and reexaminations. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 10 of 60 

 “Patent Office” means the United States Patent and Trademark Office,
European Patent Office, or other government agency or office responsible for the examination of patent applications or granting of patents in a country, region, or supra-national jurisdiction. 

“Patent Rights” means, with respect to a particular invention, any and all original (priority-establishing) patents
and patent applications filed anywhere in the world including any claim covering the invention, including provisional and nonprovisional applications, and all related applications thereafter filed including any claim covering such invention or
including a common priority right, including any continuations, continuations-in-part, divisional and substitute applications, any patents issued or granted from any such patent applications, and any reissues, renewals, reexaminations, extensions
(including by virtue of any supplementary protection certificates) of any such patents, and any confirmation patents, inventor’s certificates or registration patents or patents of addition based on any such patents, and all foreign counterparts
or equivalents in any country or jurisdiction of any of the foregoing. 
 “Patent Term Extension” means an extension
of the term of any issued patent, or a right of protection equivalent to such an extension, granted under the U.S. Drug Price Competition and Patent Term Restoration Act of 1984, the Supplementary Certificate of Protection of the member states of
the EU, or another similar law or regulation in any other country or jurisdiction. For clarity, a pediatric extension extending the term of any patent shall not be deemed a Patent Term Extension. 

“POC Data Package” means a package of materials comprising copies of written reports providing all raw data
(excluding, for the avoidance of doubt, any private patient data or any other information that cannot be provided under Applicable Law) from the POC Trial in Eiger’ possession and Control and other information, including summaries, analyses,
findings, conclusions and other results from such clinical study in EBP possession and Control. 
 “POC Trial” means
a Phase II Study of the Compound tipifarnib in patients for a hepatitis Indication in the Field, as more fully described in the Development Plan. 

“Phase I Study” means a study in humans which provides for the first introduction into humans of a product, conducted
in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in Federal Regulation 21 C.F.R. §312.21(a) and its foreign equivalents. 

“Phase II Study” means a study in humans of the safety, dose ranging and efficacy of a Product, which is prospectively
designed to generate sufficient data (if successful) to commence a Phase III Study or to file for accelerated approval, as further defined in Federal Regulation 21 C.F.R. §312.21(b) and its foreign equivalents. 

“Phase III Study” means a pivotal study in humans of the efficacy and safety of a Product, which is prospectively
designed to demonstrate statistically whether such product is 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 11 of 60 

 
effective and safe for use in a particular indication in a manner sufficient to file an NDA or MAA to obtain regulatory approval to market the product, as further defined in Federal Regulation 21
C.F.R. §312.21(c) and its foreign equivalents. 
 “Pre-Phase I” means the initial portion of a development
program prior to initiation of a Phase I Study, which starts with the selection of a NME and includes initiation of GMP scale-up activities and GLP toxicological studies. For illustrative purposes, Pre-Phase I development activities typically
include toxicological (full-scale GLP toxicology for obtaining approval from a Regulatory Authority to administer Product to humans in clinical trials), pharmacological and any other studies required for filing an IND, as well as Product formulation
and manufacturing development necessary to obtain the permission of Regulatory Authorities to begin a Phase I Study. 

“Product” means a product containing or comprising a Compound, alone or together with one or more active or inactive
ingredients, including any such product in the form of a preparation, kit, article of manufacture, composition of matter, material, formulation, or dosage or administration form. 

“Prosecuting” means, with regard to specified Patent Rights, preparing, filing, prosecuting, maintaining, and
defending such Patent Rights in Patent Office proceedings or appeals therefrom, including with respect to any reexamination, reissue, interference, revocation, invalidation, protest, or opposition proceedings. For the avoidance of doubt,
“Prosecuting” excludes any infringement suits or other legal proceedings to enforce the specified Patent Rights, regardless of whether or not such proceedings also involve the defense of the Patent Rights in suit.  

“Regulatory Authority” means a federal, national, multinational, state, provincial or local regulatory agency,
department, bureau or other governmental entity with authority over the testing, manufacture, use, storage, import, promotion, marketing or sale of a pharmaceutical product in a country or territory, including the FDA and the EMA. 

“Regulatory Exclusivity” means a right granted by a Regulatory Authority in a country with respect to a Product
affording the ability to preclude a Third Party from commercializing a product that could compete with such Product in such country, either through data exclusivity rights, new chemical entity designation, orphan drug designation, or such other
rights conferred by a Regulatory Authority in such country, other than through Patent Rights. 
 “Regulatory Filing”
means any documentation comprising or relating to or supporting any filing or application with any Regulatory Authority with respect to a Product, or its use or potential or investigative use in humans, including any documents submitted to any
Regulatory Authority and all supporting data, including Drug Master Files, INDs, supportive documents enabling a clinical program, NDAs and MAAs, and all correspondence with any Regulatory Authority with respect to any Licensed Product (including
minutes of any meetings, telephone conferences or discussions with any Regulatory Authority). 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 12 of 60 

 “Reverted Products” shall have the meaning set out in
Section 14.2(a). 
 “Royalty Term” shall have the meaning set forth in Section 6.3(b). 

“Senior Officers” shall have the meaning set forth in Section 4.3(e). 

“Taxes”means any present or future taxes, levies, imposts, duties, charges, assessments, or fees of any nature
(including any interest thereon). 
 “Term” shall have the meaning set forth in Section 14.1. 

“Territory” means the entire world. 

“Third Party” means any entity other than Janssen or Eiger or an Affiliate of Janssen or Eiger. 

“Third Party Infringement” shall have the meaning set forth in Section 8.3(a). 

“United States” or “U.S.” means the United States of America and its territories and
possessions. 
 “UT License” means the Non-Exclusive License Agreement between Board of Regents of the University of
Texas System and Janssen Pharmaceutica NV dated as of March 5, 1998. 
 “Valid Claim” means, with respect to
referenced Patent Rights, (a) a published and pending claim of a patent application that is included in the Patent Rights that is being Prosecuted diligently and in good faith, but has not been pending for more than a total of [ * ] years after
the earliest priority date for such claim and has not been finally rejected through a binding decision without filing of an appeal or with loss of all right to appeal, or (b) an issued claim of any patent included in the Patent Rights in any
country that (i) has not expired; (ii) has not been disclaimed; (iii) has not been canceled or superseded, or if canceled or superseded, has been reinstated; and (iv) has not been revoked, held invalid, or otherwise declared
unenforceable or not allowable by a tribunal or patent authority of competent jurisdiction over such claim in such country from which no further appeal has or may be taken. 

“ZARNESTRA Mark” means the trademark “ZARNESTRA”. 

1.2 Interpretations. In this Agreement, unless the context requires otherwise: 

(a) the headings are included for convenience only and shall not affect its construction; 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 13 of 60 

 (b) references to “persons” includes individuals, bodies corporate (wherever
incorporated), unincorporated associations and partnerships; 
 (c) words denoting the singular shall include the plural and vice
versa and words denoting any gender shall include all genders; 
 (d) the words “comprise”, “comprising”,
“contain”, “containing”, “include” and “including” are used in their open, non-limiting form, and shall be understood to include the words “without limitation” even if not expressly stated; 

(e) a Party includes its permitted assignees and/or the respective successors in title to substantially the whole of its undertaking;

 (f) any reference to a specified enactment, statute, regulation, or other provision of any Applicable Law is a reference to it as
it may have been, or may from time to time be amended, modified, consolidated or re-enacted at the relevant time; 

(g) all references to “EURO” or “EUR” shall mean EUROS; and 

(h) the Exhibits and other attachments form part of the operative provisions of this Agreement and references to this Agreement shall,
unless the context otherwise requires, include references to the recitals and the Exhibits and attachments. In the event of any inconsistency between the Exhibits and the terms of the body of this Agreement, the terms of the body of this Agreement
shall prevail. 
 2. GRANT OF RIGHTS 

2.1 Grant of Commercial License to EBP.  

(a) Under Compound IP. Subject to the terms and conditions of this Agreement (including Article 6), Janssen hereby grants to EBP
an exclusive (even as to Janssen, except for reservation of the Option pursuant to Section 2.2), sublicensable (subject to Sections 2.2 and 2.4), license during the Term, under the Janssen IP, to Develop, Manufacture, have Manufactured, offer
for sale, sell, and otherwise Commercialize Compounds and Products in the Field throughout the Territory, and to make, have made, use, and import Compounds and Products throughout the world for such purposes. 

(b) No License to ZARNESTRA® Trademark Rights. EBP acknowledges and agrees that
this Agreement does not grant it any license or other rights to the ZARNESTRA Mark or under any of Janssen’s trademark rights pertaining thereto. 

(c) Option for Sublicense under UT License. Janssen, upon authorization by the Board of Regents of the University of Texas, grants EBP a
non-exclusive option, exercisable by notice from EBP to Janssen at any time hereunder during the term of the UT 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 14 of 60 

 
License, to be granted a non-exclusive authorization or sublicense, under the license rights then Controlled by Janssen under the UT License, solely for purposes of exercising any rights granted
to EBP under Section 2.1(a) above to Develop or Commercialize Compounds and Products, provided that EBP agrees to and shall assume all responsibility for making all payments that become due to Janssen’s licensor under the UT License on
account of any activities by EBP or any EBP Sublicensees in exercise of its sublicense rights under the UT License. Promptly after EBP exercises such option, the Parties shall negotiate and execute a written sublicense agreement documenting the
grant of sublicense rights under the UT License to EBP and EBP’s payment obligations as provided above. 
 2.2 Reservation of Right
of First Negotiation by Janssen. 
 (a) Option Grant. Subject to the terms and conditions of this
Agreement, EBP hereby grants to Janssen an exclusive option and first right to negotiate, during the Option Term, for an exclusive license back from EBP, under the Development Program IP and the Janssen IP, to Develop and Commercialize Compounds and
Products in any or all countries of the Territory (the “Option”). Janssen may exercise the Option at any time during the [ * ] period following the Date of Delivery by EBP to Janssen
of the POC Data Package (the “Option Term”). For the avoidance of doubt, until expiration of the Option Term, without Janssen’s exercise of the Option, EBP shall not grant any Third Party any right to Develop (except as
a subcontractor on EBP’s behalf) or Commercialize any Compounds in the Field. If a POC Trial is not initiated or completed within a reasonable time after the Effective Date, then upon a Party’s request to the other, the Parties shall
confer and attempt to negotiate a redefinition of the Option Term that is reasonable in light of the circumstances. For clarity, nothing in this Section shall prohibit EBP from negotiating and completing any transaction for the sale of all or
substantially all of its business or assets that includes the assignment of this Agreement pursuant to Section 15.1 (whether by merger, sale of stock, sale of assets, or otherwise), provided that any assignee shall assume all obligations of EBP
hereunder, including with respect to the Option rights of Janssen herein. 
 (b) Delivery of POC Data
Package. Following completion of the POC Trial of a Product under the Development Plan, EBP will provide Janssen with the POC Data Package. If, within [ * ] after the date EBP first provides the POC Data Package to Janssen, Janssen
provides written notice to EBP requesting additional information that would reasonably be expected to be included in the POC Data Package, then EBP shall use Commercially Reasonable Efforts to provide Janssen such requested additional information.
The date that EBP initially provides the POC Data Package or, if Janssen requests additional information in accordance with this Section, the date that EBP provides additional information for inclusion in the POC Data Package or advises Janssen in
writing that such additional information cannot be provided after using Commercially Reasonable Efforts, as applicable, shall be the “Date of Delivery” of the POC Data Package. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 15 of 60 

 (c) Exercise of Option. Subject to the terms and conditions of this
Agreement, Janssen may exercise the Option at any time during the Option Term by sending written notice of such exercise (“Exercise Notice”) to EBP. 

(d) Effect of Expiration or Termination of Option. If Janssen does not exercise the Option during the Option Term by providing an
Exercise Notice to EBP, then Janssen’s Option shall terminate and EBP shall be free to grant rights to one or more Third Parties to Develop or Commercialize Compounds and Products in the Field. If Janssen gives EBP an Exercise Notice during the
Option Term but the Parties do not enter into a definitive license agreement within [ * ] after the Exercise Notice (the “Negotiation Period”, as may be extended or shortened by written agreement of the Parties), then
Janssen’s Option shall terminate and EBP shall be free to grant sublicense rights to one or more Third Parties to Develop or Commercialize Compounds and Products in the Field, provided that [ * ], [ * ] any such rights to Develop or
Commercialize any Compounds or Products in the Field [ * ]. 
 2.3 Reservation of Rights. Subject to the Option and to the licenses
and sublicenses that are or may be granted to each Party pursuant to Section 2.1 and/or 2.2 and the other terms and conditions of this Agreement, Janssen retains all rights under the Janssen IP that are not expressly licensed to EBP hereunder,
including with respect to: (a) chemical compounds, other than Compounds, that are Covered by any claim of the Janssen Patent Rights; or (b) applications of Compounds and Products outside the Field. No right or license under any Patent
Rights or Know-How of either Party is granted or shall be granted by implication. All rights or licenses under a Party’s intellectual property rights are or shall be granted only as expressly provided in
the terms of this Agreement.  
 2.4 Sublicense. EBP shall have the right to grant sublicenses to its subcontractors to Develop
and/or make the Compound or Product on EBP’s behalf at any time. Upon expiration of Janssen’s Option rights pursuant to Section 2.2 above, EBP shall have the right to grant sublicenses of the Development and Commercialization rights
granted to it under Section 2.1 of this Agreement to its Affiliates and to Third Parties, provided that: 
 (a) any
sublicense agreement shall be in writing and be consistent with the terms and conditions of this Agreement, and the sublicensee shall not have the right to grant further sublicense; 

(b) any such sublicense agreement shall provide for the termination of the sublicense upon termination of this Agreement; and 

(c) EBP shall be liable for all acts or omissions of its sublicensees and shall at all times, and at its own cost, enforce compliance by
the sublicensee with the terms of the sublicense agreement. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 16 of 60 

 3. ALLIANCE MANAGEMENT 

3.1 General. Except as may otherwise be provided herein, the Parties acknowledge and agree that EBP is undertaking the responsibility
for performance of the Development Program. If the Option is exercised by Janssen during the Option Term, the Parties shall negotiate a definitive agreement whereby EBP grants back to Janssen any rights to Develop or Commercialize any Compounds or
Products in the Field pursuant to Section 2.2. 
 3.2 Alliance Managers. Within fifteen (15) days after the Effective Date,
each Party will appoint a representative having a general understanding of pharmaceutical development and commercialization issues (“Alliance Manager”). The Alliance Managers will be primarily responsible for facilitating the
flow of information and otherwise promoting routine communications between the Parties hereunder. Each Party may replace its Alliance Manager on written notice to the other Party. 

3.3 Joint Development Committee. 

(a) Establishment of JDC. Promptly after the Effective Date, the Parties shall establish a Joint Development Committee, composed of the
Alliance Managers and one (1) additional representative from EBP and one (1) additional representative from Janssen as its members. Each Party will designate by written notice its initial members to serve on the JDC. Each Party may replace
its representatives on the JDC by written notice to the other Party. 
 (b) JDC Responsibilities. The JDC, which will have no
decision-making authority, will monitor the activities of EBP in the Development Program and serve as a forum for reviewing EBP progress and results of the Development Program. 

(c) JDC Meetings. The JDC shall meet at least annually through completion of the POC Trial and at such other times as the Parties may
agree. The first meeting of the JDC shall be held as soon as reasonably practicable. Meetings shall be held at such place or places as are mutually agreed or by teleconference or videoconference, provided that at least one representative of Janssen
and one representative of EBP are present at any JDC meeting. Each Party may from time to time invite a reasonable number of participants, in addition to its representatives on the JDC, to attend JDC meetings on an ad hoc basis. The JDC meetings
will be chaired by EBP. The chairperson shall set agendas for JDC meetings in advance. The Parties will rotate the responsibility for recording, preparing and, within a reasonable time, issuing draft minutes of each JDC meeting to each Party’s
Alliance Manager for review, who upon their approval shall issue final minutes to the Parties. 
 (d) Expenses. Each Party shall bear
all its own costs, including expenses incurred by its JDC members or by any additional non-member participants of such Party in connection with their attendance at JDC meetings and other activities related to the JDC. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 17 of 60 

 (e) POC Trial Design Input. Promptly after the Effective Date, EBP shall use Commercially
Reasonable Efforts to provide the JDC with EBP initial Development Plan, which shall include a description of the clinical study design for the POC Trial. The Development Plan, and any amendments thereto, shall be discussed at a JDC meeting, and EBP
shall reasonably consider the input from discussions at JDC meetings regarding the design of the POC Trial and any other plans for any Phase II Study or Phase III Study of any Compound or Product in the Development Program. 

(f) Review of Plans and Results. In advance of each JDC meeting, EBP will provide the JDC representatives with a summary regarding the
Development activities performed by or on behalf of EBP since the last JDC meeting (if any), including a description of data, results, and other information generated in, and any activities planned for, Developing any Compounds or Products. Without
limiting the generality of the foregoing, such summaries shall include (a) the status and results of any Development activities, including, non-clinical and/or preclinical studies and activities (including toxicology and pharmacokinetic
studies); and (b) the Regulatory Filings and Marketing Authorization applications with respect to any Compound and Product that EBP or any of its Affiliates or sublicensees have filed, sought, or obtained. 

(g) No Authority to Modify Agreement. For the avoidance of doubt, the JDC shall have no authority to modify any provision set forth in
the body or in any Exhibit of this Agreement, including any payment conditions or terms, periods for performance, or obligations of the Parties as set forth in this Agreement, which may be modified only by written agreement of the Parties. 

4. DEVELOPMENT PROGRAM 
 4.1
Diligence. EBP (directly and through applicable EBP Sublicensees) shall use Commercially Reasonable Efforts to Develop at least one (1) Product through Marketing Authorization in one or more of the Major Market Countries. For the avoidance
of doubt, the foregoing diligence requirement shall not be construed so as to necessitate that EBP seek Marketing Authorization in all Major Market Countries simultaneously. 

4.2 Records. EBP shall, and shall require its subcontractors to, maintain in accordance with Applicable Law complete and accurate
records in segregated laboratory notebooks of all work conducted in furtherance of the Development of Compounds and Products, including all raw data, observations, conclusions, and analyses. Such records shall be complete and accurate and shall
fully and properly reflect all work done and results achieved in sufficient detail and in a manner appropriate for patent and regulatory purposes. 

4.3 Use of Animals. In conducting any Development Program activities involving any animals, (i) the animals shall be provided with
humane care and treatment in accordance with current generally accepted veterinary practice, and (ii) in accordance with Janssen’s 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 18 of 60 

 
Guidelines on the Care & Use of Laboratory Research Animals appended to this Agreement as Exhibit 6. 

4.4 Standards for Conduct. EBP shall use Commercially Reasonable Efforts to execute and to perform, or cause to be performed,
Development activities in in good scientific manner and in compliance with Applicable Law, Good Clinical Practice, and Good Laboratory Practice. 

4.5 Development Reports. EBP shall submit to Janssen annual written progress reports by [ * ] of each year of the Term covering
EBP’s (and any of its Affiliates’, subcontractors’, and sublicensees’) activities related to the Development of each Product in the Field, the status of obtaining Marketing Authorization, and other activities undertaken in order
to meet the diligence requirement set forth in Section 4.1, until First Commercial Sale of such Product in the Field in the United States, which reports will be again required if, and for so long as, all sales of such Product are suspended or
discontinued in all countries during the Term. Upon Janssen’s reasonable request, EBP shall supplement any such Development progress report with other information in its possession that is pertinent to the Development efforts with respect to
Products in the Field for as long as the respective diligence obligation under Section 4.1 applies. For the avoidance of doubt, all information contained in such reports shall be deemed EBP’s Confidential Information.  

4.6 Drug Supply for Development.  

(a) Responsibility. Following the Effective Date, EBP will be solely responsible, itself and through its Affiliates and sublicensees at
their own expense, for Manufacturing or having Manufactured Compound and Product for Development purposes, including for producing clinical supplies. The Manufacturing of supplies of Compound and Product for human use shall be performed in
accordance with Applicable Law and Good Manufacturing Practice. 
 (b) No Supply from Janssen’s Inventory. EBP further
acknowledges that this Agreement does not grant it rights to any quantities of Compound or Product from Janssen’s supply existing as of the Effective Date, and that there is no guarantee that there will be any amount available at any given time
for transfer to EBP. 
 4.7 Know-How Transfer and Assistance. Janssen shall use commercially reasonable efforts to complete shipment
(in one shipment or on a rolling basis), during the period running [ * ] from the Effective Date, at EBP expense for out-of-pocket (but not internal Janssen) costs, to EBP or its designee, copies of all Janssen Know-How documentation listed in
Exhibit 3 (which shall be treated as Janssen’s Confidential Information) within Janssen’s possession or control, including that relating to clinical Development and Manufacture of the Compound. Janssen will prioritize for shipment
copies of Regulatory Filings within the Janssen Know-How documentation. For the period running [ * ] after EBP receipt of the complete copies of the 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 19 of 60 

 
Janssen Know-How and for no more than a cumulative of [ * ], Janssen will provide reasonable assistance requested by EBP to facilitate its understanding of the Janssen Know-How, by making one
appropriately qualified representative of Janssen reasonably available for meetings or teleconferences regarding the content of the Janssen Know-How documentation. In addition, upon EBP’s written request Janssen will provide EBP with a right of
cross-reference or access to or copies of any Regulatory Filings possessed or controlled by Janssen, as appropriate and considering Applicable Law and any license rights outside of the Field granted by Janssen to Third Parties. For clarity, Janssen
is not obligated to provide any other assistance beyond that which is set forth in Section 4.7, except as may be agreed upon by the Parties in a separate written services agreement. 

4.8 Regulatory Submissions. EBP (directly or through its EBP Sublicensees) shall be responsible for submitting (or having submitted) all
Regulatory Filings after the Effective Date, and for obtaining and maintaining all Marketing Authorizations for Products in the Field. EBP (directly or through its Sublicensees), shall use Commercially Reasonable Efforts to coordinate with Janssen
or with any Third Party identified by Janssen to EBP as having been granted licensee rights to develop and commercialize Compounds and/or Products outside of the Field as necessary to compile, maintain, and report adverse event and other relevant
safety data from use of Compounds and products as required by Applicable Laws. 
 5. COMMERCIALIZATION 

5.1 Diligence. EBP (directly and through its EBP Sublicensees) shall use Commercially Reasonable Efforts to Commercialize Products in
countries where Marketing Authorization has been obtained. 
 5.2 Legal Compliance. EBP agrees that in performing any Development,
Manufacturing and Commercialization activities with respect to any Compounds or Products as contemplated hereunder, (a) it shall, and shall use reasonable measures to cause its Affiliates, sublicensees, and subcontractors to, comply with all
applicable current international regulatory standards, including GMP, GLP, GCP and other Applicable Laws, and (b) it shall not, and shall use reasonable measures to cause its Affiliates, sublicensees, and subcontractors to not, knowingly employ
or use any person that has been debarred under Section 306(a) or 306(b) of the U.S. Federal Food, Drug and Cosmetic Act.  

5.3 Commercialization Reports. EBP shall submit to Janssen [ * ] written progress reports by [ * ] of each year of the Term covering
EBP’s (and any EBP Sublicensees’) activities related to the Commercialization of each Product in the Field and other activities undertaken in order to meet the diligence requirement set forth in Section 5.1. Upon Janssen’s
reasonable request, EBP shall supplement any such Commercialization progress report with other information in its possession that is pertinent to the Commercialization efforts with respect to Products in the Field for as long as the respective
diligence obligation under Section 5.1 applies.  

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 20 of 60 

 
For the avoidance of doubt, all information contained in such reports shall be deemed EBP’s Confidential Information. 

5.4 No Use of ZARNESTRA Mark. EBP shall not use the ZARNESTRA Mark in connection with its Development or Commercialization of Product.
For the avoidance of doubt, this Agreement does not grant Eiger any license or other rights to any trademarks, designs, logos, slogans, taglines, trade names, or trade dress that Janssen owns or otherwise controls. 

6. FINANCIAL PROVISIONS 
 6.1 Milestone
Payments. Each of the milestone payments identified in this Section 6.2 shall be due upon the achievement of the specified milestone event with respect to any Compound or Product. 

(a) Development Milestones. In further consideration of the license rights granted to EBP under Section 2.1, each of the milestone
payments identified in this Section 6.2(a) shall be due upon the first achievement of the specified milestone event with respect to any Compound or Product. EBP shall promptly provide written notification to Janssen, at Beerse (Belgium),
Turnhoutseweg 30, Attention: Finance Manager (Maarten Van Looveren) upon achievement of each Development Milestone. Such notification shall indicate that the Development Milestone was achieved and request that Janssen send a written invoice for such
milestone to a specific address, if such address is different than that indicated in Section 15.11: Notices. Within [ * ] of the receipt of the invoice for each of the corresponding Development Milestones listed below, EBP shall pay by wire
transfer the amount listed in each invoice to Janssen to the bank account identified in Section 7.2. For clarity, each milestone payment shall be due and payable only one time upon the first achievement of the event specified. 

 

					
	 Development Milestone Event
	  	Milestone Payment
(EUR)	 
	 [ * ]
	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  

 (b) Sales Milestones. In further consideration of the license rights granted to EBP under
Section 2.1, solely upon the first occurrence during the Term of aggregate annual worldwide Net Sales of all Products surpassing the sales threshold identified below, EBP shall immediately provide written notification to Janssen, at Beerse
(Belgium), Turnhoutseweg 30, Attention: Finance Manager (Maarten Van Looveren) upon achievement of each Sales 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 21 of 60 

 
Milestone. Such notification shall indicate that the one-time corresponding sales milestone was achieved and request that Janssen send a written invoice for such milestone to a specific address,
if such address is different than that indicated in Section 15.2: Notices. [ * ] of the receipt of the invoice for each of the corresponding Sales Milestones listed below, EBP shall pay by wire transfer the amount listed in each invoice to
Janssen to the bank account identified in Section 7.2. For the avoidance of doubt, if in the same reporting period multiple sales milestones are first attained, then the payments for all such milestones attained as specified below shall be due.

  

					
	 Sales Threshold (aggregate annual worldwide Net Sales of

Products) in EUR
	  	Milestone Payment
(EUR)	 
	 [ * ]
	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  

 (c) For the avoidance of doubt, different milestones as specified in this Section 6.2 may be
achieved by the same or a distinct Compound or Product. Additionally, should a Compound or Product be replaced or backed up by another Compound or Product, no additional milestone payments shall be due under Section 6.2 for milestone events
completed by the replacement or back-up Compound or Product for which corresponding milestone payments were previously made to EBP with respect to such replaced Compound or Product. 

(d) Third Party Sublicense. In the event that EBP sublicenses any of its rights to Compounds and/or Products to any Third Party, EBP
would pay Janssen: (i) [ * ] of all monetary compensation received from the Third Party sublicensee, including upfront and lump-sum payments, milestone payments, and royalties; and (ii) such amounts otherwise due based on EBP’s
milestone and royalty payment obligations under this Agreement. For example, (1) if EBP receives an upfront of EUR [ * ] from a Third Party sublicense, EBP would pay Janssen EUR [ * ]; (2) if EBP receives a milestone from a Third Party
sublicense for a milestone event that is listed in Section 6.1, EBP would pay Janssen [ * ] of the milestone from the Third Party sublicensee and the milestone event otherwise payable to Janssen under Section 6.1; and (3) if EBP
receives a milestone from a Third Party sublicense for a milestone event that is not listed in Section 6.1, EBP would pay Janssen [ * ] of the milestone from the Third Party sublicensee. EBP shall immediately provide written notification to
Janssen, at Beerse (Belgium), Turnhoutseweg 30, Attention: Finance Manager (Maarten Van Looveren) upon achievement of each Third Party Sublicense. Such notification shall indicate that a Third Party Sublicense was achieved and request that Janssen
send a written invoice for such Third Party Sublicense amount to a specific address, if such address is different than that indicated in Section 15.2: Notices. [ * ] days of the receipt of the invoice for each of the Third Party Sublicense, EBP
shall pay by wire transfer the amount listed in each invoice to Janssen to the bank account identified in Section 7. Any Third Party Sublicense monetary compensation received by EBP in a currency other than Euro shall be converted into their
Euro equivalent using the closing exchange rate as published 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 22 of 60 

 
by The Wall Street Journal, Western U.S. Edition for the day the Third Party Sublicense compensation was achieved by EBP. 

6.2 Royalty Payments.  

(a) Royalty Basis and Rate. In partial consideration of the license rights under Section 2.1, royalties shall be due from EBP on
aggregate annual Net Sales of Products during the Royalty Term throughout the Territory, and royalties shall be determined on a Product-by-Product and country-by-country basis where either: (i) any Valid Claim of the Janssen Patent Rights
Covers the applicable Product or Compound contained therein as a composition or any method of use of such Product or Compound in the Field in such country; (ii) Regulatory Exclusivity applies to such Product in such country; or (iii) [ * ]
from First Commercial Sale (for the financial convenience of the parties, and considering Janssen’s willingness to accept the very modest upfront and development milestone payments, there would be no stepdown of the royalty rate if there is no
valid patent claim or regulatory exclusivity in a particular country). Royalties due each calendar year of the Royalty Term shall be calculated by multiplying the applicable incremental Net Sales of Products against the applicable royalty rate
identified below, subject to any applicable adjustments or reductions provided for in Section 6.3(c), with each royalty rate referred to below applying only to that increment of annual Net Sales that falls within the incremental sales bracket
for such royalty rate. 
  

					
	Aggregate annual Net Sales of Products	  	Royalty Rate	 
	 Less than or equal to [ * ]
	  	 	[ * ]%	  
	 Greater than [ * ] up to and equal to [ * ]
	  	 	[ * ]%	  
	 Greater than [ * ]
	  	 	[ * ]%	  

 To illustrate, if, for example, cumulative annual worldwide Net Sales of Products upon which royalties are due and payable as
provided in this Section 6.3 were EUR[ * ] during any year of the Royalty Term, then absent any adjustments or reductions pursuant to Section 6.3(c), the royalties due would be EUR[ * ] calculated as follows: [ * ]. For the avoidance of
doubt, royalties due under this Section 6.3 shall be payable only once with respect to the same unit of Product, and different formulations (e.g., dosage strengths, delivery forms) of a Compound and Bioequivalents thereof shall be deemed the
same Product. 
 (b) Royalty Term. Royalties due on Net Sales of Products will be payable on a Product-by-Product and
country-by-country basis until the later of (a) the expiration of the last to expire Valid Claim of the Janssen Patent Rights Covering either the Product or the Compound contained therein as a composition or any method of use of such Product or
Compound in the 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 23 of 60 

 
Field in such country, (b) the expiration of any Regulatory Exclusivity with respect to such Product in such country, and (c) [ * ] from First Commercial Sale (the “Royalty
Term”). Following the Royalty Term on a Product-by-Product and country-by-country basis, EBP’s licenses with respect to such Product in such country under Section 2.1 shall continue in effect, but become fully paid-up, royalty-free,
perpetual and irrevocable. 
 (c) Adjustments to Royalties. 

(i) Compulsory Licenses. If at any time in any country a Third Party shall, under the right of a compulsory license granted or ordered
to be granted by a competent governmental authority in a given country (other than failure of a court to enjoin infringement as a remedy in a patent infringement proceeding), be granted a license, under any Janssen Patent Rights licensed to Eiger
hereunder, to sell in such country, or manufacture for distribution or sale by or on behalf the government in such country, any Product with respect to which royalties are payable pursuant to Section 6.3(a) at a royalty rate that is less than
the applicable royalty rate for a given tier of incremental annual Net Sales as provided in Section 6.3(a), and such Product is sold by such Third Party during any calendar quarter during the Royalty Term, then the royalty rate to be paid by
EBP on Net Sales of such Product in such country during such quarter that are included in such tier of incremental annual Net Sales shall be reduced to the rate paid by the Third Party compulsory licensee for so long as such compulsory license
remains in effect. 
 (ii) Generic Competition. In the event that one or more Third Parties (other than any EBP Sublicensee) markets
a Generic Product in a given country from and after the first calendar quarter in which the total amount of gross sales of such Product by EBP and EBP Sublicensees in such country is less than [ * ] of the average amount of total quarterly gross
sales of such Product by EBP and EBP Sublicensees for the [ * ] consecutive calendar quarters immediately prior to the launch of the first Generic Product in such country, as measured by reputable published marketing data for such country (e.g. by
reference to sales data collected by IMS or other reputable source) and such percentage decrease in gross sales by EBP can be reasonably attributed to erosion due to the Generic Product sales and no other cause, such as other competition or
reduction in promotional efforts, the royalties to be paid by EBP on Net Sales of such Product in such country during such quarter shall be reduced to [ * ] of the royalties otherwise due to Janssen in such quarter with respect to such Product in
such country. 
 7. REPORTS AND PAYMENT TERMS 

7.1 Payment Terms. 
 (a)
Notice of Milestone Events and Milestone Payments. Written notice of achievement of each milestone event shall be provided as set forth in Section 6.1(a) or (b), as applicable. Payments for achieving milestones shall be made as set forth in
Section 6.1(a) or (b), as applicable. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 24 of 60 

 (b) Invoices. Any payment for an amount due to Janssen under this Agreement shall be
payable, except as otherwise expressly provided herein, within [ * ] after EBP receipt of an invoice from Janssen for such amount. Each invoice shall specifically refer to this Agreement. 

(c) Royalty Reporting and Payments. Within [ * ] days after the end of each calendar quarter EBP shall submit to Janssen a sales report
to the address listed in Section 15.11 (Attention: Finance Manager) setting forth, on a Product-by-Product and country-by-country basis, the Gross Sales, the deductions taken from Gross Sales, and the Net Sales of Product and a calculation of
the amount of royalty payment due on such Net Sales. This report shall also include the exchange rates and other methodology used in converting Net Sales into Euros, from the currencies in which sales were made in order to determine the appropriate
royalty tier and royalty payable. Royalty payments shall be made within [ * ] days from receipt by EBP of an invoice from Janssen for the amount reflected in the sales report under this Section 7.1(c). 

7.2 Remittance. All payments shall be made in immediately available funds by electronic transfer, by EBP or an Affiliate on its
behalf, to the bank account identified below or such other bank account as Janssen may designate in writing to EBP. Any payments due and payable under this Agreement on a date that is not a Business Day may be made on the next Business Day. If, at
any time, legal restrictions prevent the prompt remittance of part of or all of the royalties due hereunder with respect to any country where Products are sold, EBP shall have the right and option to make such payments by depositing the amount
thereof in local currency to Janssen’s account in a bank or depository in such country or by using such lawful means or methods as EBP may determine. 

Name of Bank: ING Belgium 

Bank address: Marnixlaan 24 

1000 Brussels 
 Belgium 

Company Name and Address: Janssen Pharmaceutica NV 

Turnhoutseweg 30 
 B2340 Beerse,
Belgium 
 [ * ] 
 7.3
Currency. All payments under this Agreement shall be payable in Euro. With respect to sales of a Product invoiced in a currency other than Euro, such amounts and the amounts payable hereunder shall be converted into their Euro equivalent using
an exchange rate equal to the simple monthly period average of the rates of exchange for the currency on the first 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 25 of 60 

 
and last day of each calendar month of the country from which such payments are payable as published by The Wall Street Journal, Western U.S. Edition, during the calendar quarter in
which the applicable sales were made. 
 7.4 Taxes.  

(a) EBP will make all payments to Janssen under this Agreement without deduction or withholding for Taxes except to the extent that any
such deduction or withholding is required by Applicable Law in effect at the time of payment. 
 (b) Any Tax required to be withheld
on amounts payable under this Agreement will be paid by Eiger on behalf of Janssen to the appropriate governmental authority, and EBP will furnish Janssen with proof of payment of such Tax. Any such Tax required to be withheld will be an expense of
and borne by Janssen. 
 (c) EBP and Janssen will cooperate with respect to all documentation required by any taxing authority or
reasonably requested by EBP to secure a reduction in the rate of applicable withholding Taxes. On or before the Effective Date, Janssen will deliver to EBP an accurate and complete Internal Revenue Service Form [W-9] [W-8BEN-E certifying that
Janssen is entitled to the applicable benefits under the Income Tax Treaty between Belgium and the United States]. 
 7.5 Records and
Audit Rights. 
 (a) Maintenance of Records. Each Party shall keep (and, in the case of EBP, EBP shall cause the EBP Sublicensees
to keep) complete, true and accurate books and records in accordance with its Accounting Standards in sufficient detail for the other Party to determine the payments due and costs incurred under this Agreement, including with respect to Patent
Expenses and royalties. Each Party will keep such books and records for at least [ * ] following the date of the payment to which they pertain. 

(b) Audit Right. Upon the written request of Janssen with respect to payments made by EBP pursuant to Article 6, not more than once in
each calendar year, EBP shall permit an independent certified public accounting firm of nationally recognized standing selected by Janssen and reasonably acceptable to EBP to have confidential access during normal business hours to such of the
records of EBP and its applicable EBP Sublicensees as may be reasonably necessary to verify the accuracy of the payments made under this Agreement for any period ending not more than [ * ] prior to the date of such request. The accounting firm shall
provide each Party a correct and complete copy of the report summarizing the final results of such audit, which shall be treated as EBP Confidential Information. Janssen shall obligate its accounting firm to keep EBP information confidential, and
shall at the request of EBP cause Janssen’s accounting firm to execute a reasonable confidentiality agreement prior to commencing any such audit. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 26 of 60 

 (c) Audit Fees and Results. The fees charged by such accounting firm shall be paid by
Janssen; provided, however, that if the audit uncovers an under- or over-payment in favor of EBP exceeding [ * ] of the total amount due in accordance with this Agreement, then the fees of such accounting firm shall be paid by EBP. Any underpayments
discovered by such audit or otherwise will be paid to Janssen within [ * ] of the date that Janssen delivers to EBP such accounting firm’s written report, or as otherwise agreed upon by the Parties, plus interest calculated in accordance with
Section 7.6. For any overpayments discovered by such audit EBP shall receive a credit equal to such overpayment against the royalty otherwise payable to Janssen. 

7.6 Late Payments. Interest shall be payable by EBP on any amounts payable to Janssen under this Agreement which are not paid by the due
date for payment. All interest shall accrue and be calculated on a daily basis (both before and after any judgment) at the rate of [ * ] per annum above the then-current prime rate quoted by Citibank in New York City (but in no event in excess of
the maximum rate permissible under Applicable Laws), for the period from the due date for payment until the date of actual payment. The payment of such interest shall not limit Janssen from exercising any other rights it may have as a consequence of
the lateness of any payment. 
 8. INTELLECTUAL PROPERTY RIGHTS 

8.1 Ownership. Ownership of all inventions arising in the course of the Development Program and Development Program Patent Rights shall
be determined in accordance with inventorship pursuant to U.S. patent laws. Accordingly: (i) all Development Program Inventions made solely by employees or consultants of one Party or such Party’s Affiliate or subcontractor shall be owned
by such Party; and (ii) all Development Program Inventions made jointly by one or more employees or consultants of EBP or its Affiliate or subcontractor and one or more employees or consultants of Janssen or its Affiliate or subcontractor shall
be owned jointly by the Parties. The Parties acknowledge that they do not contemplate that there would be any Development Program Inventions owned solely by Janssen given that the Development Program will be conducted by EBP. Subject to the terms
and conditions of this Agreement, and except as prohibited or limited by its express terms, each Party shall have the right to practice and use, and grant licenses to practice and use, each jointly owned Development Program Invention (if any)
without the other Party’s consent and shall have no duty to account to the other Party for such permitted practice, use or license except as expressly provided hereunder (including in Article 6). 

8.2 Patent Prosecution. 

(a) Janssen Patent Rights. 

(i) Prosecution Control. Janssen will have the right to control the Prosecution of the Janssen Patent Rights, using outside patent
counsel directed by Janssen, provided that EBP shall have the right to review and comment on drafts of substantive patent 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 27 of 60 

 
submissions prior to their filing in Patent Offices, and Janssen shall consider EBP’s reasonable requests with respect to the Prosecution of the Janssen Patent Rights. Janssen shall keep EBP
regularly and fully informed of the status of Janssen Patent Rights in the Territory and provide copies of all substantive documentation submitted to, or received from, the Patent Offices in connection therewith. After the Effective Date, Janssen
shall not, without EBP’s prior written consent, forgo or discontinue Prosecution of any Janssen Patent Right in any country in the Territory prior to obtaining from the Patent Office having jurisdiction in such country allowance or issuance of
at least one claim Covering a Compound being developed or commercialized by EBP in such country. 
 (ii) Patent Costs. EBP shall
reimburse Janssen for [ * ] of all Patent Expenses incurred by Janssen in the Prosecution of Janssen Patent Rights in the Territory after the Effective Date. Notwithstanding the foregoing in this Section 8.2(a), EBP may terminate its license
rights under Section 2.1 under any particular Janssen Patent Rights by written notice to Janssen identifying each such Janssen Patent Right for which EBP is electing to terminate its license rights hereunder. Effective as of the date of
Janssen’s receipt of such notice, EBP’s license rights under each such Janssen Patent Right shall terminate and EBP shall not be responsible for any Patent Expenses incurred by Janssen in the Prosecution of any such Janssen Patent Rights
after such license termination. 
 (b) Protection of Privileged Advice Shared for Common Interest. For the avoidance of doubt, any
opinions or other advice of any qualified legal personnel (whether a patent attorney or other counsel) representing a Party hereunder communicated to the other Party or both Parties, directly by such legal personnel or indirectly such as through a
patent liaison for common interest purposes contemplated hereunder (including under Section 8.3), shall be held in strict confidence to protect the privileged nature thereof, and not disclosed to any Third Party without the prior written
consent of both Parties, each under the advice of its respective legal counsel. 
 8.3 Patent Infringement. 

(a) Notice. During the Term, each Party will promptly notify the other of (i) any actual or threatened infringement
by a Third Party of any Janssen Patent Rights of which it becomes aware, including any certification filed by a Third Party pursuant to 21 U.S.C. §355(b)(2)(A)(iv) or 355(j)(2)(A)(vii)(IV) or any notice under comparable U.S. or foreign law
(a “Paragraph IV Certification”), which references the foregoing; or (ii) any actual or threatened challenge to any Janssen Patent Rights by a Third Party (collectively, “Third Party
Infringement”). The Parties will consult with each other through each Party’s patent attorneys to attempt to agree on a joint program of action in response to any Third Party Infringement.  

(b) Action Against Third Parties. If the Parties fail to agree on a joint program of action with respect to Third Party Infringement of
any Janssen Patent Rights, then [ * ] bring and control any legal action (including by initiating any lawsuit or other proceeding) as it 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 28 of 60 

 
reasonably determines appropriate in connection with the Third Party Infringement with respect to Janssen Patent Rights, and [ * ] shall have the right, at its own
expense, to be represented in any such action by counsel of its own choice.  
 (c) Conduct of Enforcement Action. [ * ] shall
have full control over the conduct of an action under this Section 8.3, including settlement thereof; provided, however, that in no event shall [ * ], through any such action, enter into any settlement arrangement or make any admission of
invalidity of, or otherwise impair [ * ] any Janssen Patent Rights without [ * ] prior written consent. 
 (d) Assistance. At the
request and expense of [ * ], [ * ] shall provide reasonable assistance in connection with a Third Party Infringement action with respect to Janssen Patent Rights under this Section 8.3, including by executing any required documents,
participating in discovery (including producing documentation and providing access to employees or relevant persons), and joining as a party to the action if required. [ * ] shall [ * ] providing such assistance within [ * ]. 

(e) Allocation of Awards. Unless otherwise agreed to by the Parties as part of any cost-sharing arrangement, any recoveries
resulting from an action under this Section 8.3 relating to a claim of Third Party Infringement with respect to Janssen Patent Rights (after payment of costs and expenses relating to such action incurred by each Party) will be retained by [ *
]; provided, however, that, if any portion of such recovery (after payment of each Party’s costs and expenses related to such action) is attributable to [ * ], [ * ] shall pay to [ * ] an amount equal to [ * ] under this Agreement. 

8.4 Trademarks. Subject to Sections 2.1(b) and 5.4, EBP and the EBP Sublicensees shall have the right to brand, at their discretion, the
Products using trademarks and trade names (other than the ZARNESTRA Mark) selected at their discretion and registered at their discretion in their own names.  

8.5 Patent Term Extensions. EBP acknowledges that nothing herein prohibits Janssen from licensing any Third Party rights under the
Janssen IP to any Compound or Products for use outside the Field, and that such a Third Party licensee of Janssen may receive Marketing Authorization for a Product outside the Field in a given country before EBP receives Marketing Authorization for
a Product in the Field in the same country. Upon EBP reasonable request after it receives applicable Marketing Authorization for a Product in the Field in a given country, Janssen shall use reasonable efforts to apply for a Patent Term Extension in
such country of a relevant Janssen Patent Right, and Janssen shall thereafter provide all reasonable assistance to EBP, including permitting EBP to proceed with the application for such Patent Term Extension in the name of Janssen, if so required
under Applicable Law. 
 8.6 Patent Marking; No Endorsement. Any patent markings on any Product made, used or sold by or on
behalf of EBP or any EBP Sublicensee (or when the character of the 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 29 of 60 

 
Product precludes marking, the package containing any such Product) shall be made in accordance with all Applicable Laws relating to patent marking. 

9. CONFIDENTIALITY 
 9.1
Confidentiality Obligation. All Confidential Information disclosed or made available by a Party (directly or through its Affiliates) to the other Party will be maintained in confidence and otherwise safeguarded by the recipient Party. The
recipient Party may only use the Confidential Information of the other Party and its Affiliates for the purposes expressly permitted by this Agreement. Each Party shall hold as confidential such Confidential Information of the other Party and its
Affiliates in the same manner and with the same protection as such recipient Party maintains its own confidential information, but no less than a reasonable standard of care. A recipient Party may only disclose Confidential Information of the other
Party and its Affiliates to investors, potential investors, lenders, potential lenders, employees, agents, contractors, consultants and advisers of the recipient Party and its Affiliates, licensees and sublicensees and to Third Parties to the extent
reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this Agreement; provided that such persons and entities are bound to maintain the confidentiality of the Confidential Information in a manner consistent with the
confidentiality provisions of this Agreement. 
 9.2 Exceptions. The obligations under Section 9.1 shall not apply to any
information within the Confidential Information to the extent the recipient Party can demonstrate by competent evidence that such information: 

(a) is (at the time of disclosure) or becomes (after the time of disclosure) known to the public or part of the public domain through no
breach of this Agreement by the recipient Party or its Affiliates; 
 (b) was known to, or was otherwise in the possession of, the
recipient Party or its Affiliates prior to the time of disclosure by the disclosing Party; 
 (c) is disclosed to the recipient Party
or any of its Affiliates on a non-confidential basis by a Third Party who is entitled to disclose it without breaching any confidentiality obligation to the disclosing Party or any of its Affiliates; or 

(d) is independently developed by or on behalf of the recipient Party or its Affiliates, as evidenced by its written records, without
reference to the Confidential Information disclosed by the disclosing Party or its Affiliates under this Agreement. 
 9.3 Authorized
Disclosures. 
 (a) Authorized Disclosures. In addition to disclosures allowed under Section 9.1, a Party may disclose
information within the Confidential Information of the other Party and its Affiliates to the extent such disclosure is necessary in the following instances: 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 30 of 60 

 
(i) for Prosecuting Patent Rights as permitted by this Agreement; (ii) for making regulatory filings for Products the recipient Party has a license or right to develop hereunder;
(iii) for prosecuting or defending litigation as permitted by this Agreement; (iv) for complying with applicable court orders or governmental regulations; (v) in the case of Janssen, for disclosing in confidence to Third Parties
to the extent required to comply with Existing Third Party Agreements; and (vi) for disclosing in confidence to actual or bona-fide potential Third Party investors or other Third Party transactional partners and to their bankers, lawyers,
accountants, agents, provided, in each case that each such Third Party investor or other transactional partner or advisor thereof is bound to maintain the confidentiality of the Confidential Information in a manner consistent with the
confidentiality provisions of this Agreement. 
 (b) Notification of Patent Filings. In the event a recipient Party or any of its
Affiliates discloses to a Patent Office any Confidential Information of the other Party in connection with the Prosecution of any Patent Rights, the recipient Party shall notify the other Party of such disclosure, and, if requested, provide a copy
of such disclosure as filed (which shall, to the extent it includes non-redacted information in addition to the Confidential Information of the other Party, be considered the recipient Party’s Confidential Information). 

(c) Disclosure Required by Applicable Laws. 

(i) In the event the recipient Party is required to disclose Confidential Information of the other Party by Applicable Laws, including
to comply with any order of any court or governmental or regulatory authority, such disclosure shall not be a breach of this Agreement; provided that the recipient Party (i) informs the other Party as soon as reasonably practicable of the
required disclosure, (ii) limits the disclosure to that reasonably required for the legal purpose and seeks protective treatment as available under Applicable Laws, and (iii) at the other Party’s request and expense, reasonably
assists in its attempt to intervene to directly limit or protect the disclosure of its Confidential Information. 
 (ii) In the event
a Party seeks to make a disclosure of this Agreement or any terms hereof to a government or regulatory authority as required by United States SEC regulations or other Applicable Laws applying to securities or by the rules of any recognized stock
exchange or quotation system, the other Party shall reasonably cooperate with respect to the timing, form and content of such required disclosure to the extent practicable under the circumstances, and, if so requested by it, the Party subject to
such disclosure obligation shall use commercially reasonable efforts to obtain an order protecting to the maximum extent possible the confidentiality of such provisions of this Agreement as reasonably requested by the other Party. If the other Party
does not provide consent as to the form or content of the required disclosure, such disclosure shall be limited to the minimum required, as reasonably determined by the disclosing Party in consultation with its legal counsel. 

(d) Regardless of any obligation of confidentiality hereunder, a Party may publish information regarding any of its clinical trials of
Products in accordance with its policy 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 31 of 60 

 
regarding public disclosure of such information consistently applied, and shall register information relating to clinical studies of Products as required by applicable law (e.g., with
www.clinicaltrials.gov when required by United States law). 
 9.4 Duration of Obligations. The obligations with respect to
maintaining the confidentiality of and restrictions on use of Confidential Information shall apply during the Term of this Agreement and continue for a period running [ * ] thereafter. 

10. PUBLICATIONS AND PUBLICITY 
 10.1
Scientific Publications. Any proposed oral or written publications (such as any abstracts, manuscripts, posters, slide presentations or other materials) of any activities or results relating to the Development Program shall not be made without
the review of the other Party prior to their submission to the publisher or other release. For the avoidance of doubt, this Section 10.1 shall not apply to public disclosures required by Applicable Laws or the rules of any recognized stock
exchange or quotation system as applicable, which are governed by Section 9.3(c)(ii) above. Each Party shall have the right to review and comment on a draft of any such material proposed for publication by the other Party, including for
purposes of ensuring that none of its Confidential Information is disclosed without its permission. The Party proposing any such publication shall deliver a complete draft to the other Party at least [ * ] prior to submitting the material to a
publisher or initiating any other release. Such other Party shall review any such material and give its comments to the Party proposing publication within [ * ] of the delivery of such draft to such other Party. The publishing Party shall comply
with the other Party’s request to: delete from any such proposed publication material prior to its submission or release any references to the other Party and/or any of its Confidential Information; and/or delay any submission or release for a
period of up to an additional [ * ] to permit the other Party to prepare and file, or have prepared and filed, any patent applications for any Development Program Inventions as contemplated hereunder. 

10.2 Publicity. Janssen hereby consents to EBP’s issuance of the press release attached hereto as Exhibit 8 after execution
of this Agreement. No other press release, announcement, or other public statement, whether oral or written, disclosing the existence of this Agreement, any terms hereof, or any information relating to this Agreement or performance hereunder shall
be made, either directly or indirectly, by a Party without the prior written consent of the other Party, except as may be legally required by Applicable Laws or judicial order, without first obtaining the consent of the other Party as to the nature,
text, and timing of such announcement, which consent shall not be unreasonably withheld. A Party desiring to make any such public announcement shall provide the other Party with a draft thereof at least [ * ] prior to the date on which such Party
would like to make the public announcement. For the avoidance of doubt, this Section 10.2 shall not prohibit either Party from making any public statement as required to comply with any duty of disclosure it may have pursuant to Applicable Laws
or the applicable rules of any recognized stock exchange or quotation system as applicable. A Party may reissue a press release or public announcement or make such other public statement if the 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 32 of 60 

 
contents of such press release, public announcement or public statement have previously been made public other than through a breach of this Agreement by the issuing Party or its Affiliates. 

10.3 Use of Names. Nothing contained in this Agreement will be construed as conferring any right to a Party to use in advertising,
publicity or other promotional activities any name, trade name, trademark or other designation of the other Party or any of its Affiliates (including a contraction, abbreviation or simulation of any of the foregoing).  

11. REPRESENTATIONS, WARRANTIES AND COVENANTS; DISCLAIMERS 

11.1 Representations and Warranties by Each Party. Each Party represents and warrants to the other Party as of the Execution Date that:
 
 (a) it is duly organized, validly existing, and in good standing under the laws of its jurisdiction of formation; 

(b) it has full corporate power and authority to execute, deliver, and perform this Agreement, and has taken all corporate action
required by law and its organizational documents to authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement; 

(c) this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms (except as the
enforceability thereof may be limited by bankruptcy, bank moratorium or similar laws affecting creditors’ rights generally and laws restricting the availability of equitable remedies and may be subject to general principles of equity whether or
not such enforceability is considered in a proceeding at law or in equity); and 
 (d) the execution and delivery of this Agreement
and all other instruments and documents required to be executed pursuant to this Agreement, and the consummation of the transactions contemplated hereby do not and shall not (i) conflict with or result in a breach of any provision of its
organizational documents, (ii) result in a breach of any agreement to which it is a party; or (iii) to its knowledge, violate any Applicable Laws. 

11.2 Additional Representations and Warranties by Janssen. Janssen represents and warrants to EBP as of the Execution Date that: 

(a) Exhibit 2(A) lists all Patent Rights existing as of the Execution Date that are owned by Janssen or any of its Affiliates and
include any claim Covering any Compounds or their manufacture or use, or any Product in clinical development as of the Execution Date or its formulation or use; and Exhibit 2(B) lists all sublicensable Patent Rights that are licensed by
Janssen or any of its Affiliates and include any claim Covering any Compounds or their manufacture or use, or any Product in clinical development as of the Execution Date or its formulation or use. and to the knowledge of Janssen, neither Janssen
nor any of Affiliates owns or otherwise controls any Patent Rights necessary or reasonably useful to Develop, Manufacture, 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 33 of 60 

 
use, import, offer for sale, sell, or otherwise Commercialize any Compound or Product as formulated by Janssen for its clinical trials in the Field in the Territory other than those listed on
Exhibit 2(A) and Exhibit 2(B); 
 (b) Janssen or an Affiliate thereof is the sole and exclusive owner of the Patent
Rights listed in Exhibit 2(A), except as otherwise noted therein; 
 (c) to the knowledge of Janssen, the Janssen Know-How
contained in the records listed in Exhibit 3, which will be updated within [ * ] of the Effective Date, includes all Know-How in Janssen’s possession and Control as of the Execution Date that is necessary or reasonably useful for to the
Development and Commercialization of a Compound; 
 (d) Janssen has provided to EBP true and complete copies of the UT License as in
effect on the Effective Date (excluding the financial terms), the UT License is in full force and effect, and Janssen has complied with all terms of the UT License material to this Agreement; 

(e) to the knowledge of Janssen, the records listed in Exhibit 5 includes all Existing Third Party Agreements material to the
Development or Commercialization of any Compound in the Field in the Territory; 
 (f) Janssen has the right to grant the licenses and
other rights to EBP as purported to be granted pursuant to this Agreement, including the right to use and disclose and to enable EBP to use and disclose (in each case under appropriate conditions of confidentiality) the Janssen Know-How, and Janssen
has not granted any license or other rights to any Third Party that is inconsistent with the licenses and rights granted to EBP hereunder; 

(g) to the knowledge of Janssen and except to the extent not yet due, all necessary and material application, registration, maintenance
and renewal fees in respect of the pending or extant Janssen Patent Rights listed in Exhibit 2(A) in existence as of the Effective Date have been paid and, except to the extent not yet due, all necessary documents and certificates have been
filed with the relevant Patent Offices for the purpose of maintaining such Janssen Patent Rights; 
 (h) to the knowledge of Janssen,
there are no claims, judgments or settlements against Janssen relating to the Janssen Patent Rights listed in Exhibit 2(A); 

(i) to the knowledge of Janssen, Janssen has not received any notice from any Third Party asserting or alleging that tipifarnib (also
known as R115777) or its method of use in clinical trials by or on behalf of Janssen before the Execution Date infringed or misappropriated any intellectual property rights of any Third Party; and 

(j) to the knowledge of Janssen, there is no actual infringement of any Janssen Patent Rights by any Third Party. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 34 of 60 

 11.3 Covenants.  

(a) No Conflict. Janssen shall not grant any right or enter into any agreement with any Third Party that would conflict with any of EBP
rights or Janssen’s obligations under this Agreement. EBP shall not grant any right or enter into any agreement with any Third Party that would conflict with any of Janssen’s rights or EBP obligations under this Agreement. 

(b) Intellectual Property Ownership and Confidentiality. Each Party shall require that all of its and its Affiliates’ employees,
consultants, contractors and agents involved in the Development, Manufacture or Commercialization of Compounds or Products have entered into written confidentiality and invention assignment agreements that are consistent with the terms of this
Agreement and pursuant to which they assign any rights they may have in any inventions relating to Compounds or Products made during such work to such Party; provided, however, that such invention assignment requirement shall not apply with respect
to a contractor or consultant that is a university or other non-profit research institution or academic collaborator if a non-exclusive license (with or without any right to obtain an exclusive license), with right to grant sublicenses, to any such
inventions relating to Compounds or Products made during work performed by such contractor or consultant and to corresponding Patent Rights thereon is granted to such Party so as to preserve each Party’s ability to exercise its rights as
provided hereunder without any payment obligation to any such contractor or consultant. 
 (c) Compliance with Law. Each Party shall
perform its obligations under this Agreement in accordance with all Applicable Laws, including FCPA. No Party shall, or shall be required to, undertake any activity under or in connection with this Agreement which violates, or which it believes, in
good faith, may violate, any Applicable Laws. Without limiting the foregoing, each Party agrees that it shall, and shall cause its Affiliates and sublicensees to, (a) comply with all applicable international, national, state regional and local
laws and regulations, including FCPA, in performing its obligations and/or exercising its rights hereunder, including with respect to any use, manufacture, sale or import of Products, (b) observe all applicable United States and foreign laws
with respect to the transfer of Products and related technical data to countries other than the United States, including all Export Control Laws, and (c) manufacture Products in compliance with applicable government importation laws and
regulations of a particular country for Products made outside the particular country in which such Products are used, sold or otherwise exploited. In furtherance of the foregoing, each Party and its subcontractors and sublicensees shall conduct
their activities hereunder in accordance with the guidelines set forth in Exhibit 7 (Compliance with Laws and the FCPA). 
 11.4
Debarment. EBP shall not use in conducting any applicable Development activities under this Agreement any person who has been: 

(a) debarred, or proposed to be debarred under Section 306(a) or 306(b) of the United States Federal Food, Drug and Cosmetic Act,
as amended from time to time, and the rules, regulations and guidelines promulgated thereunder, or under 42 U.S.C. Section 1320-7; 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 35 of 60 

 (b) sanctioned by, suspended, debarred, excluded or otherwise ineligible to participate in
any federal or state health care program, including Medicare and Medicaid or in any federal procurement or non-procurement programs; or 

(c) charged with or convicted of any felony or misdemeanor under 42 U.S.C. Section 1320a-7(a) or 42 U.S.C.
Section 1320a-7(b)(1)-(3), or otherwise proposed for exclusion. 
 EBP will promptly inform Janssen, but in no event later than five (5) Business
Days, if EBP becomes aware that its or any of its Affiliates or sublicensees or subcontractors, or any employee of EBP or any of its Affiliates or sublicensees or subcontractors, in each case performing any Development activities under this
Agreement or in support of the Marketing Authorizations, is not in compliance with any of the criteria set forth in this Section 11.4 on or after the Effective Date. 

11.5 Limitations. Notwithstanding anything contained in this Agreement, Janssen gives no warranty and makes no representation that any
patent application within the Janssen Patent Rights shall proceed to grant or that any patent within the Janssen Patent Rights will be valid and enforceable. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY EXPRESSLY DISCLAIMS
ANY AND ALL REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTIES OF NON-INFRINGEMENT OR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NEITHER PARTY MAKES ANY
REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT ANY OF THE DEVELOPMENT AND/OR COMMERCIALIZATION EFFORTS WITH REGARD TO ANY PROGRAM COMPOUND OR PRODUCT WILL BE SUCCESSFUL. 

12. INDEMNIFICATION; INSURANCE 
 12.1
Indemnification by EBP. EBP shall, and shall require the EBP Sublicensees to, indemnify and hold harmless Janssen and its Affiliates, and their respective officers, directors, employees, contractors, agents and assigns (each, a
“Janssen Indemnified Party”), from and against any losses, damages and liability, including reasonable legal expense and attorneys’ fees (collectively, “Indemnified Losses”), incurred by any
Janssen Indemnified Party as a result of any Third Party demands, claims or actions, including product liability claims (collectively, “Claims”) against any Janssen Indemnified Party arising or resulting from: (a) the
negligence or willful misconduct of EBP in performing EBP’s obligations or exercising EBP’s rights under this Agreement; (b) the breach of any of the covenants, warranties and representations made by EBP to Janssen under this
Agreement; (c) Development Program activities conducted by or on behalf of EBP; or (d) the Development, Manufacture, use, sale, offer for sale, other Commercialization or importation of any Compounds or Products in the Field in the
Territory by EBP or any of its Affiliates, licensees or sublicensees (other than Janssen, if applicable). Notwithstanding the foregoing, EBBP shall not be responsible for the indemnification of any Janssen Indemnified Party to the extent that
the Indemnified Losses of such Janssen Indemnified Party were caused 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 36 of 60 

 
by: (i) the negligence or willful misconduct of such Janssen Indemnified Party; or (ii) any breach by Janssen of its covenants, obligations, warranties or representations pursuant to
this Agreement. 
 12.2 Indemnification by Janssen. Janssen shall indemnify and hold harmless EBP and its Affiliates and Sublicensees,
and their respective officers, directors, employees, contractors, agents and assigns (each, an “EBP Indemnified Party”), from and against Indemnified Losses incurred by any EBP Indemnified Party as a result of any Claims
against any EBP Indemnified Party arising or resulting from: (a) the research, development, manufacture or commercialization of any Compounds and/or Products by or on behalf of Janssen, its Affiliates or any Janssen Sublicensee; (b) the
negligence or willful misconduct of Janssen in performing Janssen’s obligations or exercising Janssen’s rights under this Agreement; or (c) the breach of any of the covenants, warranties and representations made by Janssen to EBP
under this Agreement. Notwithstanding the foregoing, Janssen shall not be responsible for the indemnification of any EBP Indemnified Party to the extent that the Indemnified Losses of such EBP Indemnified Party were caused by: (i) the
negligence or willful misconduct of such EBP Indemnified Party; or (ii) any breach by EBP of its covenants, obligations, warranties or representations pursuant to this Agreement. 

12.3 Indemnification Procedure. 

(a) Notification. Any Janssen Indemnified Party or EBP Indemnified Party seeking indemnification hereunder
(“Indemnified Party”) shall notify the Party against whom indemnification is sought (“Indemnifying Party”) in writing reasonably promptly after the assertion against the Indemnified Party of any
Claim in respect of which the Indemnified Party intends to base a claim for indemnification hereunder, but the failure or delay so to notify the Indemnifying Party shall not relieve the Indemnifying Party of any obligation or liability that it may
have to the Indemnified Party, except to the extent that the Indemnifying Party demonstrates that its ability to defend or resolve such Claim is adversely affected thereby.  

(b) Indemnifying Party Right to Handle Claims. Subject to the provisions of Section 12.3(d) and (e) below, the Indemnifying
Party shall have the right, upon written notice given to the Indemnified Party within thirty (30) days after receipt of the notice from the Indemnified Party of any Claim, to assume the defense and handling of such Claim at the Indemnifying
Party’s sole expense, in which case the provisions of Section 12.3(c) below shall govern. 
 (c) Indemnifying Party Handling of
Claims. The Indemnifying Party shall select counsel reasonably acceptable to the Indemnified Party in connection with conducting the defense and handling of such Claim, and the Indemnifying Party shall defend or handle the same in consultation
with the Indemnified Party, and shall keep the Indemnified Party timely apprised of the status of such Claim. The Indemnifying Party shall not, without the prior written consent of the Indemnified Party, agree to a settlement of any Claim which
could lead to liability or 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 37 of 60 

 
create any financial or other obligation on the part of the Indemnified Party for which the Indemnified Party is not entitled to indemnification hereunder, or would involve any admission of
wrongdoing on the part of the Indemnified Party. The Indemnified Party shall cooperate with the Indemnifying Party, at the request and expense of the Indemnifying Party, and shall be entitled to participate in the defense and handling of such Claim
with its own counsel and at its own expense. Notwithstanding the foregoing, in the event the Indemnifying Party fails to conduct the defense and handling of any Claim in good faith after having assumed such, then the provisions of
Section 12.3(e) below shall govern. 
 (d) Right of Indemnified Party to Assume Handling of Claims. If the Indemnifying Party
does not give written notice to the Indemnified Party, within thirty (30) days after receipt of the notice from the Indemnified Party of any Claim, of the Indemnifying Party’s election to assume the defense and handling of such Third Party
Claim, the provisions of Section 12.3(e) below shall govern. 
 (e) Indemnified Party Handling of Claims. Unless
Section 12.3(c) applies, the Indemnified Party may, at the Indemnifying Party’s expense, select counsel reasonably acceptable to the Indemnifying Party in connection with conducting the defense and handling of such Claim and defend or
handle such Claim in such manner as it may deem appropriate, provided, however, that the Indemnified Party shall keep the Indemnifying Party timely apprised of the status of such Claim and shall not settle such Claim without the prior written
consent of the Indemnifying Party, which consent shall not be unreasonably withheld. If the Indemnified Party defends or handles such Claim, the Indemnifying Party shall cooperate with the Indemnified Party, at the Indemnified Party’s request
but at no expense to the Indemnified Party, and shall be entitled to participate in the defense and handling of such Claim with its own counsel and at its own expense. 

12.4 Insurance. Each Party, at its own expense, shall maintain liability insurance in an amount consistent with industry standards
during the Term, but in no event shall such insurance be in an amount less than [ * ] per occurrence/annual aggregate during the Term. In addition, during the term of commercialization and for a period of at least [ * ] thereafter, EBP shall
maintain product liability insurance in an amount not less than [ * ] per occurrence and annual aggregate. A Party responsible for the conduct any clinical studies hereunder shall maintain clinical trial insurance in compliance with all Applicable
Law pertaining to the jurisdictions in which such clinical studies are conducted. Each Party shall provide a certificate of insurance evidencing such coverage to the other Party upon its written request. Each Party shall notify the other thirty
(30) days in advance of cancelation of any such insurance. 
 12.5 Materials Provided As Is. EEBP acknowledges that compounds,
reagents, and other materials supplied by Janssen hereunder are experimental in nature and provided as is, without any warranties as to merchantability or fitness for a particular purpose. EBP further acknowledges that all of such materials’
properties or characteristics are not known, and agrees that it shall use such materials with reasonable care and shall assume responsibility for any losses 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 38 of 60 

 
or injuries incurred by it or its Affiliates or subcontractors or sublicensees through use of such materials. 

13. TERM AND TERMINATION 

13.1 Term. The term of this Agreement (the “Term”) will commence on the Effective
Date and, subject to earlier termination in accordance herewith, shall expire on the last to occur of: (a) the expiry of the last-to-expire patent term, or conclusion of Prosecution of the last-to-be-Prosecuted, of the Janssen Patent Rights; or
(b) the expiration of the last-to-expire Royalty Term. 
 13.2 Termination for Cause by Either Party.  

(a) By Janssen for EBP’s Lack of Diligence. In the event that EBP fails to use Commercially Reasonable Efforts to Develop and
Commercialize at least one Product with respect to a Major Market Country as described in Sections 4.1 and 5.1, then (without limiting Janssen’s right to seek termination of the entire Agreement pursuant to Section 13.2(b) below if
such breach by EBP is material to the Agreement in its entirety) Janssen may terminate EBP’s license rights under this Agreement with respect to such Major Market Country upon written notice to EBP, provided that EBP will have a period of
[ * ] following receipt of such notice to demonstrate to Jansen’s reasonable satisfaction that EBP has not failed to use Commercially Reasonable Efforts in accordance with Section 4.1 or 5.1. Notwithstanding anything to the
contrary in this Agreement, EBP’s and the EBP Sublicensees’ collective efforts and resources expended toward Developing and Commercializing any Products throughout the Territory shall be considered in determining whether EBP has met its
diligence obligations under Sections 4.1 and 5.1 with respect to any particular Major Market Country. 
 (b) By Either Party
for the Other Party’s Material Breach. If either Janssen or EBP (in such capacity, the “Breaching Party”) is in material breach of this Agreement (excluding any breach described in Section 13.2(a), in
which case such provision shall govern), the other Party (in such capacity, the “Non-Breaching Party”) may give written notice to the Breaching Party specifying the claimed particulars of such breach, and in such event, if
the breach is not cured within [ * ] after such notice ([ * ] in the event of failure to make any payment when due), the Non-Breaching Party shall have the right thereafter to
terminate this Agreement by giving written notice to the Breaching Party to such effect, provided, however that if such breach (other than failure to make any payment when due) is capable of being cured but cannot be cured within such
[ * ] period and the Breaching Party initiates actions to cure such breach within such period and thereafter diligently pursues such actions, the Breaching Party shall have an additional [ *
] to cure such breach.  
 (c) Suspension of Time Periods for Curing Breach. From the date of
initiation of any measures under Section 15.6 to resolve a Dispute pertaining to an alleged breach under Section 13.2(a) or (b) and until such time as such Dispute has been finally resolved under

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 39 of 60 

 
Section 15.6, the running of the time periods under this Section 13.2 as to which a Party must cure a breach of this Agreement shall be suspended as to the subject matter of the
Dispute. 
 (d) By Either Party for the Other Party’s Bankruptcy. In the event of the Bankruptcy of a Party (or its successor in
interest in the event this Agreement is assigned as permitted hereunder), the other Party may terminate this Agreement by notice to the bankrupt Party. 

13.3 Termination Without Cause by EBP. EBP may terminate this Agreement at any time after the [ * ] upon [ * ] prior written notice to
Janssen.  
 14. EFFECT OF TERMINATION 

14.1 Effect of Termination of Rights in Particular Country. Upon any early termination with respect to a Major Market Country under
Section 13.2(a), any licenses and sublicenses granted by Janssen to EBP with respect to such Major Market Country will terminate and revert to Janssen, and the Territory shall be redefined to exclude such Major Market Country from the scope of
the Territory, and the terms of Section 14.2 below shall apply mutatis mutandi with respect to such Major Market Country. 

14.2 Effect of Termination by Janssen under Section 13.2(b) or by EBP under Section 13.3. Upon any early termination of this
Agreement in its entirety by Janssen pursuant to 13.2(b) or by EBP pursuant to Section 13.3: 
 (a) The licenses and
sublicenses granted by Janssen to EBP will terminate and revert to EBP (except any license in any country that has become perpetual and irrevocable as provided in Section 6.3(b)). 

(b) If EBP has initiated clinical development of, or obtained Marketing Authorization for, any Compounds or
Products or Commercialized any Products (each a “Reverted Product”), EBP shall promptly provide to Janssen a summary of the status of the Development and Commercialization of any such Reverted Products up to such termination
and: (i) Janssen shall have, and EBP hereby grants to Janssen, a paid-up, exclusive option, during the [ * ] running from termination of this Agreement, to elect to develop and commercialize any such Reverted
Products; and (ii) during such option period, prior to notice of Janssen’s election decision or upon EBP reasonable request, Janssen shall permit EBP to undertake activities to wind down in a commercially reasonable manner any ongoing
development or commercialization activities with respect to each such Product for which EBP license rights under this Agreement have been terminated (subject to EBP obligation under Sections 6.2 and 6.3 to pay any milestones and royalties that may
accrue during such wind-down period on account of Net Sales of such Reverted Products from the supply on hand as of the termination). Promptly after EBP receipt of a notice within the [ * ] option exercise period
of Janssen’s election to take over development and commercialization of such a Reverted Product, the Parties 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 40 of 60 

 
shall negotiate in good faith and enter into a written confirmatory agreement under which: (x) EBP shall grant Janssen a worldwide, exclusive, sublicenseable right and
license to develop and commercialize such Reverted Product under the EBP Patent Rights (if any) and applicable Know-How (including data submitted to Regulatory Authorities) Controlled by EBP (directly or through its Affiliates or sublicensees) that
was developed by or on behalf of EBP in its development of the Product; and (y) Janssen shall pay EBP a royalty on Net Sales of such Reverted Product [ * ], with provisions parallel to those set forth in
Sections 6.3 and 7 hereof applicable mutatis mutandi to Janssen’s royalty payments. Moreover, if Janssen reasonably requests in the notice of its exercise of such option rights under this Section that EBP also grant
Janssen rights to trademarks Controlled by EBP that are directly associated with the Reverted Product, or to any valuable core or platform technology utilized by EBP to manufacture or commercialize the Product that is Covered by Patent Rights
Controlled by EBP, the confirmatory agreement shall specify the terms (including any agreed-upon transfer cost payments from Janssen to EBP) under which EBP would transfer to such requested rights in trademarks associated with the Reverted Product
and/or licenses under such Patent Rights (solely to the extent necessary for the development and/or commercialization of the Reverted Product), which terms will be commercially reasonable and fair considering the particular reason for termination.
For clarification, any license granted to Janssen as described in this Section 14.2(b) will include the right to use clinical and regulatory data and information generated by EBP for regulatory purposes relating to the Reverted Products. In
connection with any exclusive license to Reverted Products granted under this Section 14.1(b), EBP shall transfer and assign to Janssen all of its right, title and interest in and to all U.S. and foreign Marketing Authorizations with respect to
the Reverted Products and all drug master files and drug dossiers with respect to the Reverted Products (other than those related to manufacturing facilities).  

(c) EBP or EBP Sublicensees shall continue, to the extent that EBP or EBP Sublicensees continue to have stocks of usable Reverted
Products, to fulfill orders received for Products in the Territory until [ * ] following the date of termination. For Reverted Products sold by EBP or EBP Sublicensees after the effective date of a termination, EBP shall continue to pay sales
milestones and royalties pursuant to Sections 6.2(b) and 6.3. Prior to the end of such [ * ] period, EBP shall provide Janssen written notice of an estimate of the quantity of Reverted Products and shelf life remaining in the inventory of EBP or EBP
Sublicensees and Janssen shall have the right, upon its election to take an exclusive license to Reverted Products under Section 14.2(b), to purchase any such quantities of Reverted Products from EBP and EBP Sublicensees at a price mutually
agreed by the Parties. In addition, EBP shall use commercially reasonable efforts to transition to Janssen upon Janssen’s request any arrangement with any contractor from which EBP had arranged to obtain supplies of Reverted Products (or the
Compounds therein), to the extent permitted under any such agreement with such contractor. In the event that Reverted Products are manufactured by EBP or its Affiliate, then, upon request by Janssen, EBP shall continue to provide Janssen with such
materials at a price to be agreed by the Parties for not longer than [ * ]. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 41 of 60 

 (d) In the event that EBP has any Development activities with regard to any Reverted
Products ongoing, the Parties shall negotiate in good faith and adopt a plan to wind-down the development activities in an orderly fashion or, at Janssen’s election of exclusive license rights pursuant to Section 14.2(b), promptly
transition such Development activities for any Reverted Products to Janssen or its designee, with due regard for patient safety and the rights of any subjects that are participants in any clinical trials of any Reverted Product and take any actions
it deems reasonably necessary or appropriate to avoid any human health or safety problems and in compliance with all Applicable Laws. 

(e) The provisions of this Section 14.2 shall survive such termination for so long as Janssen or any of its Affiliates, licensees
or sublicensees Develops or Commercializes any Reverted Product hereunder. 
 (f) Except as provided in this Section 14.2, Eiger
will immediately cease to use, distribute, or market the Reverted Products. 
 (g) Upon Janssen’s request, EBP will promptly
return, or at Janssen’s option, destroy, any Janssen Know-How or any materials containing the Janssen Know-How or any Confidential Information of Janssen in EBP’s possession, except for one archival copy to safekeep for legal purposes and
such records as may be required to be retained by EBP by Applicable Laws, all of which shall continue to be subject to the confidentiality and non-use obligations in Article 9. 

14.3 Effect of Termination by EBP under Section 13.2. Upon termination of this Agreement by EBP pursuant to Section 13.2: 

(a) The licenses and sublicenses granted by Janssen to EBP will terminate and revert to Janssen (except any license in any country that
has become perpetual and irrevocable as provided in Section 6.3(b). 
 (b) EBP or EBP Sublicensees shall continue, to the extent
that EBP or EBP Sublicensees continue to have stocks of usable Reverted Products, to fulfill orders received for Reverted Products in the Field until [ * ] following the date of termination. For Products sold by EBP or EBP Sublicensees after the
effective date of a termination, EBP shall continue to pay sales milestones and royalties pursuant to Sections 6.2(b) and 6.3. Except as provided in this Section 14.2(b), EBP will cease to use, distribute, or market the Products. 

(c) Following the period set forth in Section 14.2(b), each Party will promptly return, or at the other Party’s option,
destroy any Know-How of such other Party or any materials containing such Know-How or any Confidential Information of such other Party in its or its Affiliates’ possession, except for one archival copy to safekeep for legal purposes and such
records as may be required to be retained by such Party by Applicable Laws, all of which shall continue to be subject to the confidentiality and non-use obligations in Article 10. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 42 of 60 

 14.4 Survival. Expiration or termination of this Agreement shall not relieve the Parties
of any obligation (including any payment obligations in Article 6) accruing prior to such expiration or termination, nor affect in any way the survival of any other right, duty or obligation of the Parties which is expressly stated elsewhere in this
Agreement to survive such termination or expiry. Without limiting the foregoing, the provisions of Articles 1, 9, 14 (including the additional sections referenced therein) and 15 and Sections 7.5, 8.1, 10.2, 10.3, 11.5, 12.1, 12.2, 12.3 and 12.5,
and any other provisions that should survive as apparent from the express terms thereof in the context of this Agreement, shall survive expiration or termination of this Agreement.  

14.5 Exercise of Right to Terminate. The exercise by either Party of an early termination right provided for under Article 14 shall not
give rise to the payment of damages or any other form of compensation or relief to the other Party on account of such exercise. 

14.6 Damages; Relief. Subject to Section 14.5, early termination of this Agreement under Article 14 shall not preclude either Party
from claiming any other damages, compensation or relief that it may be entitled to upon such termination. 
 14.7 Rights in
Bankruptcy. All rights and licenses and sublicenses granted under or pursuant to this Agreement by a Party to the other are, and will otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code (or comparable
provisions of laws of other jurisdictions), licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code (or comparable provisions of laws of other jurisdictions). The Parties agree that the
Parties, as licensees of such rights under this Agreement, will retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code (and comparable laws of other jurisdictions). The Parties further agree that, in the event
of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code (and comparable laws of other jurisdictions), the Party that is not a party to such proceeding will be entitled to a complete duplicate of (or
complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and same, if not already in their possession, will be promptly delivered to them (a) upon any such commencement of a
bankruptcy proceeding upon their written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its obligations under this Agreement, or (b) if not delivered under subsection (a) above, following
the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party. All rights, powers and remedies granted hereunder to a Party as a licensee of any intellectual property
rights as provided in this Section 14.7 are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity, in the event of the commencement of a Bankruptcy case by or
against the granting Party under Applicable Law, and the licensee Party, in addition to the rights, powers and remedies expressly provided herein, shall be entitled to exercise all other such rights and powers and resort to all other such remedies
as may now or hereafter exist at law or in equity in such event.  

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 43 of 60 

 15. GENERAL PROVISIONS 

15.1 Assignment. Neither Party may assign its rights and obligations under this Agreement without the other Party’s prior written
consent, except that (a) either Party may assign its rights and obligations under this Agreement or any part hereof to one or more of its Affiliates without the consent of any other Party, provided that the Party assigning to an Affiliate any
part of this Agreement shall remain liable and responsible to the non-assigning Party for the performance and observance of all such duties and obligations by such Affiliate; and (b) either Party may assign this Agreement in its entirety to a
successor to all or substantially all of its business relating to Compounds and Products, whether by merger, sale of stock, sale of assets or otherwise, provided that in the event of a transaction (whether this Agreement is actually assigned or is
assumed by the acquiror by operation of law (e.g., in the context of a reverse triangular merger)), intellectual property rights of the acquiror to such transaction (if other than one of the Parties to this Agreement) existing before such
transaction, or arising after such transaction through activities conducted in good faith separately and independently by such acquiror or its Affiliates and without use of any Confidential Information of the acquired Party, as can be demonstrated
by adequate evidence, shall not become subject to this Agreement. The assigning Party shall provide the other Party with prompt written notice of any such assignment. This Agreement shall be binding upon and inure to the benefit of the Parties
hereto and their respective successors and permitted assigns. Any attempted assignment in contravention of the foregoing shall be void.  

15.2 Performance by Affiliates; EBP Performance by Subcontractor. Subject to the terms and conditions of this Agreement, any obligation
of a Party under or pursuant to this Agreement may be satisfied, met or fulfilled, in whole or in part, either by such Party directly or by any Affiliate of such Party that such Party causes to satisfy, meet or fulfill such obligation, in whole or
in part. Each Party shall remain liable for the performance of all actions, agreements and obligations to be performed by any Affiliates of such Party under the terms and conditions of this Agreement. Subject to the terms and conditions of this
Agreement, EBP shall have the right to engage subcontractors for the purpose of performing its obligations under this Agreement.  

15.3 Severability. Should one or more of the provisions of this Agreement become void or unenforceable as a matter of law, then this
Agreement shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect, and the Parties will use their commercially reasonable efforts to substitute for the invalid or
unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties.  

15.4 Special, Indirect and Other Losses. IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS AFFILIATES BE LIABLE FOR SPECIAL, INDIRECT,
INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR FOR ANY ECONOMIC LOSS OR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY, EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE 9 OR TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 44 of 60 

 
TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM SUBJECT TO INDEMNIFICATION PURSUANT TO ARTICLE 13. PAYMENTS ACCRUED AND PAYABLE UNDER ARTICLE 6 AND NOT PAID WHEN OWED SHALL BE TREATED AS GENERAL
DAMAGES (NOT SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR ECONOMIC LOSSES OR LOST PROFITS). 
 15.5 Governing
Law. This Agreement shall be governed by and construed under the laws of the State of New York, U.S., without reference to its conflicts of law principles with the exception of sections 5-1401 and 5-1402 of New York General Obligations Law
(without limiting the Parties’ rights and obligations under Section 15.6). The United Nations Conventions on Contracts for the International Sale of Goods shall not be applicable to this Agreement. 

15.6 Dispute Resolution. 

(a) Resolution of Disputes. The Parties shall negotiate in good faith and use reasonable efforts to settle any Dispute arising from or
related to this Agreement or the breach thereof. If the Parties cannot resolve the Dispute within [ * ] of a written request by either Party to the other Party, the Parties agree to hold a meeting, attended by the Senior Officers (or their designee
with executive authority), as appropriate in light of the subject matter of the Dispute, to attempt in good faith to negotiate a resolution of the Dispute prior to pursuing other available remedies. If, within [ * ] after such written request, the
Parties have not succeeded in negotiating a resolution of the Dispute, and a Party wishes to pursue the matter, each such Dispute that is not an Excluded Claim shall be resolved by binding arbitration in accordance with the Commercial Arbitration
Rules and Supplementary Procedures for Large Complex Disputes of the American Arbitration Association (AAA) as then in effect, and judgment on the arbitration award may be entered in any court having jurisdiction thereof. The decision rendered in
any such arbitration will be final and not appealable. If either Party intends to commence binding arbitration of such Dispute, such Party will provide written notice to the other Party informing the other Party of such intention and the issues to
be resolved. Within [ * ] after the receipt of such notice, the other Party may by written notice to the Party initiating binding arbitration, add additional issues to be resolved. 

(b) Arbitration Panel. The arbitration shall be conducted by a panel of three (3) neutral arbitrators, none of whom is a current or
former employee or director, or a then-current stockholder, of either Party or their respective Affiliates. Unless otherwise agreed by the Parties, each of the arbitrators will be a lawyer with at least fifteen (15) years of experience with a
law firm or corporate law department or who was a judge of a court of general jurisdiction, and who has reasonable experience in arbitrating contract disputes within the pharmaceutical and biotechnology sector. Within [ * ] after receipt of the
original notice of binding arbitration (the “Notice Date”), each Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within [ * ] of their appointment. If the
arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the third arbitrator 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 45 of 60 

 
shall be appointed by the AAA. The place of arbitration shall be New York, New York, and all proceedings and communications shall be in English. 

(c) Limited Discovery. It is the intention of the Parties that discovery, although permitted as described herein, will be limited except
in exceptional circumstances. The arbitrators will permit such limited discovery necessary for an understanding of any legitimate issue raised in the arbitration, including the production of documents. No later than [ * ] after selection of the
third arbitrator, the Parties and their representatives shall hold a preliminary meeting with the arbitrators, to mutually agree upon and thereafter follow procedures seeking to assure that the arbitration will be concluded within [ * ] from such
meeting. Failing any such mutual agreement, the arbitrators will design and the Parties shall follow procedures to such effect. 
 (d)
Governing Law. The arbitrators will, in rendering their decision, apply the governing law set forth in Section 15.5. 
 (e)
Interim Relief. Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement,
seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending the arbitration award. The arbitrators shall have no authority to award punitive or any other
non-compensatory damages, except as may be permitted by Section 15.4. Each Party shall bear its own costs and expenses and attorneys’ fees and an equal share of the arbitrators’ and any administrative fees of arbitration. 

(f) No Disclosure. Except to the extent necessary to confirm or enforce an award or as may be required by Applicable Laws, neither a
Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable
proceeding based on the Dispute would be barred by the applicable New York statute of limitations. 
 (g) Enforcement of Arbitration
Award. The Parties consent to the jurisdiction of any appropriate court for the venue in which the arbitration is held for the enforcement of these provisions and the modification, vacation or affirmation of judgment on any award rendered
hereunder. Should such court for any reason lack jurisdiction, any court with jurisdiction shall act in the same fashion. Each Party has the right before or, if the arbitrators cannot hear the matter within an acceptable period, during the
arbitration to seek from the appropriate court provisional remedies such as preliminary injunction, to avoid irreparable harm, maintain the status quo, or preserve the subject matter of the arbitration. Each Party hereto waives its right to trial of
any issue by jury. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 46 of 60 

 15.7 Injunctive Relief. Notwithstanding the provisions of Section 15.6, each Party
acknowledges that, in the event of a breach of an obligation under Article 9 to maintain in confidence the other Party’s Confidential Information, the other Party shall have the right, in addition to any other rights available under Applicable
Laws, to seek from any court of competent jurisdiction injunctive relief to restrain any breach or threatened breach of, or otherwise to specifically enforce, any covenant or obligation of such Party under such provisions. 

15.8 Force Majeure. Neither Party shall be responsible to the other for any failure or delay in performing any of its obligations under
this Agreement or for other non-performance hereunder (excluding, in each case, the obligation to make payments when due) if such delay or non-performance is caused by strike, fire, flood, earthquake, accident, war, act of terrorism, act of God or
of the government of any country or of any local government, or by cause unavoidable or beyond the control of any Party hereto. In such event, the Party affected will use commercially reasonable efforts to resume performance of its obligations. 

 15.9 Waivers and Amendments. The failure of any Party to assert a right hereunder or to insist upon compliance with any term or
condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. No waiver shall be effective unless it has been given in writing and signed by
the Party giving such waiver. No provision of this Agreement, including any of its Exhibits or other attachments, may be amended or modified other than by a written document signed by authorized representatives of each Party.  

15.10 Relationship of the Parties. Nothing contained in this Agreement shall be deemed to constitute a partnership, joint venture, or
legal entity of any type between EBP and Janssen, or to constitute one as the agent or employer of the other. Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give any Party the power or
authority to act for, bind, or commit the other.  
 15.11 Notices. All notices, consents, waivers, and other communications
under this Agreement must be in writing and will be deemed to have been duly given when (a) delivered by hand (with written confirmation of receipt), (b) sent by fax (with written confirmation of receipt), provided that a copy is sent by
an internationally recognized overnight delivery service (with delivery tracking and confirmation), or (c) when received by the addressee, if sent by an internationally recognized overnight delivery service (with delivery tracking and
confirmation), in each case to the appropriate addresses and fax numbers set forth below (or to such other addresses and fax numbers as a Party may designate by notice):  

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 47 of 60 

 If to EBP: 

David Cory 
 President and CEO,
EB Pharma, LLC. 
 1115 Lafayette Street 

Santa Clara, CA 95050 
 With a
copy to: 
 Glen Sato 

Corporate Counsel, EB Pharma, LLC 

Cooley LLP 
 3175 Hanover Street

 Palo Alto, CA 94304 
 If to
Janssen: 
 Attn: Chairman 

Janssen Pharmaceutica NV 

Turnhoutseweg 30 
 2340 Beerse

 Belgium 
 With a copy to:

 Chief Intellectual Property Counsel 

Johnson & Johnson 
 One
Johnson & Johnson Plaza 
 New Brunswick, NJ 08933, U.S.A. 

Fax: 732-524-2788 
 15.12
Further Assurances. Janssen and EBP each hereby covenants and agrees, without the necessity of any further consideration, to execute, acknowledge and deliver any and all such other documents and take any such other action as may be reasonably
necessary to carry out the intent and purposes of this Agreement.  
 15.13 No Third Party Beneficiary Rights. This Agreement
is not intended to and shall not be construed to give any Third Party any interest or rights (including, without limitation, any third party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or
contemplated hereby.  
 15.14 Entire Agreement. This Agreement, including its Exhibits and any other attachments, sets forth
the entire agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other communications 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 48 of 60 

 
between the Parties with respect to such subject matter, including the Confidentiality Agreement. In the event of any conflict between any provisions of the body of this Agreement and any Exhibit
or other attachment hereto, the provisions of the body of this Agreement shall prevail. 
 15.15 Counterparts. This Agreement may be
executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Signatures provided by facsimile transmission or in AdobeTM Portable Document Format (PDF)
sent by electronic mail shall be deemed to be original signatures. 
 15.16 Expenses. Each Party shall pay its own costs,
charges and expenses incurred in connection with the negotiation, preparation and completion of this Agreement. 
 15.17 English
Language. This Agreement is in the English language, and the English language shall control its interpretation. In addition, all notices required or permitted to be given under this Agreement, and all written, electronic, oral or other
communications between the Parties regarding this Agreement, shall be in the English language. 
 15.18 Additional Agreements. Each
Party further agrees that it has not entered into this Agreement in reliance upon any representation, warranty or undertaking of the other Party which is not expressly set out in this Agreement or the Equity Agreement. 

15.19 Effect of Laws. Nothing in this Agreement shall operate to: 

(a) exclude any provision implied into this Agreement by law that may not be excluded by law; or 

(b) limit or exclude any liability, right or remedy to a greater extent than is permissible under law. 

15.20 Government Approvals. 

(a) Each Party will use commercially reasonable efforts to obtain any government approval required in its country of domicile to enable
this Agreement to become effective, or to enable any payment hereunder to be made, or any other obligation hereunder to be observed or performed. Each Party will keep the other informed of progress in obtaining any such government approval, and will
cooperate with the other Party in any such efforts, and notwithstanding anything to the contrary herein, this Agreement shall become effective upon obtaining any such required government approval. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 49 of 60 

 IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be
executed by their duly authorized representatives. 
  

									
	JANSSEN PHARMACEUTICA NV	 		  	EB PHARMA LLC
					
	By:	 	 /s/ Tom Hayman
	 		  	By:	 	 /s/ David Cory

	Name:	 	Tom Hayman	 		  	Name:	 	David A. Cory
	Title:	 	Managing Director, Chairman	 		  	Title:	 	President and CEO
					
	Date:	 	December 15, 2014	 		  	Date:	 	December 15, 2014

 SIGNATURE PAGE TO COLLABORATION,
OPTION AND LICENSE AGREEMENT 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 50 of 60 

 EXHIBIT 1 

Structures of R115777 and R208176 
  

 
  

			
		  	R115777
	[ * ]	  	
		  	R208176

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 51 of 60 

 EXHIBIT 2(A) 

Janssen Patent Rights Owned by Janssen or an Affiliate as of the Execution Date 

[[ * ]] 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 52 of 60 

 EXHIBIT 2(B) 

Janssen Patent Rights Licensed by Janssen or an Affiliate as of the Execution Date 

US Patent No. [*] 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 53 of 60 

 EXHIBIT 3 

Records of Janssen Know-How as of the Execution Date 

On Appended DVD(s) with a label including the following: “Exhibit 3 to Tipifarnib License Agreement” 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 54 of 60 

 EXHIBIT4 

Existing Third Party Agreements as of the Execution Date 

On Appended DVD with a label including the following: “Exhibit 4 to Tipifarnib License Agreement” 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 55 of 60 

 EXHIBIT 5 

Guidelines on Care and Use of Service Animals 
  

	 	•	 	All laboratory research animals housed or used in connection with the Development Program will be treated humanely. They will be housed and cared for in compliance with the Applicable Law governing animal care and use
for research (e.g., the Animal Welfare Act (7 USC 2131), the National Research Council Guide for the Care and Use of Laboratory Animals, the EU Commission, or the Japanese Ministry of Health and Welfare). 

 

	 	•	 	No laboratory animal will be subjected to unnecessary pain and/or distress. Where pain and/or distress are unavoidable, appropriate analgesics, anesthetics and tranquilizers will be used except where their use will
interfere with the scientific results. Exceptions should be reviewed and approved on a case-by-case basis by the Institutional Animal Care and Use Committee (IACUC) or the Ethics Committee on Animal Experiments. 

 

	 	•	 	Only humane and appropriate methods of euthanasia will be used, as described by the American Veterinary Medical Association Guidelines on Euthanasia (current version) and the EU Commission. 

 

	 	•	 	Prolonged physical restraint will be used only after alternative procedures have been considered and found inadequate. 

  

	 	•	 	Vivaria are or will be accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). 

 

	 	•	 	Purpose-bred animals will be used. In those geographic regions of the world where purpose-bred animals are not available, animals must be obtained through regulated dealers that meet reasonable criteria for the humane
care and use of laboratory research animals. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 56 of 60 

 EXHIBIT 6 

Compliance with Laws and the FCPA 
  

	1.1.	Each Party shall comply with all laws and regulations concerning its efforts in the Development Program where it is providing work under the Agreement. Each Party shall become familiar with the FCPA, its prohibitions
and purposes, and shall not undertake any actions that may violate the FCPA. Accordingly, each Party hereby agrees that: 

  

	 	(i)	no person shall be employed by it is an official or employee of any government or any department, agency or instrumentality thereof (including, but not limited to, any health or medical providers owned or controlled by
the government); 

  

	 	(ii)	no payment or offer to pay, or the giving or offering to give, anything of value to an official or employee of any department, agency or instrumentality thereof (including, but not limited to, any health or medical
providers owned or controlled by the government), or to any political party or any candidate for political office, shall be made with the purpose of influencing any decisions favorable to either Party or its Affiliates in contravention of the FCPA
or the laws of the country in which it is providing work; 

  

	 	(iii)	it not pay, nor offer or agree to pay, nor caused to be paid, directly or indirectly, any political contributions, fees or commissions to any governmental employee or representative (including, but not limited to, any
employee of any health or medical provider owned or controlled by the government) that could cause a violation of the FCPA; 

  

	 	(iv)	it will not, directly or indirectly, in connection with the Agreement and the business resulting therefrom, offer, pay, promise to pay, or authorize the giving of money or anything of value to any governmental official
or representative, to any political party or official thereof, or to any candidate for political office, or to any person, while knowing or being aware of the probability that all or any portion of such money or thing of value will be offered,
given, or promised, directly or indirectly, to any government official, to any political party or official thereof, or to any candidate to political office, for the purpose of: 

 

	 	a.	influencing any act or decisions of such official, political party, party official, or candidate in its official capacity, including a decision to fail to perform official functions; or 

 

	 	b.	inducing such official, political party, party official, or candidate to use influence with the government or instrumentality thereof to affect or influence any act or decision of such government or instrumentality, in
order to assist either Party in obtaining or retaining business for or with, or directing business to, any third party. 

  

	 	(v)	Each Party will immediately notify the other Party if it becomes aware of any apparent violation of the FCPA in connection with its activities hereunder. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 57 of 60 

	1.2.	Each Party shall provide the other Party and its agents and representatives (collectively, “Agents”), as well as any regulatory authorities having regulatory oversight of the Party or its Affiliates, with
access to its facilities, records (financial and otherwise), and supporting documentation as may be requested by any Agents in order to document or verify compliance with the provisions of this Exhibit. Each Party acknowledges that the
provisions of this Exhibit granting the other Party certain audit rights shall in no way relieve the Party of any of its obligations under the Agreement, nor shall such provisions require the other Party to conduct any such audits.

  

	1.3.	Each Party shall maintain true and accurate records necessary to demonstrate compliance with the Agreement (including the requirements of this Exhibit). 

 

	1.4.	If a Party fails to comply with any of the provisions of this Exhibit (irrespective of the size, nature or materiality of such violation), such failure may be treated by the other Party as a material breach.

  

	1.5.	Notwithstanding anything to the contrary in the Agreement, a Party may disclose its terms and conditions (including any financial terms) to any government authority that it determines in good faith has a legitimate need
for access to such information (including, but not limited to, any governmental authorities in the U.S. or those in the country where research is being provided). 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 58 of 60 

 EXHIBIT 7 

EBP Press Release 
 EB Pharma Announces
License Agreement for Investigational Drug, Tipifarnibfrom Janssen Pharmaceutica for Development in Hepatitis Delta (HDV) 
 Palo Alto, November X, 2014
/PRNewswire/ — EB Pharma, LLC., a subsidiary of Eiger BioPharmaceuticals, Inc., today announced that it has executed an agreement with Janssen Pharmaceutica NV, (“Janssen”), for an exclusive license, , to tipifarnib in the field of
virology and a related, clinical stage back-up compound. EB Pharma is conducting clinical studies in patients infected with Hepatitis Delta (HDV) and will assess the efficacy and tolerability of tipifarnib as a potential new therapy. 

“This novel approach to treating HDV is the culmination of decades of research”, said Jeffrey Glenn, MD, PhD, Scientific Founder and Associate
Professor of Medicine, Stanford University. “I think it has the potential to change the treatment paradigm for the worst form of human viral hepatitis, and offers new hope for these patients.” 

“HDV is the least common but has the poorest outcome of all forms of viral hepatitis”, said David Cory, President and Chief Executive Officer of
Eiger. “We are excited to license tipifarnib from Janssen and study a potential new therapy for this life threatening disease.” 
 About
Tipifarnib  
 Tipifarnib is a well-characterized, late stage, orally active inhibitor of farnesyl transferase, an enzyme involved in modification
of proteins through a process called prenylation. HDV uses this host cell process inside liver cells to complete a key step in its life cycle. Tipifarnib inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of
the virus to multiply. Since prenylation is a host process, not under control of HDV, and tipifarnib inhibits prenylation, there is also a theoretical higher barrier to resistance with tipifarnib therapy. Virus mutation, a common pathway to drug
resistance, is not expected to be a potential pathway to tipifarnib resistance by HDV. 
 Tipifarnib is not approved for sale for any indication. 

About HDV 
 Hepatitis Delta is caused by infection with
the hepatitis D virus (HDV) and is considered to be the most severe form of viral hepatitis in humans. Hepatitis D occurs only as a co-infection in individuals with hepatitis B (HBV), leads to more severe liver disease than HBV alone, and is
associated with accelerated liver fibrosis, liver cancer, and liver failure. HDV is a disease with a significant impact on global health affecting ~15 million people worldwide. The prevalence of HDV varies

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 59 of 60 

 
between different parts of the world. HDV meets criteria for Orphan Designation in the United States (less than 200,000 people), Europe (less than 5 in 100,000 people), and Japan (less than
50,000 people). Globally, HDV infection is reported to be present in approximately 4% - 6% of chronic hepatitis B carriers. In some parts of the world, including certain areas of China, Russia, Central Asia, Turkey, Africa, and South America,
prevalence as high as 40% has been reported in HBV infected patients. 
 About EB Pharma 

EB Pharma is a privately held subsidiary of Eiger BioPharmaceuticals, Inc., focused on the research, development and commercialization of innovative
therapies in viral hepatitis. The company will focus on developing tipifarnib for the treatment of Hepatitis Delta Virus (HDV), the most severe form of viral hepatitis. Tipifarnib is not approved for sale. EB Pharma’s research programs are
focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious liver diseases. 

  
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Page 60 of 60

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]